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ADDENDUM for ARSENIC 
 




This addendum to the Toxicological Profile for Arsenic supplements the profile that was released in 2007. 
 
Toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act 
(SARA) of 1986 which amended the Comprehensive Environmental Response, Compensation, and 
Liability Act of 1980 (CERCLA or Superfund).  CERCLA mandates that the Administrator of ATSDR 
prepare toxicological profiles on substances on the CERCLA Priority List of Hazardous Substances.  
CERCLA further states that the Administrator will “establish and maintain inventory of literature, 
research, and studies on the health effects of toxic substances” [Title 42, Chapter 103, Subchapter I, § 
9604 (i)(1)(B)]. 
 
The purpose of this addendum is to provide to the public and federal, state, and local agencies a non-peer 
reviewed supplement of the scientific data that were published in the open peer-reviewed literature since 
the release of the profile in 2007. 
 
Chapter numbers in this addendum coincide with the Toxicological Profile for Arsenic (ATSDR 2007).  
This document should be used in conjunction with the profile.  It does not replace it. 
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3. HEALTH EFFECTS 
3.1 INTRODUCTION
A large number of studies on the toxicity of arsenic have been published since the most recent update of
the ATSDR Toxicological Profile for Arsenic (Agency for Toxic Substances and Disease Registry 2007).  
The scope of this addendum is focused on new data in humans and on information that advances the
understanding of arsenic-induced toxicity. Toxicity studies in humans primarily were selected from a 
recent EPA draft development document that identified studies with a low risk of bias and provided 
measures of arsenic exposure (EPA 2014a). All toxicity outcomes were considered for inclusion in this
addendum, except for studies on well-established effects of arsenic exposure (skin lesions, hematological
effects, and acute arsenicosis). Where multiple epidemiology studies were available on the same end
point, the discussion focuses mainly on the strongest study designs (e.g., prospective cohort studies, case-
control studies, large cross-sectional cohort studies). As it is widely accepted that arsenic is carcinogenic,
studies confirming the carcinogenesis of arsenic in humans are identified, but are not reviewed in detail; 
however, studies on the transplacental carcinogenesis potential of arsenic are reviewed in detail.  Animal
studies are limited to those that focus on toxicity outcomes that are difficult to assess or have not been
assessed in humans (e.g., developmental effects, transplacental carcinogenesis, toxicokinetics) and 
toxicity of organic arsenicals, which has a very limited database.  For most toxicological end points, 
studies details are provided in tables, with summaries of results described in the text.
Since publication of the 2007 ATSDR Toxicological Profile for Arsenic (Agency for Toxic Substances
and Disease Registry, 2007), numerous epidemiological studies have examined associations between 
exposure to arsenic in drinking water and various health outcomes. These have included large-scale 
longitudinal cohort studies, case-control studies, and cross-sectional studies. The newer studies
strengthen the evidence that exposure to arsenic in drinking water can produce a wide array of health
effects. Increasing levels of arsenic in drinking water and/or urinary arsenic levels have been associated
with increasing risks for the following outcomes:
•	 death and pulmonary disease in adults and increased risk of respiratory disease in children
following in utero and early life exposure;
•	 cardiovascular outcomes including arrhythmia (e.g., QTc interval prolongation), increased blood 
pressure and hypertension, atherosclerosis, and death from various forms of cardiovascular
disease, including ischemic heart disease and stroke;
•	 diarrhea in children and lesions of the gums and tongue in adults;






   
 












   
 
 




    
 
 






     
        
       
  
     
    




•	 diabetes in children and adults;
•	 ocular effects, including conjunctivitis, cataract/ocular opacity, and pterygium;
•	 disturbances in immune responses including delayed hypersensitivity response in adults and risk
of infection in infants;
•	 impairment of neurological function in adults including decreased peripheral nerve conduction 
velocity, peripheral neuropathy, and altered sensory function;
•	 developmental effects ranging from fetal and infant deaths, congenital heart anomalies, delays in
growth and neurological development, and increased susceptibility to infections; and 
•	 cancer of the bladder and urothelium, gastrointestinal tract, kidney, liver, lung, pancreas, and 
skin; with associations between in utero exposure and cancers of the bladder and kidney.
Recent studies also provide additional evidence for the role of genetic polymorphisms in contributing to 
population variability in pharmacokinetics and sensitivity to the adverse effects of exposure to arsenic.
Polymorphisms that have been examined include AS3MT, cystathione-β-synthase, glutathione
S-transferase π1, glutathione S-transferase ω1, methylenetetrahydrofolate reductase, and N-6 adenine-
specific DNA methyltransferase 1.  Individuals with polymorphisms associated with a higher
monomethylarsonic acid (MMA):dimethylarsinic acid (DMA) ratio in urine may be more susceptible to 
arsenic-induced toxicity.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
3.2.1 Inhalation Exposure
3.2.1.3 Immunological and Lymphoreticular Effects
Inorganic Arsenicals. Humoral immunity was suppressed in male C57B1/6N mice following inhalation 
exposure (nose-only) to arsenic trioxide (mean measured concentrations: 0, 0.064, or 1.0 mg/m3) for 
14 days (3 hours/day). The primary T cell-dependent antibody response to sheep red blood cell challenge
was suppressed by >70% (data presented graphically; p<0.05) in both arsenic trioxide exposure groups.  
No effects on immune response were observed following stimulation of B cells to lipopolysaccharide or
of T cells to Concavalin A.  No cytotoxicity was observed in spleen cells and no effects were observed for 
spleen cell surface markers expression for B cells, T cells, natural killer cells, or macrophages (Burchiel
et al. 2009).










    
      







     
  
   
   
       
   
    
 
    
    
  
  




    
 
      
 
      
    




Inorganic Arsenicals. Several epidemiological studies have evaluated the association between exposure 
to arsenic in drinking water with deaths due to respiratory disease, cardiovascular disease, and cancer.  




Inorganic Arsenicals. Several epidemiological studies have examined associations between exposure to
 
inorganic arsenic in drinking water and mortality from nonmalignant respiratory disease and morbidity, as
 
measured by pulmonary function and respiratory symptoms (Dauphine et al. 2011; Ghosh et al. 2007;
 
Majumdar et al. 2009; Nafeess et al. 2011; Parvez et al. 2010, 2013; Paul et al. 2013b; Pesola et al. 2012;
 
Smith et al. 2013). Details of the individual study designs and outcomes are provided in Table 3-1.

These studies have found increased risks of death and pulmonary disease in adults and increased risk of
 
respiratory disease in children following in utero and early life exposure.
 
The risk of death due to nonmalignant respiratory disease in humans exposed to arsenic in drinking water
 
was examined in a large prospective study of 26,043 adults in Bangladesh (Argos et al. 2014). Increased
 
risk of mortality due to nonmalignant respiratory disease occurred, with an adjusted hazard ratios of
 
1.75 (95% confidence interval [CI]: 1.15, 2.66) for urine arsenic concentrations ≥332.0 µg/g creatinine, 
respectively. A positive trend for increasing risk with increasing urinary arsenic level (p=0.008) was
observed.
The risk of nonfatal respiratory disease in humans exposed to arsenic in drinking water has been 
examined in prospective cohort studies in adults (Parvez et al. 2010, 2013) and children (Smith et al. 
2013). The risk of clinical symptoms of respiratory disease, including cough and breathing problems, 
was increased in a cohort of 10,833 adults in Bangladesh exposed to arsenic in drinking water (Parvez et
al. 2010). Adjusted hazard ratios for cough were increased at drinking water concentration ranges of 90– 
178 µg/L (adjusted hazard ratio: 1.52; 95% CI: 1.23, 1.88) and >178 µg/L (adjusted hazard ratio: 1.51;
95% CI: 1.21, 1.87). Adjusted hazard ratios for breathing problems were increased at a drinking water
concentration range of 7–40 µg/L (adjusted hazard ratio: 1.44; 95% CI: 1.20, 1.74), with slightly higher
risk estimates for arsenic concentration ranges of 90–178 and >178 µg/L. Similar results were observed























   











   






















































Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Death due to lung disease
Argos et al. Study design: Exposure measures: Variables assessed: death due The risk of mortality due to nonmalignant
2014 prospective cohort arsenic concentration in to nonmalignant lung disease lung disease was increased in T2 and T3,
Location: Bangladesh urine, adjusted for Adjustments: age, sex, BMI, compared to T2, with a positive test for trend 
Population: creatinine education, smoking (p=0.008).  Adjusted hazard ratios (95% CI):
26,043 adults As concentration:  Analysis: Cox proportional - T2: 1.37 (0.90, 2.08)
Data collection Tertiles: hazards regression - T3: 1.75 (1.15, 2.66)
period: initial - T1: <132.5 µg/g
enrollment 2000– - T2: 132.5–331.9 µg/g
2002, with an average - T3: ≥332.0 
8.5-year follow-up
Respiratory symptoms and pulmonary function
Dauphine et Study design: Exposure measures: Variables assessed: any All pulmonary function tests were 
al. 2011 retrospective cohort
Location: Chile
arsenic concentration in 
drinking water calculated 
respiratory symptom, chronic
cough, chronic phlegm, chronic
significantly decreased (p=0.02–0.03) in T3,
but not T2, compared to T1.  Trend tests
Population: from municipal water bronchitis, trouble breathing, across tertiles showed a statistically
32 exposed adults sources breathlessness upon walking significant decreasing trend for all pulmonary
(mean age: 48 years; As concentration:  fast/uphill, at group pace, at one function tests (p=0.005–0.008).
exposed to >800 µg/L Tertiles: pace, pulmonary functions tests
before age 10);
compared to 
- T1: <50 µg/L
- T2: 50–250 µg/L
(predicted FEV1, predicted 
FVC, FEV1 residual, FVC
In the exposed group, FEV1 and FVC were 
decreased by 11.5% (p= 0.04) and 12.2%
65 reference adults - T3: >800 µg/L residual) (p=0.04), respectively, compared to controls.
with high early-life Adjustments: age, sex,
exposure smoking, childhood The prevalence odd ratio was significant for
Data collection secondhand smoke, use of breathlessness while walking at group pace 
period: 2008 wood, charcoal, or kerosene in
childhood home, occupational
(prevalence odd ratio: 5.94; 95% CI: 1.36,
26.0; p=0.009).
air pollution, education
Analysis: multivariate logistic No association was observed for other
regression respiratory symptoms or variables.























   
 




















































    
 
   




Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 










(373 with skin lesions,
352 without skin 
lesions), 389 controls;









3,451; children and 
adults (age range 
specified as ≤9– 






arsenic concentration in 







- control: 6.97±2.10 µg/L
- cases (no skin lesions):
186.89±124.67 µg/L







drinking water from wells
used by each participant.
As concentration: 
Quintiles:
- Q1: <50 µg/L
 
- Q2: 50–199 µg/L
 
- Q3: 200–499 µg/L
 
- Q4: 500–799 µg/L
 
- Q5: ≥800 µg/L
	
Variables assessed: respiratory
illness based on presence of
history of cough, chest sounds
in lungs, shortness of breath
Adjustments: age, sex, smoking
Analysis: logistic regression
Variables assessed: chronic
lung disease, diagnosed based 
on symptoms of cough and
respiratory distress, as reported 
by participants to a physician,




Exposure to arsenic in drinking water was
associated with a higher risk of respiratory
illness compared to controls.  Exposed
participants with skin lesions had a higher
risk of developing respiratory illness than 
those without skin lesions: Adjusted odds
ratios (95% CI):
- cases (no skin lesions): 3.21 (1.65,
6.26)
- cases (with skin lesions): 13.54 (7.45,
24.62)
A trend test for odds ratios was statistically
significant (p<0.001).
The prevalence of chronic lung disease in
female, but not male, participants in was
significantly increased in Q5 compared to 
Q1.  Prevalence odds ratios (95% CI):
- males:  0.93 (0.65, 1.3)
 
- females: 1.76 (1.1, 2.6)
 









































    
 
















   
  
   
   




























Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 






























arsenic concentration in 
drinking water from primary





- Q1: ≤7 µg/L
- Q2: 7–40 µg/L
- Q3: 40–90 µg/L
- Q4: 90–178 µg/L
- Q5: >178 µg/L
Urine quintiles:
- Q1: ≤90 µg/g





















cough, breathing problems, and 
blood in sputum, evaluated by
physicians
Adjustments: age, sex, smoking 
BMI, education, skin lesion
Analysis: hazard ratios
determined by Cox proportional
hazards models
For arsenic exposure to drinking water
concentrations ≥100 µg/L, FVC was
significantly (p=0.028) decreased by
221.9 mL, compared to controls.  No
statistically significant decreases in FEV1 or
FEV1/FVC were observed.
For arsenic exposure to drinking water
concentrations ≥250 µg/L, FEV1 and FVC
were significantly decreased by 226.4 mL 
(p=0.030) and 354.8 mL (p=0.003), 
respectively. No statistically significant
decrease in FEV1/FVC was observed.
No association was observed between 
arsenic exposure and symptoms of
respiratory disease.
Significant positive associations between 
exposure to arsenic (based on levels in 
drinking water and urine) and clinical 
symptoms of respiratory disease.
For chronic cough based on arsenic
concentration in drinking water, adjusted 
hazard ratios were significant in Q3–Q5, 
compared to Q1. Based on urine, adjusted 
hazard ratios were significant for Q4 and Q5,
compared to Q1.
Adjusted hazard ratios (95% CI) for cough 
(drinking water):
- Q3: 1.40 (1.11, 1.75)
- Q4: 1.57 (1.25, 1.97)
- Q5: 1.60 (1.27, 2.01)
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Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Reference
Study design and 





Adjusted hazard ratios (95% CI) for cough 
(urine):
- Q4: 1.52 (1.23, 1.88)
- Q5: 1.51 (1.21, 1.87)
Adjusted hazard ratios for breathing 
problems were significant based on drinking 
water in Q2–Q5, compared to Q1, and 
based on urine in Q4 and Q5, compared to 
Q1.
Adjusted hazard ratios (95% CI) for
breathing problems (drinking water):
- Q2: 1.44 (1.20, 1.74)
- Q3: 1.52 (1.25, 1.84)
- Q4: 1.42 (1.16, 1.73)
- Q5: 1.41 (1.56, 1.72)
Adjusted hazard ratios (95% CI) for
breathing problems (urine):
- Q4: 1.28 (1.06, 1.54)
- Q5: 1.27 (1.05, 1.53)
Hazard ratios for blood in sputum were
significant drinking water for Q3 and Q4, but
not Q5, compared to Q1.  Hazard ratios
based on urine were not significant.








































     
 


















































Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 






















period: Data were 
collected from same 
participants for two
time periods: 2005– 
Exposure measures: 

arsenic concentration in 

drinking water from primary
 










- T1: <19 µg/L
 
- T2: >19–97 µg/L
 
- T3: >97 µg/L
 
Urine tertiles:
- T1: <125 µg/g
- T2: >125–285 µg/g












function tests (FEV1, FVC)
Adjustments: age, sex, BMI,
















Analysis: ratio of incidence in 

exposed to control groups
 
Negative associations were observed 
between arsenic levels in drinking water and 
in urine and pulmonary function.  Adjusted 
betas (95% CI) based on drinking water
were significant for T3 for FEV1 and FVC:
- FEV1 for T3: -80.6 (-181.4, -17.5);
p=0.01
- FVC for T3: -97.3 (-181.8, -12.7);
p=0.02
The adjusted betas (95% CI) based on urine
was significant for T3 for FEV1
- FEV1 for T3: -90.5 (-173.6, -7.4); p=0.03
For each increase of 1 SD for arsenic
concentration in water (118.1 µg/L), FEV1
and FVC were decreased by 46.5 mL 
(p=0.01) and 53.1 mL (p=0.005),
respectively.  For each increase of 1 SD for
arsenic concentration in urine (277.2 µg/g),
FEV1 and FVC were decreased by 48.3 mL 
(p=0.005) and 55.2 mL (p=0.02),
respectively.
The risk of development of respiratory
symptoms was significantly increased in 
cases compared to controls for both 
collection periods.  Odds ratios (95% CI):
2005–2006:
- 6.07 (2.47, 14.95)
2010–2011:
- 11.45 (5.04, 25.97)
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Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Reference
Study design and 














arsenic concentration in 
drinking water and urine
As concentration:  
Drinking water quintiles:
- Q1: <7 µg/L
- Q2: 7–<39 µg/L
- Q3: 39–<91 µg/L
- Q4: 91–<179 µg/L
- Q5: ≥179 µg/L
Urine quintiles were not
reported
Variables assessed: history of
dyspnea, as determined by a 
physician
Adjustments: age, sex,
education, BMI, blood pressure
Analysis: unconditional logistic
regression for odds ratios; Chi-
squared test for trend test
A significant positive association was
observed between arsenic concentrations in 
drinking water and urine and dyspnea in 
nonsmokers for Q3–A5, compared to Q1.
Positive trends (p<0.01) were observed for
arsenic in drinking water and urine.
Adjusted odds ratios (95% CI) for drinking 
water:
- Q3: 1.96 (1.43, 2.70); p<0.001
- Q4: 2.14 (1.56, 2.92); p<0.001
- Q5: 1.80 (1.31, 2.49); p<0.001
Adjusted odds ratios (95% CI) for urine:
- Q3: 1.92 (1.38, 2.65); p<0.001
- Q4: 1.94 (1.41, 2.68)’ p<0.001
- Q5: 1.87 (1.36, 2.58); p<0.001












period: wells sampled 
2002–2003; dates for
Exposure measures: 
arsenic concentration in 
drinking water in utero and 
early life (first 5 years of life)
from tube wells for each 
participant
As concentration:  
Tertiles:
- T1 (control): <10 µg/L
- T2: 10–499 µg/L




shortness of breath), respiratory
disease (asthma, pneumonia),
pulmonary function tests (FEV1, 
FVC)
Adjustments: age and gender
for respiratory symptoms: age,
gender, height, mother’s and 
father’s education, father’s
smoking status, number of
rooms in the house for
Analysis based on tertiles: Relative to 
controls, children exposed to arsenic were 
significantly more likely to have cough (when 
not having a cold), wheezing (all wheezing 
and wheezing when not having a cold), and 
shortness of breath (walking fast/uphill and 
walking on level ground). Significant
adjusted odds ratios (95% CI):
Cough:
- T3: 2.53 (1.12, 5.69); p=0.01
data collection in 
children not specified
- Q1: <10 µg/L
- Q2: 10–199 µg/L
- Q3: 200–399 µg/L
- Q4: 400–599 µg/L




- T2: 2.14 (1.36, 3.36); p<0.001
- T3: 2.17 (1.26, 3.75); p<0.01
Wheeze (when not having a cold):
- T3: 8.41 (1.66, 42.6); p<0.01










    
 
 
   







    























Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Shortness of breath (walking fast/climbing):
- T2:2.74 (1.18, 6.37); p<0.01
- T3: 3.19 (1.22, 8.32); p<0.01
Shortness of breath (walking on level
ground):
- 3.86 (1.08, 13.7); p=0.02
Asthma:
- T2: 1.84 (1.04, 3.26); p=0.02
- T3: 2.33 (1.19, 4.57); p<0.01
Analysis based on quintiles: Compared to 
Q1, significant adjusted odds ratios were 
observed for all wheezing, wheezing when 
not having a cold, cough when not having a 
cold, shortness of breath when walking 
fast/climbing, shortness of breath when 
walking on level ground, and asthma.
Adjusted odds ratios (95% CI):
Wheezing (all):
- Q2: 1.98 (1.03, 3.80)
- Q3: 1.51 (0.83, 2.74)
- Q4: 3.17 (1.78, 5.64)
- Q5: 2.12 (1.19, 3.76)
Wheezing when not having a cold:
- Q4: 8.65 (1.64, 45.7)
- Q5: 8.21 (1.56, 43.1)
Cough without having a cold:
- Q5: 2.47 (1.05, 5.79)
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Table 3-1.  Respiratory Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Shortness of breath (walking fast/climbing):
- Q3: 2.89 (1.06, 7.91)
- Q4: 4.09 (1.56, 10.7)
- Q5: 3.20 (1.18, 8.71)
Shortness of breath (walking on level
ground):
- Q4: 4.50 (1.17, 17.3)
Asthma:
- Q4: 2.26 (1.13, 4.49)
- Q5: 2.38 (1.17, 4.83)
Statistically significant trends were observed 
for wheezing (p<0.001), asthma (<0.01),
cough when not having a cold (p=0.03),
shortness of breath when walking 
fast/climbing (p<0.01), shortness of breath 
when walking on level ground (p=0.01), and 
wheezing when not having a cold (p<0.01).
No association was observed between 
arsenic exposure and pulmonary function.
As = arsenic; BMI = body mass index; CI = confidence interval; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; SD = standard deviation






     
 
    
         
    
        
   
    
     
 
   
   
    
  




    
    
      
     
     
  
 
    
 
 
   
     
   
    
      
        
      
12ARSENIC
for this cohort based on urine arsenic concentrations. Associations were observed between arsenic 
concentrations in drinking water and urine and decrements in pulmonary function, measured by forced 
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), in a cohort of 950 adults in 
Bangladesh (Parvez et al. 2013). For each increase of 1 standard deviation (SD) for arsenic concentration
in water (118.1 µg/L), FEV1 and FVC were decreased by 46.5 mL (p=0.01) and 53.1 mL (p=0.005),
respectively. For each increase of 1 SD for arsenic concentration in urine (277.2 µg/g creatinine), FEV1 
and FVC were decreased by 48.3 mL (p=0.005) and 55.2 mL (p=0.02), respectively. The risk of asthma 
and respiratory symptoms was increased in a cohort of 491 children (aged 7–17 years) exposed in utero
and throughout childhood (Smith et al. 2013). Elevated risk of asthma was observed at drinking water
concentration ranges of 400–599 µg/L (adjusted odds ratio: 2.26; 95% CI: 1.13, 4.49) and ≥600 µg/L
(2.38; 95% CI: 1.17, 4.83). Similarly, adjusted hazard ratios for symptoms of respiratory disease (wheeze 
and shortness of breath) were increased at arsenic drinking water ranges of 200–399 µg/L and higher.
Retrospective cohort and cross-sectional studies also show increased risks for decreased pulmonary
function and symptoms of respiratory disease (Dauphin et al. 2011; Ghosh et al. 2007; Majumdar et al.
2009; Nafeess et al. 2011; Paul et al. 2013b; Pesola et al. 2012).
Cardiovascular Effects.
Inorganic Arsenicals. Several epidemiological studies have examined effects of exposure to inorganic 
arsenic in drinking water and effects on the cardiovascular system, including death due to, and incidence 
or prevalence of, cardiovascular disease, cardiac arrhythmias, increased blood pressure, pulse pressure
and hypertension, and atherosclerosis. Details of the individual study designs and outcomes are provided 
in Table 3-2. In general, these studies have found increased risk in association with exposures to arsenic
in drinking water and/or urinary arsenic concentrations for the following cardiovascular outcomes:
arrhythmia (e.g., QTc interval prolongation), increased blood pressure and hypertension, atherosclerosis, 
and death from various forms of cardiovascular disease, including ischemic heart disease and stroke.
Risk of death due to cardiovascular disease in humans exposed to arsenic in drinking water have been 
examined in several prospective cohort studies (Chen et al. 2011b; Liao et al. 2012; Moon et al. 2013;
Rahman et al. 2014; Wade et al. 2009). Most of these studies found positive associations (Chen et al.
2011b; Moon et al. 2013; Rahman et al. 2014; Wade et al. 2009). Increased risk for cardiovascular-
related deaths occurred in association with drinking water arsenic concentrations ranging from 50 to 
900 µg/L. The largest prospective cohort studies were conducted in Bangladesh (Chen et al. 2011b;
Rahmann et al. 2014).  The Chen et al. (2011b) study (11,746 adults) found increased risk of mortality
due to heart disease in association with drinking water concentrations ranging from 148.1 to 864.0 μg/L






















































































Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes





























- Q1: 0.1–12.0 μg/L
- Q2: 12.1–62.0 μg/L
- Q3: 62.1–148.0 μg/L

















Variables assessed: death 
due to cardiovascular disease 
(circulatory disease, ischemic
heart disease and other forms










Variables assessed: death 






A dose-response relationship was observed 
for arsenic exposure in drinking water and 
mortality from ischemic heart disease and 
other heart disease (p=0.0019) and from
ischemic heart disease (p=0.0294).
Hazard ratios (95% CI) for ischemic heart
disease and other heart disease:
- Q1: 1
- Q2: 1.22 (0.65, 2.32)
- Q3: 1.35 (0.71, 2.57)
- Q4: 1.92 (1.07, 3.43)
Hazard ratios (95% CI) for ischemic heart
disease:
- Q1: 1
- Q2: 1.22 (0.56, 2.65)
- Q3: 1.49 (0.70, 3.19)
- Q4: 1.94 (0.99, 3.84)
No relationship was observed for exposure 
to arsenic in drinking water and death due to 
circulatory disease or cerebrovascular
disease.
Compared to controls, no association was
observed between cumulative arsenic
exposure and death due to cardiovascular
disease (hazard ratio: 1.89; 95% CI: 0.50,
7.10).
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Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 




















- Q1: <5.8 μg/g
- Q2: 5.8–9.7 μg/g
- Q3: 9.8–15.7 μg/g
- Q4: >15.7 μg/g
Variables assessed: death 
due to cardiovascular disease,
coronary heart disease, and 
stroke
Adjustments: study center, 




For the highest exposure group, but not
lower exposure groups, significant elevated 
risk of death due to cardiovascular disease,
coronary artery disease, and stroke was
observed. Adjusted hazard ratios (95% CI)
for the Q4 group:
- cardiovascular disease: 1.65 (1.20, 2.27
- coronary artery disease: 1.71 (1.19,
2.44)
- stroke: 3.03 (1.08, 8.50)
A positive trend was observed for mortality
due to cardiovascular disease (p<0.001) and
coronary artery disease (p<0.001), but not
mortality due to stroke (p=0.061).
Note that hypertension, diabetes, and kidney
disease were identified as confounding 
factors.
































   
  
 







   
   
 
  
   















   
  
   





















Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 






























- T1: <10 μg/L
	
- T2: 10–49 μg/L
	
- T3: ≥50 μg/L
	
Exposure measures: arsenic
concentration in drinking 
water from each household
As concentration range:
Quintiles:
- Q1: 0–5 μg/L
- Q2: 5.1–20 μg/L
- Q3: 20.1–100 μg/L
- Q3: 100.1–300 μg/L













Analysis: multivariate Poisson 
regression
Exposure to arsenic in drinking water was
associated with an increased risk of mortality
due to stroke.  The association was
significant for combined males and females
and for females, but not males, exposed to 
≥50 μg/L. Significant trends were observed
for combined males and females
(p=0.00058) and for females (p=0.00004),




- T1: 1.20 (0.92, 1.57)
- T3: 1.35 (1.04, 1.75)
Females:
- T1: 1
- T2: 1.31 (0.87, 1.98)
- T3: 1.72 (1.15, 2.57)
A significant association was observed 
between arsenic concentration in drinking 
water and death due to heart disease at
arsenic concentrations >300 μg/L (adjusted
incidence ratio risk: 5.08; 95% CI: 1.45,
17.81; p=0.011).
No association was observed at lower
drinking water arsenic concentrations and 
mortality due to cardiovascular disease or for
any drinking water arsenic concentration and 
mortality due to stroke.







































   
   
 
   
 
   
 






























    
 
 





Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Incidence of cardiovascular disease




























- Q1: <5.8 μg/g
- Q2: 5.8–9.7 μg/g
- Q3: 9.8–15.7 μg/g







Variables assessed: incidence 
of fatal and nonfatal
cardiovascular disease,
coronary heart disease, and 
stroke
Adjustments: study center, 








use, occupation, farm work,
water source
Analysis: logistic regression
For Q4, but not lower quartiles, significant
elevated risk for incidence of cardiovascular
disease and coronary artery disease was
observed. Adjusted hazard ratios (95% CI)
for the >15.7 μg/g group:
- cardiovascular disease: 1.65 (1.20, 
2.27)
- coronary artery disease: 1.71 (1.19, 
2.44)
- stroke: 3.03 (1.08, 8.50)
A positive trend was observed for
cardiovascular disease (p<0.001), coronary
artery disease (p<0.004) and stroke 
(p=0.061). 
Note that hypertension, diabetes, and kidney
disease were identified as confounding 
factors.
A borderline association for cardiovascular
disease with arsenic exposure was observed 
in males (odds ratio: 1.10, p=0.07), but not
females (odds ratio: 0.99, p=0.80).
The presence of arsenic-induced skin 
lesions was associated with cardiovascular
disease (odds ratio: 1.62, p<0.01) but not
associated with stroke (odds ratio 1.04,
p=0.89).














































   





























   
 






Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 










1,715 male (61%) and 
female (39%) adults
(HEALS participants);
















concentration of arsenic in 
well water (measured in 
10,971 contiguous wells) and 
urine (adjusted for urinary
creatinine)
As concentration range:
- well water: 0.1– 
790 µg/L




As concentration range: 
mean 0.069 μg/g; range 
0.052–0.11 μg/g
Variables assessed: PR
interval, QRS duration and 
QTc interval (QT interval
corrected for heart rate); QTc
prolongation defined as
≥450 mseconds in men and
≥460 mseconds in women)
Adjustments: sex, age, BMI,
smoking status, education
Analysis: linear regression 
using continuous dependent
variable
Variables assessed: QT and 
QTc interval
Adjustments: age, body mass
index, mean arterial pressure,
fasting glucose, serum C-
reactive protein, smoking,




Based on the adjusted odds ratio for a 1-SD
increase in baseline well water (108.7 µg/L)
and in urinary arsenic concentration 
(270.7 μg/g creatinine), a positive 
association was observed for QTc
prolongation in women. Adjusted odds ratio 
(95% CI):
- well water arsenic: 1.24 (1.05, 1.47)
- urinary arsenic: 1.24 (1.01, 1.53)
A positive trend for QTC prolongation in 
women was also observed for both well
water (p=0.01) and urinary arsenic (p=0.04).
No associations for QTc prolongation in men 
or PR or QRS prolongation in men or women 
were observed.
Positive association between toenail arsenic
concentration and QT and QTc interval
duration.
- QT interval increase of 3.8 mseconds
per interquartile range arsenic toenail
concentration (corresponding to a 
0.059 μg/g increment of toenail arsenic
concentration); p<0.05
- QTc increase of 2.5 msec per
 

































































































Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Wang et al. Study design: cross- Exposure measures: arsenic Variables assessed: P wave Statistically significant (p<0.001) exposure­
2009b sectional cohort measured in drinking water duration, PR interval, QRS related trends were observed for increased 
Location: Taiwan (measured in main wells from duration, QT and QTc interval duration of QT and QTc intervals.
Population: each village); lifetime (>460 mseconds)
441 exposed cumulative exposure (arsenic Adjustments: age, gender, Significant associations were observed 
(257 with 0.1– concentration in drinking hypertension, diabetes between QTc interval and ischemic heart
19.9 mg/L cumulative water x duration of exposure mellitus, serum total disease and carotid intima-medium thickness
arsenic exposure and As cumulative exposure: cholesterol and triglyceride and plaque.
184 with ≥20 mg/L - ~0 mg/L-year levels, BMI, smoking, alcohol 
cumulative arsenic - 0.1–19.9 mg/L-year consumption No apparent associations were observed 
exposure); - ≥20 mg/L-year Analysis: multiple logistic between cumulative arsenic exposure and 




Chen et al. Study design: cross- Exposure measures: urine Variables assessed: blood A statistically significant trend (p=0.021)
2012b sectional cohort
Location: Taiwan
arsenic (adjusted for urinary
creatinine)
pressure (hypertension
defined as average systolic
between urine arsenic concentration and risk
of hypertension was observed.
Population: As concentration range: blood pressure ≥130 mmHg,
240 adults; 95 males - Q1: <1.4 μg/g average diastolic blood Odds ratio for development of hypertension 
and 145 females creatinine pressure ≥85 mmHg, and/or was significant in Q2 (odds ratio: 2.1; 95%
(60 per quartile); - Q2: 1.4–4.3 μg/g history of hypertension that CI: 1.0–4.4; p<0.05) and Q4 (odds ratio: 3.0;
lowest quartile treated 
as control
creatinine
- Q3: 4.3–8.0 μg/g 
was regularly treated with 
antihypertensive drugs)
95% CI: 1.4–6.3; p<0.01)
Data collection creatinine Adjustments: not reported
period: not reported - Q4: >8.0 μg/g Analysis: unconditional logistic
creatinine regression


























































   
  
 























    
  
   
  
   
 
 
   
 




Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 




























measured in wells of each 
participant; cumulative 
arsenic exposure (mg/L-year) 











maternal urine arsenic at
 
weeks 8 and 30 of gestation;
 






- maternal (8 weeks):
80 μg/L (10th, 90th 
percentile: 24,
383 μg/L)
- maternal (30 weeks):
83 μg/L (10th, 90th: 26, 
415 μg/L) at week 30 
- child (18 months):
34 μg/L (10th, 90th 
percentile: 12,
154 μg/L)
Variables assessed: blood 
pressure (hypertension
defined as systolic blood 
pressure ≥140 mmHg or
diastolic blood pressure 
≥90 mmHg)




and systolic blood pressure
children at 4.5 years of age
Adjustments: sex, age,
parental wealth index, height





A positive association between cumulative 
exposure to >4.5 mg/L-year and 
hypertension was observed.  Adjusted odds
ratio: 2.87 (95% CI: 1.26, 4.83).
A dose-response relationship was observed 
between increasing cumulative arsenic
exposure and arsenic level in hair and 
hypertension (p-values not reported).
In utero exposure to arsenic was associated 
with a minimal increase in blood pressure at
4.5 years of age.
Each 1 mg/L increase in maternal urinary
arsenic during pregnancy was associated 
with a 3.69 mmHg (95% CI: 0.74, 6.63;
p=0.01) increase in child systolic and a 
2.91 mmHg (95% CI: 0.41, 5.42; p=0.02)
increase in child diastolic blood pressure.
Adjusted beta (95% CI), based on combined 
8- and 30-week maternal urine arsenic:
- systolic: 3.69 (0.74, 6.63)
- diastolic: 2.91 (0.41, 5.42)
A 1 mg/L increase in child urinary arsenic at
18 months of age was associated with an 
8.25 mmHg (95% CI: 1.37, 15.1; p=0.02)
increase in systolic blood pressure at
4.5 years. Adjusted beta (95% CI), based on 
child urine arsenic:
- systolic: 8.25 (1.37, 15.1)










    
































































Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes












concentration in drinking 




- Q1: 10–22 μg/L
- Q2: 23–32 μg/L
- Q3: 33–261 μg/L
- Q4: >262 μg/L
Variables assessed: systolic
blood pressure ≥140 mmHg 
(systolic hypertension),
diastolic blood pressure 
≥90 mmHg (diastolic




religion, monthly income, BMI
Analysis: multiple logistic
regression; Cuzick’s
nonparametric test for trend
A dose-response relationship (p for trend 
<0.01) between arsenic concentration in
drinking water and increased pulse pressure 
was observed, based on exposure quartiles.
Adjusted odds ratios (95% CI):
- Q1: 1 
- Q2: 3.87(1.22, 12.20)
- Q3: 4.32 (1.23, 15.11)
- Q4: 7.32 (2.18, 24.60)
No association was observed between 
















arsenic and DMA in urine
As concentration:  
Total arsenic median:
8.3 µg/L 
Total DMA: 3.6 µg/L
Variables assessed: 
hypertension, defined as a 
mean systolic blood pressure 
≥140 mmHg, a mean diastolic
blood pressure ≥90 mmHg, a 
self-reported physician
diagnosis, or use of
antihypertensive medication.
Adjustments: age, sex, race,
ethnicity, education, BMI,
serum cotinine, urine 
No association was observed between 
urinary total arsenic or DMA concentration 
and systolic or diastolic blood pressure.
creatinine levels
Analysis: logistic regression















































































    
  
  






Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Kunrath et al.
2013



















concentration in drinking 
water (from main drinking 
water source for each
participant)
As concentration range 
(mean±SD):
- controls: 1.0±0.2 μg/L
- cases: 40.2±30.4 μg/L
Exposure measures: arsenic
concentration in drinking 
water (from main drinking 
water source for each
participant), cumulative 










Variables assessed: blood 
pressure (hyperreactivity
defined as a combined stress-
induced change in systolic
pressure of >20 mmHg and 
diastolic pressure of
>15 mmHg) under conditions
of anticipatory stress





Variables assessed: blood 
pressure (hypertension
defined as systolic blood
pressure ≥140 mmHg,
diastolic blood pressure










Compared to controls, cases had a higher
percentage of individuals with blood 
pressure hyperreactivity to anticipatory
stress (12.5 versus 47.4%, p=0.035) and 
cold stress (37.5 versus 73.7%; p=0.044).
Logistic regression analysis showed that
blood pressure hyperactivity was associated 
with arsenic concentration in drinking water.
Odds ratios (95% CI):
- anticipatory stress: 6.30 (1.11, 35.67);
p=0.038
- cold stress: 4.67 (1.11–19.65); p=0.036
The risk of hypertension for the highest
tertile was 1.937 (95% CI: 1.018, 3.687) and
was significantly increased (p<0.05)
compared to the lowest tertile.  The adjusted 
odds ratio for T2 was not significant
compared to the lowest exposure group.
A dose-response trend for prevalence of
hypertension was observed (p-value not
reported).

























































Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Li et al. 2013b	 Study design: cross- Exposure measures: Variables assessed: blood 
sectional cumulative arsenic exposure pressure (hypertension
Location: China (based on arsenic in main defined as systolic blood
(Shanyin county of drinking water source for pressure ≥140 mmHg,
Shanxi province) each participant and duration diastolic blood pressure
Population: 604 adult of residence); urine arsenic ≥90 mmHg, or history of
males (42%) and concentration (adjusted for hypertension under regular
females (58%) creatinine) treatment with
Data collection As cumulative exposure: antihypertensive agents)
period: not reported Range: 0–0.65 mg/L-year Adjustments: gender, age,
Tertiles: smoking, alcohol
- T1: <0.10 mg/L-year consumption, BMI





- T1: <93.77 µg/g
- T2: 93.77–250.61 µg/g
- T3: >250.61 µg/g
For the T3, a positive association was
observed, based on arsenic cumulative 
exposure (adjusted odd ratio: 1.871; 95% CI:
1.022, 3.424).  The adjusted odds ratio
based on total urinary arsenic was
1.648 (95% CI: 0.999, 2.721).
Significant trends were observed for
increased risk of hypertension based on 
arsenic cumulative exposure (p=0.040) and 
on total urinary arsenic (p=0.046).

























































Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 







males (46%) and 
females (54%)
Data collection 
period: 1990 to 2002– 
2003
Exposure measures: arsenic
concentration in drinking 
water (main drinking water
source for each 
participant);cumulative 
arsenic exposure; urine 
arsenic concentration 
(adjusted for creatinine)
As in drinking water:
Tertiles:
- T1: <538 μg/L
- T2: 538–700 μg/L
- T3: >700 μg/L
As cumulative exposure:
Tertiles:
Variables assessed: blood 
pressure (hypertension
defined as systolic blood
pressure ≥140 mmHg,
diastolic blood pressure






Compared to T1, an association was
observed between urinary As(V) and 
hypertension (adjusted relative risk: 2.43;
95% CI%: 1.10, 5.86; p=0.047) for T3.  No 
association was observed for T2.
No association was observed between 
cumulative arsenic exposure or arsenic
concentration in drinking water and
hypertension.
Diastolic blood pressure increased with 
increased cumulative arsenic exposure 
(beta=0.27; p<0.001).
- T1: <5.6 mg/L-year
- T2: 5.6–15.6 mg/L-year
- T3: >15.6 mg/L-year
As(V) in urine:
Tertiles:
- T1: <1.20 µg/g
- T2: 1.20–2.67 µg/g
- T3: >2.67 µg/g








































   
   




   
 
  

















   
  
























   
 
   
  
   





Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Atherosclerosis/carotid thickness/carotid plaque
Study design: cross- Exposure measures: arsenic Variables assessed: carotid Every 1 SD increases in urinary arsenic
Chen et al. sectional cohort concentration in drinking intima-media thickness concentration (357.9 μg/g creatinine) was
2013a Location: Bangladesh
Population: 959 adult
water from 10,971 tube wells;
arsenic concentration in urine 
Adjustments: gender, age,
BMI, smoking, systolic blood 
associated with an increase of 11.7 μm in 
carotid intima-media thickness.
males (40%) and (adjusted for creatinine) pressure, diabetes - adjusted Beta:




- mean 81.1 μg/L




(95% CI: 1.8, 21.6); p=0.020
Every 1 SD increase in well water
As in urine: concentration (102.0 μg/L) was associated 
- Mean: 259.5 µg/g
- 10th-90th percentiles:
with an increase of 5.1-μm in carotid intima­
media thickness, although the association 
60.3–538.6 µg/g was not statistically significant (p=0.058).
- adjusted Beta: 5.1 μm/102.5 µg/gL 
(95% CI: −0.2, 10.3)
Hsieh et al. Study design: case Exposure measures: well Variables assessed: presence A significant trend was observed for the 
2008b control water (individual homes); of carotid atherosclerosis relationship between both arsenic
Location: Taiwan cumulative arsenic exposure based on ultrasound results concentration in well water (p=0.0049) and 
Population: adult As in drinking water: for intima-media thickness cumulative arsenic exposure (p=0.0047) and 
males and females; Tertiles: (≥1.0 mm), plaque carotid atherosclerosis.
235 cases;
244 controls
- T1: ≤10 μg/L
- T2: 10.1–50.0 μg/L
(occurrence in at least
two locations) and presence of A positive association was observed for T3 
Data collection - T3: ≥50.1 μg/L stenosis >50% in the left or based on arsenic concentration in well water
period: 1997–1998 Cumulative As exposure: right common carotid artery and for arsenic cumulative exposure and 
Tertiles: Adjustments: age, gender carotid atherosclerosis.
- T1: ≤0.2 mg/L-year
- T2: 0.3–1 mg/L-year
Analysis: multiple logistic
regression Adjusted odds ratios (95% CI) for well water:
- T3: ≥1.1 mg/L-year - T1: 1.0
- T2: 1.5 (0.7, 2.1)
- T3: 2.4 (1.2, 4.6); p<0.05


















































    
 
  
    





   








































Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes











Osorio-Yanze	 Study design: cross-
et al. 2013	 sectional cohort
Location: Mexico
Population: 199 male 
(54%) and female 
(46%) children 3– 




concentration in drinking 
water (obtained from
previous surveys of village
well water); cumulative 
arsenic exposure 
As in drinking water:
Tertiles:
- T1: <1 μg/L
	
- T2: 1–700 μg/L
	




- T1: <0.1 mg/L-year
- T2: 0.1–15.0 mg/L-year









- T2: 35–70 µg/L
 




carotid artery intima-media 
















Adjusted odds ratios (95% CI) for cumulative 
arsenic exposure:
- T1: 1.0
- T2: 1.1 (0.5, 2.1)
- T3: 1.9 (1.1, 3.1); p<0.05
Prevalence of carotid atherosclerosis was
increased in cases compared to controls
Adjusted odds ratios (95% CI) for arsenic in
drinking water:
- T1: 1
- T2: 3.04 (1.48, 6.24); p<0.01
- T3: 1.99 (0.90, 4.37)
Adjusted odds ratios (95% CI) for cumulative 
arsenic exposure:
- T1: 1
- T2: 2.20 (0.95, 5.09)
- T3: 2.74 (1.34, 5.60); p<0.01
A dose-response trend was positive for
arsenic cumulative exposure and carotid
atherosclerosis (p<0.003), but not for arsenic
concentration in drinking water and carotid 
atherosclerosis.
Compared to T1, T3 was associated with a 
0.058 mm increase in carotid intima-media 
thickness (p=0.003).  No association for
carotid intima-media thickness was observed 
T2.  Adjusted Betas (95% CI):
- T1: 1
- T2: 0.035 mm per µg/L (-0.0028–0.072);
p=0.070
- T3: 0.058 mm per µg/L (0.0198–0.095);
p=0.003




























   
  
  
   
   
 
   
  




















   
   
   
 
   
 
  
   
  
 
   




Table 3-2.  Cardiovascular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes














concentration in drinking 




- Q1: ≤10 μg/L
- Q2: 10.1–50 μg/L
- Q3: 50.1–100 μg/L
- Q4: 100.1–300 μg/L
- Q5: >300 μg/L
LMN cohort tertiles:
- T1: ≤300 μg/L
- T2: 300–750 μg/L










The risk of atherosclerosis was associated 
with increased arsenic concentration in 
drinking water for both low and high 
exposure cohorts.  A positive trend also was
observed for high, but not low, exposure 
cohort (p<0.05).
Adjusted odds ratios (95% CI) for Lanang 
cohort:
- Q1:1
- Q2: 2.68 (0.70, 9.56)
- Q3: 2.98 (1.21, 7.34); p<0.05
- Q4: 3.07 (1.23, 7.65); p<0.05
- Q5: 2.62 (1.04, 6.60); p<0.05




- T3: 2.78 (1.14–6.78); p<0.05
ANOVA = analysis of variance; As = arsenic; BMI = body mass index; CI = confidence interval; DMA = dimethylarsinic acid; HDL = high-density lipoprotein;
LDL = low-density lipoprotein; NHANES = National Health and Nutrition Examination Survey; SD = standard deviation
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(adjusted hazard ratio: 1.92; 95% CI: 1.07, 3.43). The Rahman et al. (2014) study (61,074 adults) found 
increased risk of death due to stroke in females (but not males) in association with drinking water
concentrations ≥50 μg/L (adjusted hazard ratio: 1.72; 95% CI: 1.15, 2.57).  A retrospective cohort study 
conducted in China (572 adults) found increased risk of death due to heart disease associated with 
exposure to drinking water concentrations >300 μg/L (adjusted incidence ratio risk: 5.08; 95% CI 1.45, 
17.81; Wade et al. 2009). Increased risk of cardiovascular death was also associated with urinary arsenic 
in a prospective cohort study conducted in the United States (3575 adults; Moon et al. 2013). The highest
risk was for stroke (adjusted hazard ratio: 3.03; 95% CI: 1.08, 8.50), which occurred in association with
urinary arsenic levels >15.7 μg/g creatinine.
Several studies have examined increased risk of nonfatal cardiovascular disease in humans exposed to
arsenic in drinking water (Chen et al. 2012b, 2013a, 2013c; Guha-Mazumder et al. 2012; Hawkesworth et
al. 2013; Hsieh et al. 2008b; Islam et al. 2012a; Jones et al. 2011; Li et al. 2009, 2013a, 2013b;
Morduhkovich et al. 2009; Osorio-Yanze et al. 2013; Wang et al. 2009a, 2011; Wu et al.2010).  
Morbidity outcomes have included coronary artery disease, stroke, increased blood pressure, and cardiac 
arrhythmias.  Increased risks occurred in association with drinking water arsenic concentrations and were
also associated with increased urinary arsenic levels.
Case-control studies have found increased risk of coronary artery disease in association with exposure to 
arsenic in drinking water (Hsieh et al. 2008b; Wu et al. 2010).  In the Hsieh et al. (2008b) study
(235 cases, Taiwan), occurrence of carotid atherosclerosis was associated with increasing well water
concentration and cumulative exposure.  Risk was elevated in association with well water concentrations
>50 µg/L (adjusted odds ratio: 2.4; 95% CI: 1.2, 4.6).  In the Wu et al. (2010) study (250 cases, Taiwan), 
risk of carotid atherosclerosis was elevated in association with drinking water concentrations of 50– 
100 µg/L (adjusted odds ratio: 2.98 (95% CI: 1.21, 7.34). Elevated risk of carotid atherosclerosis was 
also found in several cross-sectional cohort studies (Chen et al. 2013a; Li et al. 2009; Osorio-Yanze et al.
2013).  In the Li et al. (2009) study (adults; 145 exposed; 345 controls; Taiwan), the adjusted odds ratio 
for carotid atherosclerosis was 3.04 (95% CI: 1.48, 6.24) in association with drinking water arsenic levels
of 1–700 µg/L.  The Osorio-Yanze et al. (2013) study evaluated thickening of the carotid intima-media in 
children (199 children, Mexico) and found thickening to be significantly associated with urinary arsenic
levels. The estimated strength of the effect was a 58 µm increase per µg As/L urine (95% CI: 19.8, 95) in 
subjects who had urinary arsenic levels >70 µg/L.  Chen et al. (2013a) also found a significant association 
between carotid thickening and urinary arsenic levels (959 adults, Bangladesh). The effect size was 
11.7 µm per 357.8 µg As/g creatinine (95% CI: 1.8, 21.6).
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Associations between arsenic exposure in drinking water and cardiac arrhythmias have been studied in a 
prospective cohort study and in several cross-sectional cohort studies (Chen et al. 2013b; Morduhkovich 
et al. 2009; Wang et al. 2009a). The largest of the studies was a prospective cohort study conducted in
Bangladesh (1,715 adults; Chen et al. 2013b).  Risk of QTc interval prolongation was elevated in females 
(but not males).  The adjusted odds ratio in females was 1.24 (95% CI: 1.05, 1.47) for a 108.6 µg/L
increase in well water arsenic concentration and 1.24 (95% CI: 1.01, 1.53) for a 270.7 µg/g creatinine
increase in urinary arsenic level. Prolongation of QTc interval was also observed in a cross-sectional
cohort study (411 adults, Taiwan) in association with cumulative exposures to arsenic in drinking water 
over the range 0.1–>20 mg/L-year (Wang et al. 2009a).
Associations between arsenic in drinking water and blood pressure have been studied in cohort and case-
control studies. Outcomes evaluated have included increased blood pressure, increased pulse pressure, 
and hypertension (Chen et al. 2012b; Guha-Mazumder et al. 2012; Hawkesworth et al. 2013; Islam et al.
2012a; Jones et al. 2011; Kunrath et al. 2013; Li et al. 2013a, 2013b; Wang et al. 2011).  A case-control
study conducted in India (280 cases) found a significant association between cumulative exposure to 
arsenic in well water and hypertension (Guha-Mazumber et al. 2012).  The adjusted odds ratio for
hypertension associated with cumulative exposure >4.5 mg/L-year was 2.87 (95% CI: 1.26, 4.83). In a
prospective cohort study (352 adult subjects, Taiwan), risk of hypertension was elevated in association 
with urinary arsenic levels >2.67 µg/g creatinine (adjusted relative risk: 2.43; 95% CI: 1.10, 5.86; Wang
et al. 2011). Several cross-sectional cohort studies have also found significant associations between 
arsenic exposure and hypertension (Chen et al. 2012b; Kunrath et al. 2013; Li et al. 2013a, 2013b).  Chen 
et al. (2012b, 240 adults, Bangladesh) found elevated risk of hypertension in association with urinary
arsenic levels >8.0 µg/g creatinine (adjusted odds ratio: 3.0; 95% CI: 1.4, 6.3). Li et al. (2013a, 2013b) 
examined associations between risk of hypertension and drinking water arsenic concentration in two 
populations in China (669 and 604 adults).  In one population, risk of hypertension increased in 
association with drinking water arsenic concentrations >50 µg/L (adjusted odds ratio: 1.937; 95% CI:
1.018, 3.687; Li et al. 2013a).  In another population, risk of hypertension increased in association with 
cumulative drinking water arsenic exposure >0.35 mg/L-year (adjusted odds ratio: 1.871; 95% CI: 1.022, 
3.424; Li et al. 2013b). 
A prospective cohort study examined blood pressure outcomes children (4.5 years of ages) born in areas
with endemic contamination of well water (2,499 child-mother pairs, Bangladesh; Hawkesworth et al.
2013). Systemic and diastolic blood pressure in the children increased in association with both maternal
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and child urinary arsenic levels. The estimated effect size was an increase of 3.69 mmHg systolic (95%
CI: 0.74, 6.63) and 2.91 mmHg diastolic (95% CI: 0.41, 5.42) per mg/L increase in maternal urinary
arsenic. In relation to child urinary arsenic levels, the effect size was 8.25 mmHg systolic (95% CI: 1.37, 
15.1) and 2.75 mmHg diastolic (95% CI: -3.09, 8.59) per mg/L increase in urinary arsenic measured at
age 18 months.  A cross-sectional study (1,004 adults, Bangladesh) found increased risk of elevated pulse 
pressure (>55 mmHg) in association with drinking water arsenic concentrations of 23–32 µg/L (3.87;
95% CI: 1.22, 12.20; Islam et al. 2012a).  Adjusted odds ratios were 7.32 (95% CI: 2.18, 24.6) for
exposures to >262 µg/L.
Gastrointestinal Effects.
Inorganic Arsenicals. Epidemiological studies have examined effects of exposure to inorganic arsenic in 
drinking water on the gastrointestinal system (Majumdar et al. 2009; Syed et al. 2013).  Details of the
individual study designs and outcomes are provided in Table 3-3.  The prevalence of diarrhea was 
increased in a cross-sectional study (3,451 children and adults, India) (Majumdar et al. 2009).  Prevalence
odds ratios for males and females were 4.97 (95% CI: 2.0, 12.0) and 5.49 (95% CI: 2.7, 10.9), 
respectively, for drinking water concentrations ≥800 µg/L.  Results of a cross-sectional study in 
11,454 adults (Bangladesh) showed an increased risk of lesions of the gums and tongue at urine arsenic 
concentrations of 134–286 µg/g creatinine, but not at urine arsenic concentrations >286–5,000 µg/g 
creatinine (Syed et al. 2013).  Adjusted multinomial odds ratios for lesions of the gums and tongue were
2.90 (95% CI: 1.11, 7.54; p<0.05) and 2.79 (95% CI: 1.51, 5.15; p<0.01), respectively.
Musculoskeletal Effects.
Inorganic Arsenicals. Endochondrial ossification in rats was affected by exposure to inorganic arsenic in 
drinking water (Aybar Odstrcil et al. 2010).  Male Wistar rats were exposed to drinking water with 0 or
10 mg/L sodium arsenite (equivalent to 0.21 mg/kg body weight/day, as reported by study authors) for 45 
days.  Microscopic examination of sections of the tibia showed significant increases (p<0.05) in the
thickness of growth plate cartilage (124% of control) and the hypertrophic zone (113% of control) in 
arsenic-exposed rats, compared to controls. Bone volume and the number of circulating osteocytes were 
not affected by arsenic exposure.
Hepatic Effects.
Inorganic Arsenicals. The prevalence of hepatomegaly was investigated in a cross-sectional cohort
study of 3,825 children and adults (age range ≤9–≥60 years) exposed to arsenic in drinking water in India
(Majumdar et al. 2009).  The study authors did not report any adjustments for confounding factors.  









































   














Table 3-3.  Gastrointestinal Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes



















- Q1: 7–134 µg/g
- Q2: >134–286 µg/g
- Q3: >286–5,000 µg/g
Variables assessed: lesions of
the gums, lips, and tongue
Adjustments: study authors
state that adjustments to odds





A significant association between urinary 
arsenic concentrations for Q2 participants,
but not Q3 participants, for arsenical lesions
of the gums, compared to participants in Q1.
Adjusted multinomial odds ratio: 2.90; 95%
CI: 1.11–7.54; p<0.05.
A significant association between urinary
arsenic concentrations for Q2 participants,
but not Q3 participants, for arsenical lesions
of the tongue, compared to participants in 
Q1. Adjusted multinomial odds ratio: 2.79;
95% CI: 1.51, 5.15; p<0.01.
No statistically significant (p>0.05)
association between urinary arsenic
concentration and lesions of the lips were 
identified.





























   
  




















Table 3-3.  Gastrointestinal Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 










drinking water from wells
used by each participant.
As concentration: 
Quintiles:
Variables assessed: diarrhea as
reported to a physician
Adjustments: none reported
Analysis: Chi-square
The overall prevalence of diarrhea in male 
and female participants in Q5 was
significantly increased compared to Q1.  
Prevalence:
children and adults
(age range specified 
as ≤9–≥60 years); no 
participants had
arsenical skin lesions
Data collection period: 
not reported
- Q1: <50 µg/L
- Q2:59–199 µg/L
- Q3: 200–499 µg/L
- Q4: 500–799 µg/L
- Q5: ≥800 µg/L
- males: 4; p=0.01
- females: 3.8; p=0.04
Prevalence odds ratios (95% CI):
- males:  4.97 (2.0, 12.0)
- females: 5.49 (2.7, 10.9)
AS = arsenic; CI = confidence interval






    




   
       
   
       
  
     
    
     
  
  
        
   
   
    
    
    




     
  
  
      
     
       
       




Prevalence odds ratios were increased for drinking water concentrations ≥500 µg/L in males (5.13; 95%
CI: 3.4, 7.6) and females (4.34; 95% CI: 2.8, 6.5), compared to controls exposed to <50 µg/L.
Renal Effects.
Organic Arsenicals. Effects of subchronic exposure to methylated arsenic metabolites in drinking water
on the bladder urothelium have been studied in F344 rats (Shen et al. 2006; Wang et al. 2009b).  Shen et
al. (2006) exposed male and female rats to drinking water containing 0, 187 mg/L monomethylarsonic
acid [MMA(V)], 184 mg/L dimethylarsinic acid [DMA(V)], or 182 mg/L trimethylarsine oxide (TMAO)
for 13 weeks.  Examination of the urothelium by scanning electron microscopy showed that rats exposed
to MMA(V) or TMAO were similar in appearance to controls.  In rats exposed to DMA(V), the 
urothelium showed several pathological changes including leafy or ropy microridges, short uniform
microvilli, and pleomorphic microvilli exfoliation, necrosis, and epithelial separation. In
DMA(V)-exposed rats, the average urothelial lesion severity score in females was 83% higher than the
score in males, indicating that females rats are more sensitive than rats to DMA(V)-induced bladder
toxicity. Similar effects were observed in female rats exposed to 0, 1, 4, 40, or 100 mg/L DMA(V) for
13 weeks (Wang et al. 2009b).  Examination of the urinary bladder by light microscopy showed 
vacuolization and nuclear hyperchromatin in the transitional epithelium for all exposure groups, with a
dose-dependent increase in incidence.  Electron microscopy of rats exposed to 100 mg/L revealed sites of
necrotic and exfoliated cells of the transitional epithelium and round superficial transitional cells of
variable size with polymorphic microvilli (an indication of regeneration and hyperplasia).  Rats exposed
to 1–40 mg/L were similar in appearance to controls.
Endocrine Effects.
Inorganic Arsenicals. Several case-control and cross-sectional cohort studies have examined
associations between exposure to inorganic arsenic in drinking water and diabetes (Chen et al. 2010c, 
2011a, 2012a; Coronado-Gonzolez et al. 2007; Del Razo et al. 2011; Gribble et al. 2012; Islam et al. 
2012b; James et al. 2013; Kim and Lee 2011; Kim et al. 2013; Li et al. 2013a; Navas-Acien et al. 2008,
2009; Pan et al. 2013; Rhee et al. 2013; Steinmaus et al. 2009). A prospective cohort study evaluated the 
association between arsenic exposure and impaired glucose tolerance during pregnancy (Ettinger et al.
2009). Details of the individual study designs and outcomes are provided in Table 3-4. Most, but not all, 
studies found an increased risk of diabetes in association with exposures to arsenic in drinking water
and/or urinary arsenic concentrations.
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Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 













11,319 participants in 
HEALS 








Data collection period: 
2002–2005 







Data collection period: 
2003
Exposure measures: 
arsenic in drinking water
from 5,966 area wells and 
arsenic concentration in 
urine
As concentration range: 
- range in drinking 
water: 0.1–864 µg/L
- range in urine: 1– 
205 µg/L
Exposure measures: 





- Q1: ≤35 µg/g
- Q2: >35–75 µg/g
- Q3: >75–200 µg/g
- Q4: >200 µg/g
Exposure measures: 






- T2: 63.5–104 µg/g
- T3: >104 µg/g
Variables assessed: self-
reported physician diagnosis of








(fasting plasma glucose 
≥126 mg/dL or treatment with 
diabetic therapy)







of diabetes (fasting glucose
values 126 mg/100 mL or a
history of diabetes treated with 
insulin or oral hypoglycemic
agents)
Adjustments: age, sex,
hypertension, family history of




No association or dose-response trends
were observed between arsenic
concentration in drinking water or urine and 
the prevalence of diabetes mellitus or
glucosuria.
For subjects in Q3 and Q4, the risk for type 
2 diabetes was increased approximately
2-fold compared to Q1.  A dose-response 
relationship was observed (p<0.05).
Adjusted odds ratios (95% CI):
- Q3: 2.08 (1.05, 3.69)
- Q4: 2.22 (1.21, 4.09)
Compared to T1, urine arsenic
concentrations of arsenic for T2 and T3 were 
associated with an increased risk of
diabetes.  Adjusted odds ratios (95% CI):
- T2: 2.16 (1.23, 3.79)
- T3: 2.84 (1.64, 4.92)
























































    
 
 
   
 
   
 
   
 
     




Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Del Razo et al. Study design: cross- Exposure measures: Variables assessed: fasting A positive association was observed 
2011 sectional arsenic concentration in blood glucose (FBG), fasting between arsenic concentration in drinking 
Location: Mexico main drinking water source plasma insulin (FPI), oral water and urine levels of DMA (but not total
Population: 258 male for participant; arsenic glucose tolerance oral (OGTT), arsenic) and the prevalence of diabetes.
and female children concentration (total and glycated hemoglobin (HbA1c), Adjusted odds ratios (95% CI):
(28% ≤18 years old) metabolites) in urine insulin resistance (IR) - drinking water: 1.13 (1.05, 1.22); p<0.01
and adults (72% As concentration range: Adjustments: age, sex, - urine DMA: 1.24 (1.00, 1.55); p=0.05
>18 years old) Drinking water: hypertension, obesity
Data collection period: - range: 3.1–215.2 µg/L Analysis: log-transformed linear Negative associations were observed for
not reported - geometric mean regression arsenic concentration in drinking water and
(GSD): 24.4 (2.9) µg/L for concentration of total arsenic in urine.
Urine: Results indicate that different arsenic­
- range total arsenic: induced diabetes has a different underlying 
2.3–233.7 ng/mL mechanism that type 2 diabetes
- geometric mean (characterized by insulin resistance).
(GSD): 24.7 (2.8) Adjusted beta (95% CI:
ng/mL - FPI (drinking water) =: -2.084 (-2.720,
- range DMA: 0– -1.448); p<0.01
64.8 ng/mL - IR (drinking water): -1.641 (-2.358,
- geometric mean -0.924); p<0.01
(GSD): 0.9 (3.2) ng/mL - FPI (total arsenic in urine:
-5.313 (8.068, -2.559); p<0.01
- IR (total arsenic in urine): -4.538 
(-7.514, -1.562); p<0.01











































































     
  
    
  









Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 












3,925 male (41%) and 
female (59%) adults
from Native American 
communities























- Q1: <7.9 µg/L
- Q2: 7.9–<14.0 µg/L
- Q3: 14.1–<24.1 µg/L
- Q4:≥24.2 µg/L
Exposure measures: 





- Q1: 10–22 µg/L
- Q2: 23–32 µg/L
- Q3: 33–261 µg/L
- Q4: ≥262 µg/L
Variables assessed: diabetes
(fasting plasma glucose 
≥126 mg/dL, 2-hour glucose 
level






Analysis: Poisson regression 
models
Variables assessed: diagnosis
of diabetes (fasting blood
glucose >126 mg/dL or self-
reported physician diagnosis
of type 2 diabetes)
Adjustments: age, sex,




The prevalence of diabetes was associated 
with urine total arsenic concentration in Q2– 
Q4, although the association was restricted 
to participants with poorly controlled 
diabetes (i.e., HbA1c ≥8%. Adjusted
prevalence ratios (95% CI):
- Q2: 1.15 (1.04, 1.27)
- Q3: 1.21 (1.08, 1.34)
- Q4: 1.28 (1.14, 1.44)
For data stratified into two groups by arsenic
concentration in drinking water (referents:
<50 µg/L; exposed: ≥50 µg/L), exposure was
associated with an increase in the risk of
diabetes of 2.1-fold. Adjusted odds ratios:
- <50 µg/L: 1
- >50 µg/L: 2.1 (95% CI: 1.3, 3.2)
For data stratified into quartiles, an 
association for arsenic exposure and the risk
of diabetes was observed Q4 compared to 
Q1 (adjusted OR: 1.9; 95% CI: 1.1–3.5), but 
not Q2 and Q3 compared to Q1. A positive
trend (p<0.01) was observed across 
quartiles.













































   
   
 







































   
  
   
  






Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
James et al.
2013
Kim and Lee 
2011
































Data collection period: 
2007–2009 
Exposure measures: 
arsenic concentration in 
drinking water in individual
residences; TWA exposure 
As concentration in drinking 
water:





- Q1: 1–<4 µg/L-year
- Q2: ≥4–<8 µg/L-year
- Q3: ≥8–<20 µg/L-year
- Q4: ≥20 µg/L-year
Exposure measures: 
























(self-reported diagnosis with 
medical record verification,




ethnicity, BMI, physical activity
level
Analysis: Cox proportional 
hazards model
Variables assessed: diagnosis
of diabetes (fasting serum
glucose ≥126 mg/dL, self-
reported physician diagnosis of
diabetes, or self-reported use of
insulin or oral hypoglycemic
medication)
Adjustments: age, sex, BMI,
smoking, alcohol use,
education, hypertension,
regional area, residential area,
seafood consumption
Analysis: multiple regression 
analysis
A significant association was observed 
between arsenic exposure and risk of
diabetes.  For each 15 µg/L increase in TWA
arsenic exposure, the risk of diabetes
increases by 27%. Adjusted hazard ratio:
1.27 (95% CI: 1.01, 1.59); p=0.04
For exposure based on quartiles, significant
 
adjusted hazard ratios (95% CI) were 

observed Q4, but not Q2 or Q3 compared to 









Based on continuous exposure, total urinary
 
arsenic was associated with diabetes in 

combined male and female and in female 

participants, but not in male participants.

Adjusted odds ratio (95% CI):
 
- combined: 1.312 (1.040, 1.655)
- males: 1.126 (0.803, 1.577)
- females: 1.502 (1.038, 2.171)
Results indicate that a doubling of urinary
arsenic (log-transformed) in females and in 
combined males and females is associated 
with an increased risk of diabetes of
approximately1.5 and 1.3, respectively.













































Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Kim et al.
2013









Data collection period: 
1982–2007
Exposure measures: 
arsenic concentration in 
urine, adjusted for creatinine 
[Note: units as reported in 
the publication (µg/L) are 
not typical for urine 




- total arsenic: 6.6– 
Variables assessed: diagnosis
of diabetes (2-hour post-load
plasma glucose following a 
75-g oral glucose tolerance test
of ≥200 mg/dL)
Adjustments: age, sex, BMI
Analysis: logistic regression
Risk for diabetes was not significantly
elevated for total arsenic or inorganic
arsenic in urine.  Adjusted odds ratio (95%
CI):
- Total arsenic: 1.11 (0.79, 1.57)
- Inorganic arsenic: 1.16 (0.89, 1.53)
123.1 µg/L
- inorganic arsenic: 0.1– 
36.0 µg/L





































































    
   
 





Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes








men (43%) and 
women (57%)























- T1: <10 µg/L
- T2: 10–50 µg/L
- T3: >50 µg/L
Exposure measures: 




20th percentile: 3.0 µg/L
80th percentile: 16.5 µg/L
Tertiles:
- T1: <4.8 µg/L
- T2: 4.8–10.8 µg/L








of diabetes (defined as fasting 
serum glucose level
≥126 mg/dL, self-reported 
physician diagnosis of diabetes,




education, BMI, hypertension 
medication use, urine markers
of seafood intake
Analysis: logistic regression
No significant association was observed 
between arsenic exposure and type 2 
diabetes.  Adjusted odds ratios (95’% CI):
- T2: 1.362 (0.519, 3.571)
- T3: 1.578 (0.584, 4.262)
Total urine arsenic for the 80th percentile 
was associated with an increased 
prevalence of type 2 diabetes.  Adjusted 
odds ratios (95 CI):
- 20th percentile: 1.05 (0.57, 1.94)
- 80th percentile: 3.58 (1.18, 10.83)
A significant trend was observed for tertiles
(p=0.03), although adjusted odds ratios were 
not significant based on intertertile 
comparison.
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Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Navas-Acien Study design: cross- Exposure measures: Variables assessed: diagnosis Total urine arsenic for the 80th percentile 
et al. 2009 sectional arsenic concentration in of diabetes (defined as fasting was associated with an increased 
Location: US urine serum glucose level prevalence of type 2 diabetes.  Adjusted odd 
Population: 





20th percentile: 3.4 µg/L
80th percentile: 17.2 µg/L
≥126 mg/dL, self-reported 
physician diagnosis of diabetes,
or self-reported use of insulin or
oral hypoglycemic medication)
ratios (95% CI):
- 20th percentile: 1
- 80th percentile: 2.86 (1.23, 6.63)
diabetes; aged Adjustments: age, sex, For a subset of participants with
≥20 years) race/ethnicity, urine creatinine, undetectable arsenobetaine, an association
Data collection period: urine arsenobetaine, blood was observed between arsenic in urine and 
2003–2006 mercury the prevalence of diabetes.  Adjusted odds
Analysis: not reported ratios (95% CI)
- 20th percentile: 1
- 80th percentile: 2.60 (1.12, 6.03)




























































Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Pan et al. Study design: case Exposure measures: Variables assessed: diagnosis
2013 control arsenic concentration in of diabetes (based on 
Location: Bangladesh drinking water and toenails hemoglobin A1c levels ≥6.5%)
Population: adult for each participant Adjustments: age, sex, BMI,
males and females; Drinking water (µg/L): smoking, skin lesions, arsenic
84 cases, - mean±SD, controls: in drinking water, arsenic in
849 controls 142±278.1 toenails
Data collection period: - mean±SD, exposed: Analysis: logistic regression
2001–2011 202.4±277.2 
Quartiles:
- Q1: ≤1.7 µg/L
- Q2: 1.8–15.5 µg/L
- Q3: 15.6–170 µg/L







- Q1: ≤0.93 µg/g
- Q2: 0.94–2.12 µg/g
- Q3: 2.13–6.18 µg/g
- Q4: ≥6.19 µg/g
An association was observed between 
exposure to arsenic in drinking water (Q3 
and Q4 compared to Q1) and in toenails
(Q2–Q4 compared to Q1) and increased risk
of diabetes.
Drinking water adjusted odds ratios (95%
CI):
- Q3: 3.07 (1.38, 6.85)
- Q4: 4.51 (2.01, 10.09)
Toenail adjusted odds ratios (95% CI):
- Q2: 3.34 (1.46, 7.64)
- Q3: 3.40 (1.46, 7.89)
- Q4: 6.22 (2.63, 14.69)


























   
 
  

























































Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 























males (53%) and 
females (47%)
Data collection period: 
2003–2004
Exposure measures: 






- Q1: <70.7 µg/g
- Q2: 70.7–117.7 µg/g
- Q3: 117.7– 
<193.4 µg/g
- Q4: ≥193.4 µg/g
Exposure measures: 











- T1: ≤5.2 µg/L
- T2: 5.3–11.8 µg/L




- T1: ≤2.7 µg/L
- T2: 2.8–5.0 µg/L
- T3: >5.0 µg/L
Variables assessed: diagnosis
of diabetes (self-reported 
physician diagnosis or
treatment with insulin or oral
antidiabetic medication);
glucose tolerance test, insulin
resistance test, insulin secretion 
capacity





Analysis: logistic regression (for
risk of diabetes based on 





physician diagnosed or use of
insulin or other antidiabetic
medications)
Adjustments: sex, age,
ethnicity, BMI, serum cotinine,
current use of hypertensive
medication
Analysis: logistic regression
Arsenic exposure is associated with 
increased risk of diabetes for Q4, but not Q2 
or Q3, compared to Q1.  A positive trend 
across quartiles was observed (p=0.009).
Adjusted odd ratios (95% CI):
- Q3: 1.42 (0.94, 2.13)
- Q4: 1.56 (1.03, 2.36)
No evidence of increased risk of diabetes for
T2 or T3 compared to T1 was observed 
using total urinary arsenic or inorganic
arsenic.








































    
  
    










Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Metabolic syndrome
Chen et al. Study design: case- Exposure measures: Variables assessed: metabolic Adjusted odds ratios were not significant for
2012a control drinking water (measured in syndrome (a strong predictor of an association between arsenic drinking 
Location: Taiwan
Population: adult
village wells) and 
cumulative exposure
type 2 diabetes); defined as the 
presence of three or more of
water concentration or cumulative arsenic
exposure and increased risk of metabolic
males and females; As concentration: the risk factors: fasting plasma syndrome.
exposed 111; controls Drinking water tertiles: glucose (≥110 mg/dL),
136 - T1: <700 µg/L triglycerides (≥150 mg/dL), HDL 
Data collection period: 
2002–2003
- T2: 700–767.65 µg/L
- T3: >767.65 µg/L
(≤40 mg dL for men and 
≤50 mg dL for
Cumulative exposure women),increased systolic
- T1: <12.60 µg/L-year (≥130 mm Hg) or diastolic
- T2: 12.60–18.90 µg/L­ (≥85 mm Hg) blood pressure,
year and waist girth (≥90 cm for men 
- T3: >18.9 µg/L-year and ≥80 cm for women).

































































   
 
   
 
     




Table 3-4.  Endocrine Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Impaired glucose tolerance during pregnancy
Ettinger et al. Study design: Exposure measures: Variables assessed: glucose Arsenic concentration in blood was
2009 prospective cohort arsenic concentration in tolerance test (impair glucose associated with an increased risk of
Location: United blood (collected at delivery) tolerance defined as blood impaired glucose tolerance at 24–28 weeks
States (Oklahoma) and hair glucose level of >140 mg/dL of gestation for Q3 and Q4, compared to Q1.
Population: Blood As: 1 hour after oral challenge with Adjusted odds ratios (95% CI):
532 pregnant women, Range: 0.2–24.1 µg/L 50-g oral glucose - Q3: 2.65 (1.12, 6.36)
examined during Mean±SD:1.7±1.5 Adjustments: age, Native - Q4: 2.79 (1.13, 6.87)
weeks 24 and 28 of Quartiles: American race, pre-pregnancy 
gestation - Q1: 0.23–0.92 µg/L BMI, Medicaid use, marital Arsenic concentration in blood was
Data collection period: - Q2: 0.93–1.39 µg/L status significantly correlated with 1-hour blood 
2002–2008 - Q3: 1.40–2.08 Analysis: multivariate logistic glucose levels (p=0.02).  An interquartile 
- Q4: 2.09–24.07 regression increase in blood arsenic concentration of
Reporting discrepancy 1.2 µg/L was associated with 1.76 times
noted for maximum higher odds of impaired glucose tolerance.
concentration and upper
value for the highest quartile No correlation was observed for arsenic
concentration in hair (p=0.08) and 1-hour
Hair As (range): blood glucose levels. Blood and hair levels
1.1–724.4 ng/g of arsenic were not significantly correlated 
(p=0.08) with each other.
As = arsenic; BMI = body mass index; CI = confidence interval; DMA = dimethylarsinic acid; GSD = geometric standard deviation; HEALS =  Health Effects for
Arsenic Longitudinal Study; KNHANES = Korea National Health and Nutrition Examination Survey; NHANES = National Health and Nutrition Examination Survey
SD = standard deviation; TWA = time-weighted average
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A case-cohort study conducted in Colorado (141 adult cases) found a significant association between 
exposure to arsenic in drinking water and the risk of diabetes (James et al. 2013). For exposure based on 
time-weighted average drinking water concentrations ≥20 µg/L-year, the adjusted hazard ratio for
diabetes was 1.55 (95% CI: 1.00, 2.51). In a case-control study conducted in Mexico (200 adult cases),
adjusted odds ratios were 2.16 (95% CI: 1.23, 3.79) and 2.84 (95% CI: 1.64, 4.92) for urine arsenic
concentrations of 63.5–104 and >104 µg/g creatinine, respectively (Coronado-Gonzales et al. 2007).
Increased risk of diabetes was also observed in a case-control study conducted in Bangladesh (84 adult
cases, Pan et al. 2013). Adjusted odds ratios of 3.07 (95% CI: 1.38, 6.85) and 4.51 (95% CI: 2.01, 10.09)
were observed for drinking water arsenic concentrations of 15.6–170 and ≥170 µg/L, respectively.
Several cross-sectional cohort studies also found significant associations between arsenic exposure and
diabetes (Chen et al. 2011a; Del Razo et al. 2011; Gribble et al. 2012; Islam et al. 2012b; Kim and Lee
2011; Navas-Acien et al. 2008, 2009; Rhee et al. 2013). Risk estimates in these studies ranged from
1.13 (95% CI: 1.05, 1.22) based on drinking water concentration of arsenic (Del Razo et al. 2011) to 
3.58 (95% CI: 1.18, 10.83) based on urine arsenic concentrations (Navas-Acien et al. 2008). 
A prospective cohort study of 532 pregnant women from Oklahoma showed a significant association 
between arsenic concentration in blood and impaired glucose tolerance during weeks 24–28 of gestation 
(Ettinger et al. 2009). Adjusted odds ratios were 2.65 (95% CI: 1.12, 6.36) and 2.79 (95% CI: 1.13, 6.87)
for blood arsenic concentrations of 1.40–2.08 and 2.09–24.07 µg/L, respectively. An interquartile
increase in blood arsenic concentration of 1.2 µg/L was associated with 1.76 times higher odds of
impaired glucose tolerance.
Dermal Effects.
Inorganic Arsenicals. Skin lesions are one of the most common and characteristic effects of arsenic 
ingestion in humans.  Dermal effects include generalized hyperkeratosis and formation of hyperkeratotic
warts or corns on the palms and soles, along with areas of hyperpigmentation interspersed with small
areas of hypopigmentation on the face, neck, and back.  Recent epidemiological studies provide
additional evidence of adverse dermal effects associated with exposure to arsenic-contaminated drinking 
water (Argos et al. 2011; Barati et al. 2010; Fatmi et al. 2009, 2013; Hashim et al. 2013; Li et al. 2013a;
Lindberg et al. 2008; Melkonian et al. 2011; Pesola et al. 2012; Pierce et al. 2011; Xia et al. 2009).
Ocular Effects.
Inorganic Arsenicals. Ocular effects of exposure of humans to drinking water have been studied in
cross-sectional and cross-sectional cohort studies (Ghosh et al. 2007; Lin et al. 2008; Paul et al. 2013b; 






    
   
     
 
   
    
  
     
      
    
    
 
 
   






       
      
   
   
   
  
  
   
       
    
    




See et al. 2007).  These studies have shown associations between exposure to arsenic in drinking water
and increased risk ocular effects, including conjunctivitis, cataract/ocular opacity, and pterygium.  Details
of the individual study designs and outcomes are provided in Table 3-5.
Studies evaluating the risk of conjunctivitis show an increased risk at mean arsenic drinking water
concentrations >39.94 µg/L, with risk estimates ranging from 4.66 (95% CI: 2.45, 8.85) for exposure to a
mean arsenic concentration in drinking water of 186.89 µg/L to 37.22 (95% CI: 20.56, 67.36) for
exposure to a mean arsenic concentration in drinking water of 200.83 µg/L (Ghosh et al. 2007; Paul et al. 
2013b). Ghosh et al. (2007) reported a positive trend for increasing risk with increasing drinking water
arsenic level (p<0.001). In a study conducted in Taiwan (349 adults), a dose-response relationship
(p<0.05) between cumulative arsenic exposure and posterior subcapsular opacity was observed (See et al.
2007).  Adjusted odds ratios for cumulative exposure to 12.1–20 and >20 mg/L-year were 4.78 (95% CI: 
1.03, 22.18) and 5.70 (95% CI: 1.23, 26.32), respectively.  A cross-sectional study in adults (223; 
Taiwan) showed that an increased cumulative exposure to arsenic in drinking water was associated with 
an increase in the prevalence of pterygium (Lin et al. 2008).  Adjusted odds ratios for cumulative
exposure to 0.1–15.0 and >15.1 mg/L-year were 2.04 (95% CI: 1.04, 3.99) and 2.88 (95% CI: 1.42, 5.83), 
respectively.
3.2.2.3 Immunological and Lymphoreticular Effects
Inorganic Arsenicals. Effects of exposure to arsenic in drinking water on immunological function was
investigated in a cross-sectional study in of 577 children (mean age 4.5 years) in Bangladesh (Ahmed et
al. 2014).  Following adjustments for age, gender, and socio-economic status, the delayed hypersensitivity
response following intradermal challenge with purified protein derivative was negatively associated with
urine arsenic concentrations of 126–1,228 µg/L, (adjusted risk ratio: 1.37; 95% CI: 1.07, 1.74) compared 
to the control group with urine arsenic concentrations of 12–34 µg/L.  A statistically significant (p=0.003)
trend across the urine concentration range of 35–1,228 µg/L was observed.  Associations also were
observed between the urine concentration range of 107–1,228 µg/L and decreasing plasma concentrations 
of cytokines IL-2 (adjusted beta: -1.57; 95% CI: -2.56, -0.57) and TNF-α (adjusted beta: -4.53; 95% CI:
-8.62, -0.42).  Results are consistent with effects on cell-mediated immunity. In addition, epidemiological
studies have found associations between maternal exposure to arsenic in drinking water and susceptibility
to infections and thymic function of infants; results of these studies are reviewed in Section 3.2.2.6 
(Developmental Effects).
























   
 





























































Table 3-5. Ocular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 










(373 with skin lesions,
352 without skin 
lesions), 389 controls;












period: Data were 
collected from same 
participants for two
time periods: 2005– 
2006 and 2010–2011
Exposure measures: 
arsenic concentration in 







- control: 6.97±2.10 µg/L
- cases (no skin lesions):
186.89±124.67 µg/L

















reported history of conjunctivitis
Adjustments: age, sex, smoking
Analysis: logistic regression
Variables assessed: 
conjunctivitis (not caused by
bacterial or viral infections or
allergens), diagnosed by an 
ophthalmologist
Adjustments: none
Analysis: ratio of incidence in 
exposed to control groups
Exposure to arsenic in drinking water was
associated with a higher risk of conjunctivitis
compared to controls.  Exposed participants
with skin lesions had a higher risk of
developing conjunctivitis than those without
skin lesions: Adjusted odds ratios (95% CI):
- Controls: 1
- Cases (no skin lesions): 4.66 (2.45,
8.85)
- Cases (with skin lesions): 37.22 (20.56,
67.36)
A trend test for odds ratios was statistically
significant (p<0.001).
The risk of development of conjunctivitis was
significantly increased in cases compared to 









- cases: 20.51 (9.84, 42.72)























































































Table 3-5. Ocular Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Cataracts/ocular opacity
A dose-response relationship (p<0.05)
between cumulative arsenic exposure and 
posterior subcapsular opacity was observed.
Adjusted odd ratios (95% CI):
- Q1: 1
- Q1: 2.19 (0.40, 12.07)
- Q3: 4.78 (1.03, 22.18); p<0.05
- Q4: 5.70 (1.23, 26.32); p<0.05
Adjusted odds ratios were not statistically
significant for cortical opacity, nuclear












arsenic exposure; eye 
examinations
conducted in 1996 
Exposure measures: 
drinking water, expressed 
as cumulative arsenic
exposure, based on well





- Q1: 0.1–12 mg/L-year
- Q3: 12.1–20 mg/L-year
- Q4: >20 mg/L-year
Variables assessed: cortical 
opacity, nuclear opacity, overall
cataracts, posterior subcapsular
opacity, as diagnosed by an 
ophthalmologist
Adjustments: age, sex, diabetes















drinking water, expressed 
as cumulative arsenic
exposure, based on well
water concentration and 
time of residence













Increased cumulative exposure to arsenic in 
drinking water was associated with a 
significant increase in the prevalence of
pterygium.  Adjusted odds ratios (95% CI):
- <0.1 mg/L-year: 1
- 0.1–15.0 mg/L-year: 2.04 (1.04, 3.99),
p<0.05
- ≥15.1 mg/L-year: 2.88 (1.42, 5.83);
p<0.05
As = arsenic; CI = confidence interval






    
   







     
     
      
     
     
    
  
    
   
 
    
   
      
 
  
     
      
   






A study in animals provides evidence of immune effects following intermediate-duration exposure to oral
arsenic (Ezeh et al. 2014).  Exposure of male C57BL/6J mice to drinking water concentrations of 19, 75, 
or 300 µg As/L (as sodium arsenite) for 30 days suppressed humoral immunity. The T-dependent
antibody response to sheep red blood cells was significantly (p<0.05) decreased by approximately 55 and 
49% of control in the 75 and 300 µg/L groups, respectively.  Lymphoid progenitor cells were more
sensitive to effects of arsenic than myeloid progenitor cells.
3.2.2.4 Neurological Effects
Inorganic Arsenicals. Several epidemiological studies have examined effects of exposure to inorganic
arsenic in drinking water on the neurological system using cross-sectional or cross-sectional cohort study
designs (Ali et al. 2010; Ghosh et al. 2007; Guo et al. 2007; Li et al. 2006; Paul et al. 2013b; Tseng et al.
2006). Details of the individual study designs and outcomes are provided in Table 3-6.  These studies 
found increased risks in association with exposures to arsenic in drinking water and/or urinary arsenic
concentrations for decreased plasma cholinesterase activity, decreased peripheral nerve conduction
velocity, peripheral neuropathy, and altered sensory function.  In addition, effects on neurological
function and development have been observed in children exposed to arsenic in utero and early life; 
results of these studies are reviewed in Section 3.2.2.6 (Developmental Effects).
In a cross-sectional study conducted in Bangladesh (141 adults), a significant, negative correlation was
observed between plasma cholinesterase activity and arsenic concentration in drinking water (Spearman
correlation coefficient: 0.52; p<0.001) (Ali et al. 2010). A cross-sectional study of 130 adolescents in
Taiwan showed an association between exposure to drinking water concentration >50 µg/L and decreased 
nerved conduction velocity (adjusted odds ratio: 7.8; 95% CI: 1.001, 69.5) (Tseng et al. 2006).  Exposure
to arsenic in drinking water was associated with increased risk of peripheral neuropathy in adults in India
and China (Ghosh et al. 2007; Li et al. 2006; Paul et al. 2013b). Increased risk of peripheral neuropathy
was observed at mean drinking water concentrations ranging from 37.94 to 200.83 µg/L (Ghosh et al. 
2007; Paul et al. 2013b) and at a drinking water concentration range of 400–700 µg/L (Li et al. 2006).  A 
cross-sectional cohort study conducted in China (680 exposed) showed significant increases in the
incidence of hearing loss (p=0.005), loss of taste (p=0.001), and blurred vision (p<0.001) in participants 
exposed to an arsenic drinking water concentration >50 µg/L, compared to participants (189) exposed to
≤50 µg/L (Guo et al. 2007).
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Table 3-6.  Neurological Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Enzyme activity
Ali et al. 2010 Study design: cross- Exposure measures: Variables assessed: plasma A statistically significant, negative correlation 
sectional arsenic concentration in cholinesterase activity (PChE) was observed between PChE activity and 
Location: Bangladesh water (tube wells for Adjustments: arsenic concentration in water (rs=-0.52;
Population: individual households or Analysis: Spearman correlation p<0.001), hair (rs=-0.47; p<0.001) and nails
141 participants; communities), hair, nails coefficient (rs) test (rs=-0.35; p<0.001).
89 male and As concentration: 
52 female; mean age: Water (mean±SD): PChE activity was significantly lower (23%
37.7 years (range not - 224.92±57.20 µg/L decrease; p<0.001) for participants with
reported) Hair (mean±SD): exposure to arsenic water concentrations
Data collection period: - 5.27±7.06 µg/g >50 µg/L compared to those with exposure 
not reported Nails (mean±SD): to ≤50 µg/L. PChE activity was also 
- 7.51±7.64 µg/g significantly lower (20% decrease; p<0.001)
in participants with arsenic-induced skin 
lesion compared to those without lesions.
Peripheral neuropathy/conduction velocity
Ghosh et al. Study design: cross- Exposure measures: Variables assessed: peripheral Exposure to arsenic in drinking water was
2007 sectional cohort arsenic concentration in neuropathy assessed by pain associated with a higher risk of peripheral







participants with skin lesions had a higher
risk of developing peripheral neuropathy
(373 with skin lesions, As concentration:  anesthesia, hypoesthesia, than those without skin lesions: Adjusted 
352 without skin Range (all participants): decreased reflects as assessed odds ratios (95% CI):
lesions), 389 controls; - 0–1,188 µg/L by a neurologist - controls: 1
age range: 15– Mean±SD: Adjustments: age, sex, smoking - cases (no skin lesions): 3.99 (1.95,
70 years
Data collection period: 
- Control:
6.97±2.10 µg/L
Analysis: logistic regression 8.09)
- cases (with skin lesions): 15.61 (8.2,
2003–2005 - Cases (no skin 29.71)
lesions):
186.89±124.67 µg/L A positive trend for increasing risk of
- Cases (with skin 
lesions):
peripheral neuropathy with increased
concentration of arsenic in drinking water
200.83±145.83 µg/L was observed (p<0.001).





















































































Table 3-6.  Neurological Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes







Data collection period: 
not reported
Paul et al.	 Study design: cross­
2013b	 sectional cohort
Location: India
Population: male and 




Data collection period: 
Data were collected 
from same
participants for two
time periods: 2005– 
2006 and 2010–2011
Exposure measures: 





- T1: 0–20 µg/L
- T2: 100–300 µg/L











- controls: 3.7±3.0 µg/L




symptoms (amnesia, impaired 
autonomic nervous system
[ANS], headache, hearing loss,
impaired heat/cold sensation,
numbness, pain, impaired 
sense of smell, impaired 
vibration sensation), pin prick







neurological symptoms (muscle 
cramps, numbness, pain,
paraesthesias of stocking and 
glove regions), assessed by a 
neurologist
Adjustments: none
Analysis: ratio of incidence in 
exposed to control groups
The incidence if self-reported neurological
symptoms was significantly (p<0.05)
elevated in the T3, relative to T1, for pain 
and impaired vibration sensation, but not for
other self-reported symptoms.  No 
statistically significant increases for self-
reported neurological symptoms were 
observed for T2 compared to T1.
The probability of an increased pin prick
score for arms and legs was significantly
increased (p>0.005) T3, but not T2,
compared to T1.
The risk of development of peripheral
neuropathy was significantly increased in 
cases compared to controls for both 
collection periods.  Odds ratios (95% CI):
2005–2006:
- controls: 1
- exposed: 9.08 (3.48, 23.72)
2010–2011:
- controls: 1
- exposed: 18.48 (7.75, 44.06)


































































   
 
  
   
 
  
   
 
   





Table 3-6.  Neurological Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Tseng et al. Study design: cross- Exposure measures: Variables assessed: sural A significant (0.01≤p<0.05) association was
2006 sectional arsenic concentration in sensory action potential nerve observed between exposure to a cumulative 
Location: Taiwan drinking water; cumulative conduction velocity arsenic dose for T3, but not T2, and 
Population: dose of arsenic Adjustments: gender, height decreased conduction velocity. Adjusted 
130 adolescents, As concentration:  Analysis: multiple logistic odds ratio: 2.9 (95% CI: 1.1, 7.5).
ages 12–14 years Drinking water tertiles: regression
Data collection period: - T1: ≤10 µg/L For drinking water concentration, a
not reported - T2: 10–50 µg/L significant (0.01≤p<0.05) decrease in nerve 
- T3: >50 µg/L conduction velocity was observed in T3, but
Cumulative arsenic dose not T2, compared to T1.  Adjusted odds
tertiles: ratio: 7.8 (95% CI: 1.001, 69.5).
- T1: ≤50.0 mg
- T2: 50.1–100.0 mg
- T3: >100.0 mg
Sensory function
Guo et al. Study design: Cross- Exposure measures: Variables assessed: loss of The incidence of hearing loss, loss of taste,
2007 sectional cohort arsenic concentration in hearing, loss of taste, blurred blurred vision, and numbness of limbs was
Location: drinking water from primary vision, and numbness of limbs, significantly increased in cases compared to 
Population: exposed: drinking water source based on physical examination controls.  Incidence (%) for each endpoint in 
680, controls: 189 As concentration:  Adjustments: none reported controls and cases:
(age not reported) Controls: ≤50 µg/L Analysis: not reported Loss of hearing
Data collection period: Exposed: >50 µg/L - controls: 2
1992–2004 - exposed: 40 (p=0.005)
Loss of taste
- controls: 0
- exposed: 37 (p=0.001)
Blurred vision
- controls: 7
- exposed: 118 (p<0.001)
Numbness of limbs
- controls: 0
- exposed: 228 (p<0.001)
As = arsenic; CI = confidence interval










   
   
  
     
    
  
    
      
    
   
 
      
   
     
      
  
       
   
   
    
  
   
  
  
   
 
   
  





Inorganic Arsenicals. Human epidemiological studies have examined associations between exposure to 
inorganic arsenic in drinking water and semen quality or endometriosis (Pollack et al. 2013; Xu et al. 
2012).  Details of study designs and outcomes for these studies are provided in Table 3-7.  The risk of
decreased sperm concentration was associated with urine DMA concentrations in a cross-sectional study
of 96 men in China (Xu et al. 2012).  Urinary concentrations of DMA above the median value of 
20.9 µg/g creatinine were associated with decreased sperm concentrations (adjusted odds ratio: 7.2; 95%
CI: 1.4, 37.1). No significant associations were observed between urinary concentration of DMA and 
sperm motility or semen volume, or between urinary concentrations of inorganic arsenic MMA and sperm
concentration, sperm motility, or semen volume. In a matched cohort study of 473 women in California
and Utah, no association between urine arsenic concentrations ≥10.83 µg/L (upper range not reported)
and endometriosis was observed (Pollack et al. 2013).
Several studies in animals have shown adverse effects of oral exposure to inorganic arsenic on male and 
female reproductive systems (Akram et al. 2010; Chatterjee and Chatterji 2010; Li et al. 2012; Pachnanda
and Singh 2012; Reilly et al. 2013; Singh et al. 2011).  Details of study designs and outcomes for these
studies are provided in Table 3-8. In male mice and rats, oral exposure arsenic produced several adverse
effects, including decreased testicular weight, decreased spermatogenesis and sperm motility, decreased
fertility, and histopathological changes to testes and epididymes (Li et al. 2012; Pachnada and Singh
2012; Singh et al. 2011).  Of these studies, the lowest exposure found to be associated with reproductive
effects was a study in which male rats exposed to drinking water collected from wells in India (arsenic 
concentration 0.102 mg/L) for 1–3 weeks resulted in significant testicular toxicity (Singh et al. 2011).  
Findings included duration-dependent decreases in testicular weight (10–28%), sperm count (20–57%), 
and sperm motility (26–58%), compared to controls, and atrophic changes in testes due to degenerative 
changes in spermatogenic and Leydig cells.  Exposure of female rats to drinking water containing 4.0– 
200 mg/L arsenic for 1–4 weeks days caused significant decreases in uterine weight and length, serum
levels of hormones (estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone), and 
histopathological changes to the uterus (Akram et al. 2010; Chatterjee and Chatterji 2010).  In addition, 
the time to onset of puberty was significantly delayed by approximately 2 days and changes to mammary
gland morphology were observed in immature female rats exposed (gavage) to 10 mg/kg/day as sodium
arsenite (Reilly et al. 2013). Effects of pre- and postnatal exposure on the female reproductive system are
reviewed in Section 3.2.2.6 (Developmental Effects).






























































   
 
  
   







Table 3-7.  Reproductive Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 







States (Salt Lake 











As concentration:  
Mean: 8.37 µg/L (95% CI:
7.41, 9.46)
Tertiles:
- T1: <4.94 µg/L
- T2: 4.94– 
10.83 µg/L





smoking, location, race, vitamin 
use
Analysis: logistic regression
No association was observed between As
concentration in urine and endometriosis,
based on comparison of adjusted odds
ratios for tertiles.
Semen quality






Exposure measures: urine 
total inorganic As (Asi) 
DMA and MMA, adjusted
for creatinine
As concentration (median): 
- Asi: 4.03 µg/g
- DMA: 20.9 µg/g
- MMA: 2.77 µg/g
Variables assessed: semen 
volume, sperm concentration,





Analysis: assessments based 
on dichotomous urinary As
concentration for each variable 
by binary logistic regression
Urinary concentrations of DMA above the 
median value were associated with 
decreased sperm concentrations (adjusted
odds ratio: 7.2; 95% CI: 1.4–37.1; p=0.02).
No significant associations were observed 
between urinary concentration of DMA and
sperm motility or semen volume, or
between urinary concentrations of Asi or
MMA and any variable.
AS = arsenic; BMI = body mass index; CI = confidence interval; DMA = dimethylarsinic acid; MMA = monomethylarsonic acid



































   
  
 









    
 










Table 3-8.  Reproductive Effects of Oral Exposure to Inorganic Arsenicals in Animals
Reference Species Exposure Variables assessed Outcomes
Effects on the male reproductive system
Li et al. 2012	 Male mice (strain Drinking water Sperm activity and 
and age at containing 0, 1, 2, or malformation,
initiation of 4 mg/L arsenic trioxide spermatogenesis, 
treatment not for 60 days relative weight of testes
specified); 10 per and epididymes,
group histopathology of testis
and epididymis
Sperm activity: Significantly (p<0.05) decreased by 15–17%
in the 2 and 4 mg/L groups compared to controls.
Percentage of sperm malformation: Significantly (p<0.05)
increased 2.5-fold in the 4 mg/L group
Spermatogenesis (numbers of developing sperm at different
stages): 
- Spermatogonia: significantly (p<0.05) decreased by
approximately 31 and 41% in the 2 and 4 mg/L groups,
respectively, compared to control.
- Spermatocytes: significantly (p<0.05) decreased by
approximately 25 and 40% in the 2 and 4 mg/L groups,
respectively, compared to control.
- Spermatids: significantly (p<0.05) decreased by
approximately 17% in the 4 mg/L group compared to 
control.
- Mature spermatids: significantly (p<0.05) decreased by
approximately 12% in the 4 mg/L group compared to 
control.
Relative weight of testes and epididymes: 
- Testes: significantly decreased (p<0.05) by
 




- Epididymes: significantly decreased (p<0.05) by
 




Histopathology of testes: In the 2 and 4 mg/L groups,
seminiferous tubules showed disruption of spermatogenesis,
reduced layers of germs cell alignment, and decreased
numbers of spermatozoa.
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Table 3-8.  Reproductive Effects of Oral Exposure to Inorganic Arsenicals in Animals
Reference Species Exposure Variables assessed Outcomes
No effects observed in the 1 mg/L group.
Histopathology of epididymis: In the 2 and 4 mg/L groups,
microscopic examination of the epididymis showed marked 







10 rats per group 
Gavage; 0, 1, 2, or
3 mg/kg body
weight/day sodium






Body and testicular weight: No significant changes in body
weight; significant (p<0.05), dose-related decreases in 
testicular weight, ranging from approximately 22% (1 mg/kg 
bw/day) to 54% (3 mg/kg body weight/day).
Testicular histopathology: Pathological findings in treatment
groups included shrunken seminiferous tubules with 
defective spermatogenesis and decreased layers of germ
cells, changes to organization of spermatogonia and 
spermatocytes, spermatocytes with swollen nuclei, atrophied 
spermatocytes, sloughing of dead germ cells into the lumen,
dissolution of the tubule membrane, and leakage of germ
cells into the interstitial space.  Severity of changes
increased with dose. Spermatogenesis was markedly
inhibited at the highest dose.
Fertility: In matings with females, the percentage of infertile 
males was 80% in the 1 mg/kg/day group, compared to




Adult male albino 
rats; 5 per group
Drinking water collected 
from Agra, India 
containing 0.102 mg/L 
for 7, 14, or 21 days;







Body weight: Significant, but small, decreases in body weight
(approximately 6–7%; p<0.05) for all treatment durations.
Testicular weight: Significant (p<0.05) duration-dependent
decreases of approximately 10, 20, 28% at 7, 14, and 
21 days, respectively.
Sperm count: Significant duration-dependent decreases of
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Table 3-8.  Reproductive Effects of Oral Exposure to Inorganic Arsenicals in Animals
Reference Species Exposure Variables assessed Outcomes
approximately 20 (p<0.05), 43 (p<0.001), and 57% (p<0.001)
at 7, 14, and 21 days, respectively.
Sperm motility: Significant decreases of approximately
26 (p<0.01), 42 (p<0.01), and 58% (p<0.001) at 7, 14, and 
21 days, respectively.
Testicular histopathology: Atrophic changes in testis due to
degenerative changes in spermatogenic and leydig cells;
specific observations included: apical degeneration and 
obliterated lumen; irregular shape of seminiferous tubules,
blood vessels, sertoli cells, spermatatids, myoid cells, and 
tunica albugenia; decreased number of spermatids; and 
reduced number of interstitial Leydig cells.










0, 50, 100, or 200 mg/L 
sodium arsenite for
28 days (to maturity of
animals)
Uterine weight and 
height; histology of
uterus; plasma hormone 
levels (estradiol,
progesterone, FSH and 
LH)
Uterine weight: Over the dose range, significant (p<0.001)
decreases in uterine weight ranged from 32% (50 mg/L) to 
85% (200 mg/L) of control.
Uterine length: Over the dose range, significant (p<0.001)
decreases in uterine length ranged from 16 (50 mg/L) to 40%
(200 mg/L) of control.
Uterine histopathology: Dose-dependent alterations included 
cuboidal epithelial cells, decreased epithelial height, loss of
basement membrane, loss of demarcation between epithelial
and endometrial stroma, dense endometrial stroma with 
irregular cells, AND decreased thickness of endometrium
and myometrium.
Hormone levels: Significant (p<0.001) dose-dependent
decreases compared to control:
- estradiol: 49% (50 ppm) to 72% (200 mg/L)
- progesterone: 16% (50 ppm) to 53% (200 mg/L)
- FSH: 32% (50 ppm) to 60% (200 mg/L)








     







































































Table 3-8.  Reproductive Effects of Oral Exposure to Inorganic Arsenicals in Animals











studies; 5 rats per
















4.0 mg/L for 7, 14, 28,
or 56 days;
Main study: 0 or
4.0 mg/L for 28 days
Gavage exposure to 
10 mg/kg arsenic, as
sodium arsenite; dosing 
from postnatal day 12 to 









(measured by time to 
vaginal opening and 
diestrus); mammary 
gland morphology;
serum levels of puberty-
related (insulin-like
growth factor 1 [IGF-1], 
GH, FSH, LH, and 
estradiol)
- LH: 24% (50 ppm) to 47% (200 mg/L)
Dose-ranging study: Significant (p<0.05) decreases in serum
estradiol levels occurred at all arsenic groups, reaching a 
maximum decrease (approximately 85%) at ≥4 mg/L.
Duration-ranging study: Significant (p<0.05) decreases in 
serum estradiol levels occurred at 14, 38 and 56 days, with a 
maximum decrease (approximately 88%) at 28 days.
Main Study: 
- Hormone levels: FSH and LH significantly (p<0.05)
decreased by 77 and 65%, respectively, compared to 
control.
- Uterine weight: significantly (p<0.01) decreased by 29%
compared to control.
- Histopathology: significant findings include decreased 
luminal diameter, height of luminal epithelial cells,
diameter of endometrial glands, and width of longitudinal
muscle layer.
Time to onset of puberty: Time to vaginal opening
significantly (p<0.05) decreased by 1.8 days; time to diestrus
significantly (p<0.05) decreased by 1.95 days.
Mammary gland morphology: Compared to controls, the 
following were observed in arsenic-treated rats: higher mean 
number of terminal end buds, undifferentiated progenitor
cells, increased presence of alveolar buds; fewer terminal
ducts, absence of lobular type 1 structures.
Hormone levels: IGF-1 levels in serum were significantly
(p<0.01) decreased by 22% compared to controls; no
significant changes in levels of GH, FSH, or LH, compared to
controls
As = arsenic; FSH = follicle-stimulating hormone; GH = growth hormone; LH = luteinizing hormone









   
    
  
       
  
       
   
   
      
   
 
  
   
  
      
  
    
   
 
  
     
   
   
     
    
 
    
      





Inorganic Arsenicals. Several case-control, prospective cohort, and cross-sectional cohort studies have 
examined associations between exposure to inorganic arsenic in drinking water and developmental
outcomes (Ahmed et al. 2012; Farzan et al. 2013; Guan et al. 2012; Hamadini et al. 2010, 2011; Hsieh et
al. 2014; Jin et al. 2013; Khan et al. 2012; Kippler et al. 2012; Nahar et al. 2014; Parvez et al. 2011;
Rahman et al. 2007, 2009, 2010, 2011; Raqib et al. 2009; Roy et al. 2011; Rudnai et al. 2014; Saha et al. 
2012; Vall et al. 2012; Wasserman et al. 2007, 2011, 2014; Wu et al. 2014). Outcomes investigated
included fetal death, fetal malformations, fetal and neonatal growth, neurodevelopment, infection 
vulnerability and thymus function, and cancer (see Section 3.2.2.7 Cancer). Details of the individual
study designs and outcomes are provided in Table 3-9. In general, these data provide evidence for
associations between exposure to arsenic and developmental effects ranging from fetal and infant deaths,
congenital heart anomalies, delays in growth and neurological development, and increased susceptibility
to infections.  Although exposures in most study populations were from drinking water, most studies
evaluated internal exposure metrics such as urinary arsenic or blood arsenic levels, rather than drinking
water exposure levels.  Increased risk of fetal heart anomalies was observed in association with drinking
water arsenic concentrations >10 µg/L (Rudnai et al. 2014). Increased risk of fetal or infant death was
associated with exposures to drinking water arsenic levels >222–408 µg/L or maternal urinary arsenic 
concentrations >261 µg/L (Rahman et al. 2007, 2011).  Increased risk of infant respiratory infections was 
associated with maternal urinary arsenic concentrations >39 µg/L (Rahman et al. 2011).  
Prospective cohort studies have examined associations between exposure to arsenic in drinking water and
fetal or infant death (Rahman et al. 2007, 2011). A large cohort study (29,134 pregnancies, Bangladesh)
found increased risk of fetal death and infant death (occurring <12 months of age death) and postnatal
death (occurring >28 days and <12 months of age) in association with drinking water arsenic
concentrations in the range of 227–408 µg/L (Rahman et al. 2007). Relative risks were 1.14 (95% CI:
1.01, 1.30) for fetal death, 1.29 (95% CI: 1.08, 1.53) for infant death, and 1.55 (95% CI: 1.17, 2.05) for
postnatal death.  In a smaller prospective study (2,924 pregnancies, Bangladesh), risk of infant death was
also elevated in association with urinary arsenic concentration >268 µg/L (adjusted hazard ratio: 5.01;
95% CI: 1.41, 17.84; Rahman et al. 2010). An ecological study of villages in Shanxi province of China
found significant correlations between cropland soil arsenic concentrations and prevalence of birth defects 
(Wu et al. 2014).








































   
 
 





   
   
   
   
 
 







Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes









Data collection period: 
1991–2000 
Exposure measures: 
arsenic concentration in 
water for each participant
As concentration: 
Quintile ranges (mean)
- Q1: <10 µg/L (<1)
- Q2: 10–166 µg/L (77)
- Q3: 167–276 µg/L 
(225)
- Q4: 277–408 µg/L 
(340)
- Q5: ≥409 µg/L (515)
Variables assessed:  fetal loss
(fetal death after week 28 of
gestation), infant death (death 
<12 months after birth),
neonatal death (death within 
28 days of birth), postnatal
death (death >28 days and 
<12 months after birth)




hazards and logistic regression
A significant increase in relative risk for fetal
loss was observed for the 277–408 µg/L 
quintile (relative risk: 1.14; 95% CI: 1.01,
1.30), but not for other quintiles.
Significant increases in relative risk were 
observed for infant death for the three 
highest quintiles. A significant (p=0.02)
dose-response relationship for arsenic
exposure and risk of infant death also was
observed.  Relative risk:
- Q1: 1
- Q2: 1.13 (95% CI: 0.95, 1.35)
- Q3: 1.19 (95% CI: 1.00, 1.42)
- Q4: 1.29 (95% CI: 1.08, 1.53)
- Q5: 1.19 (95% CI: 1.00, 1.41)
The relative risk of neonatal death was not
increased for any of the exposure quintiles.
A significant increase in relative risk for
postnatal death was observed for the 277– 
408 µg/L quintile (relative risk: 1.55; 95% CI:
1.17, 2.05), but not for other quintiles.
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Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Reference
Study design and 









Data collection period: 
2002–2004
Exposure measures: 
arsenic concentration in 
urine, adjusted for specific
gravity; collected at 8 and 
30 weeks of gestation
As concentration:  
Quintile ranges (median) for
mean of 8- and 30-week
urine
- Q1: <38 µg/L (30)
- Q2: 39–67 µg/L (50)
- Q3: 68–133 µg/L (94)
- Q4: 134–267 µg/L 
(189)




infant mortality (birth to 
365 days; excluding birth 
asphyxia and accidental death)
Adjustments: none for
spontaneous abortion; asset
index, and gestational age for
stillbirth and infant mortality,
plus season and location of
women’s residence for infant
mortality
Analysis: logistic regression for
spontaneous abortion and 
stillbirth; Cox proportional
hazards for infant death
No association was observed between urine
arsenic concentrations and spontaneous
abortion (based on 8-week urine) or still birth 
(based on mean of 8- and 30-week urine).
A significant (p<0.005) dose-related 
increased in infant mortality was observed
with increasing arsenic exposure (based on 
mean of 8- and 30-week urine). Adjusted 
hazard ratios:
- Q1: 1
- Q2: 1.78 (95% CI: 0.44, 7.16)
- Q3: 1.83 (95% CI: 0.45–7.35)
- Q4: 2.29 (95% CI: 0.58, 9.05
- Q5: 5.01 (95% CI: 1.41–17.84)
Fetal malformations
Jin et al. 2013 Study design: case Exposure measures: Variables assessed: neural
control arsenic concentration in tube defects
Location: China placenta Adjustments: none
Population: maternal- As concentration:  Analysis: multivariate logistic
fetal pairs, with infants - ≤8.93 ng/g regression
diagnosed with neural - >8.93 ng/g
tube defects; cases
80; controls 50
Data collection period: 
started in 2003
No association was observed between 
placental levels of arsenic at concentrations
>8.93 ng/g and elevated risk of neural tube 
defects (odds ratio: 0.88; 95% CI: 0.43,
1.78).










































   
   
   
 
 
   
    




























Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes






Data collection period: 
1987–2003













- S1: 0–10.0 µg/L
- S2: 10.1–20.0 µg/L
- S3: 20.1–30.0 µg/L
- S4: 30.1–40.0 µg/L
- S5: 40.1–50.0 µg/L
- S6: >50.0 µg/L
Exposure measures: 
arsenic concentration in 
cropland soil
As concentration: 
- minimum: 7.86 µg/g
- maximum: 91.59 µg/g
- median: 17.12 µg/g
- mean (SD): 20.29 
(11.52) µg/L
Variables assessed: congenital
heart anomalies (all, ventral
septal defect, atrial septal
defect, ductus Botalli





Variables assessed: all birth 




Statistically significant associations were
observed between drinking water arsenic
concentrations (10.1 through 40.0) and all 
congenital heart anomalies.  Adjusted odds
ratios (95% CI):
- S1: 1
- S2: 1.51 (1.33, 1.71); p<0.001
- S3: 1.30 (1.04, 1.63); p=0.022
- S4: 1.42 (1.06, 1.91); p=0.019
Significant associations were observed 
between arsenic concentration >10 µg/L and 
atrial septal defect and ductus Botalli
persistens. Adjusted odds ratios (95% CI):
- atrial septal defect: 1.79 (1.59, 2.01);
p<0.001
- ductus Botalli persistens: 1.81 (1.54,
2.11); p>0.001
A statistically significant correlation was
observed between cropland soil
concentration of arsenic (log transformed)
and risk of birth defects.  Pearson 
correlation: 0.239; p=0.019


































   
   




























    
  
  






Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes






















maternal and cord blood at
birth
As concentration: 
Mean maternal: 6.91 µg/L
Mean cord: 3.71 µg/L
Exposure measures: 
arsenic concentration in 
maternal urine at 8 and 
30 weeks of gestation
As concentration 
Mean±SD:










Variables assessed: biparietal 
diameter, occipito-frontal 
diameter, head circumference,
abdominal circumference, and 
femur length as assessed by
ultrasound at 14 and 30 weeks
of gestation.
Adjustments: maternal BMI,
socio-economic status, birth 
order, fetal sex
Analysis: mixed effect linear
regression
A negative association was observed 
between maternal arsenic blood 
concentration and birth weight, birth height,
and chest circumference, but not head 
circumference.  Adjusted beta (CI not
reported):
- Weight: -0.19 (p=0.015)
- Height: -0.20 (p=0.017)
- Chest circumference: -0.31 (p=0.001)
A negative association was observed 
between cord blood and head 
circumference.  Adjusted beta (CI not
reported): -0.19 (0=0.021).
At 14 weeks of gestation, a negative 
association between maternal urine arsenic
concentration (log2 transformed) and fetal
occipito-frontal diameter (in all fetuses) was
observed (adjusted beta:
-0.060; 95% CI: 0.11, -0.0079; p=0,024).
However, no association was observed at
30 weeks of gestation (adjusted beta:
-0.016; 95% CI: -0.048, 0.016; p=0.32).
No associations were observed between
maternal urine arsenic concentration (log2
transformed) and other fetal size measures.
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Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 



















Data collection period: 
2001–2003
Exposure measures: 
arsenic concentration in 
maternal urine collected at 8 
and 30 weeks of gestation 
exposure values expressed








arsenic concentration in 

urine of mothers (collected 

at 8 and 30 weeks of
 
gestation) and children 





Mother quintiles (8 weeks):
 
- Q1: 1.2–33 µg/L
- Q2: 33–57 µg/L
- Q3: 57–115 µg/L
- Q4: 116–245 µg/L
- Q5: 246–1,611 µg/L
Mother quintiles (30 weeks):
- Q1: 1.8–36 µg/L
- Q2: 36–63 µg/L
- Q3: 63–120 µg/L
- Q4: 121–272 µg/L
- Q5: 273–1,632 µg/L
Child quintiles:









Variables assessed: attained 
length and weight at 3, 6, 8, 12, 
18, 21, and 24 months
Adjustments: urinary arsenic,




Significant negative associations were 
observed between arsenic concentration in
urine and birth weight, head circumference 
(p=0.041), and chest circumference 
(p<0.001).  Adjusted beta coefficients:
- Weight (g per g/L) -1.68; SE: 0.62;
p=0.007
- Head (mm per g/L): -0.05; SE: 0.03; 
p=0.041
- Chest (mm per µg/L): -0.14; SE:0.03; 
p<0.001
Based on maternal urine arsenic
concentration at 30 weeks of gestation, a 
significant (p<0.05) linear trend was
observed for decreasing weight at 3, 6, 9,
12, and 24 months and decreasing length at
3–9 months (combined males and females).
No significant trends were observed for
maternal urine arsenic concentration at
8 weeks of gestation and weight or length 
throughout the 24-month period.
Inverse associations were observed 
between child urine arsenic concentration 
and weight of females at 18, 21, and
24 months.  Effects were typically significant
and most pronounced for the second and
third quintiles. For example, adjusted betas
(95% CI) at 24 months:
- Q1: reference
 
- Q2: -0.11 (-0.31, 0.094)
 
- Q3: -0.35 (-0.56, -0.14)
 















    




   
  
 
    
  
   
    
    





































Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes






Data collection period: 
2006–2007
- Q2: 16–26 µg/L
- Q3: 26–46 µg/L
- Q4: 46–96 µg/L




reported; categorized as “As




gestational age at birth, birth 




- Q4: -0.22 (-0.42, -0.014)
 
- Q5: -0.13 (-0.34, 0.074)
 
Inverse associations were also observed 
between child urine arsenic concentration 
and length of females at 18, 21, and
24 months, with results showing a similar
pattern of significance as weight.  For




- Q2: -0.025 (-0.60, 0.55)
 
- Q3: -0.71 (-1.30, -0.12)
 
- Q4: -0.64 (-1.21, -0.058)
 
- Q5: -0.39 (-0.97, 0.19)
 
No associations were observed between
 
child urine arsenic concentration and weight
 
or length of males or combined males and 

females at 18, 21, or 24 months.

Birth weight was significantly (p=0.043)
 
increased for infants with arsenic in 







- No meconium: 3,235.5 (405.2)
 
- Meconium: 3,459.3 (537.4)
 
Based on comparison to infants with no 
arsenic detected in meconium, no 
statistically significant differences (p>0.05)
were observed for infant mortality,
prematurity, gestational age at birth, birth 
length, or cranial perimeter for infants with 
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Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Reference
Study design and 
population Exposure Variables assessed Outcomes




















Data collection period: 
2002–2008
Exposure measures: 
arsenic concentration in 
mothers (mean of urine 
collected at 8 and 30 weeks
of gestation) and children 
(at 18 months)
As concentration: 

















arsenic concentration in 
mothers (collected at 8 and
30 weeks of gestation) and 
children (collected at
1.5 and 5 years)
As concentration range: 
Mean (8 and 30 weeks)
mothers: 80 µg/L
Quartiles mothers at
30 weeks (slightly higher
concentrations relative to 






18 months of age





performance IQ (PIQ), verbal
IQ (BIQ), and full-scale IQ
(FSIQ) at 5 years of age
Adjustments: home stimulation,
fathers education, mother’s BMI
and IQ, assets, number of
children in household,
gestational age, birth length,
current height-for-age score
Analysis: linear regression
No effects on developmental parameters
were observed based on mother or child 
urine arsenic concentration.
Means of PIQ, VIQ, and FSIQ (combined 
males and females) by quartile of mother’s
and children’s urinary arsenic showed 
significant negative trends (p≤0.008).
Negative associations were observed 
between (log) urine arsenic and VIQ in 
females, but not for males or combined 
males and females.  The association for girls
was strongest for the 5-year urine arsenic.
Adjusted betas (95% CI) for VIQ:
- Mother (8 weeks): -1.2 (-2.4, -0.06);
p=0.039


























    
 
   
 




   
 
 




































   
  
  





Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 





Mean children at 1.5 years:
34 µg/L
Mean children at 5 years:
51 µg/L
Quartiles children (at
5 years; slightly higher
concentrations relative to 




- >120 µg/L 
Hsieh et al. Study design: case- Exposure measures: Variables assessed: clinical
2014 control arsenic concentration in assessment of cognitive,
Location: China urine (corrected for speech and language, gross
Population: 63 cases, creatinine) and fine motor, social/emotional
35 controls (4–6 years As concentration(µg/g delays
of age) creatinine): Adjustments: age, sex, birth 
Data collection period: Mean: weight, ethnicity, gestation
2010–2012 - 31.68 (cases) length, blood lead or mercury
- 25.75 (controls
Tertiles: Analysis: logistic regression
- T1: ≤ 13.56
- T2: 13.57–24.71
- T3: >24.71
- Mother (30 weeks): -1.5 (-2.6, -0.4);
p=0.007
- Child (1.5 years): -0.9 (-2.1, 0.4);
p=0.164
- Child (5 years): -2.4 (-3.8, -1.1);
p<0.001
A significant negative association was
observed between (log) urine at 5 years and 
FSIQ in females, but not for females based 
on mother gestational urine arsenic or child 
1.5 years urine arsenic or for males or
combined males and females for any urine
arsenic.
- Child (5 years): -1.4 (-2.7, -01); p=0.029
Urine arsenic concentration of 100 µg/L at
age 5 years was associated with a 2.6-point
decrease in VIQ and 0.9-point decrease in 
FSIQ in females.
Significant association between urinary
arsenic concentration (µg/g creatinine) and
risk of any single or multiple developmental
delays. Adjusted odds ratio (95% CI):
- T1: 1
 
- T2: 5.95 (0.64 55.57)
 
- T3: 11.83 (1.52, 91.82)

Based on a multivariate model which
included blood lead, age, birth weight, length 
of gestation and ethnicity of mother, the 
odds ratio for (95% CI) for urinary arsenic
was 3.03 (1.23–7.44).
























































   








   
  






     





Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 









840 children (8– 
11 years of age)







15 years of age;
44% males, 56%
females
Data collection period: 
not reported
Exposure measures: 
arsenic concentration in 
urine (corrected for
creatinine) and in drinking 









Urine range: 47.4– 
2,589.7 mg/g
Exposure measures: 
arsenic concentration in 
drinking water (for each 
participant) and urine
As concentration: 
Water mean: 71.7 µg/L
Water range: 0.8– 
621.9 µg/L
Water arsenic quartiles:
- Q1: 0.8–10 µg/L
- Q2: 11–50 µg/L
- Q3: 51–100 µg/L
- Q4: >100 µg/L
Urine mean: 205.3 µg/L
Urine range: 6–2,794 µg/L
Urine arsenic tertiles:
- T1: 1-≤137 µg/L
- T2: >137–≤400 µg/L
- T3: >400–1,312 µg/L
Variables assessed: Bangla 
language score, English 
language score, math score





Analysis: spline regression 
model




Analysis: one-way analysis of
variance and one-way analysis
of covariance
No association was observed between 
drinking water or urine arsenic concentration 
and scores for Bangla language, English 
language, or math.
IQ percentiles were significantly decreased
by 17, 16, and 22% in quartiles 2, 3, and 4,
respectively. SC percentiles were
decreased by approximately 6 and 7% in 
quartiles 3 and 4, respectively.
Based on urine arsenic concentration, IQ
and SC scores were significantly lower in the 
2nd and 3rd tertiles compared to the 1st tertile.
In the 2nd and 3rd tertiles, IQ percentiles were 
decreased by approximately 20% and SC
percentile was decreased by approximately
10%, compared to the 1st tertile.
















































    
    
    
 
   
    
    
 
    
    
 
    
    
 
    

































    
68ARSENIC
Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes
Parvez et al.
2011






304 children, 8– 
11 years of age.






526 children, 6– 
7 years of age (first
graders)
Data collection period: 
2001
Exposure measures: 
arsenic concentration in 

















- Q1: 7.7–35.9 µg/L
- Q2: 36–55.2 µg/L
- Q3: 55.3–75.6 µg/L
- Q4: 75.7–215.9 µg/L
Variables assessed: motor
function assessed by fine motor
function (FMF), manual
coordination (MC), body
coordination (BC), strength and 






blood levels of manganese,
lead, and selenium




rated by parents and teachers
(ADHD index, cognitive 
problems, hyperactive behavior,
oppositional behavior, mean 
behavior scores)
Adjustments: age, sex, mothers
education, crowding at home 
socio-economic status,
ownership of home, child’s
Inverse associations were observed for
 
arsenic concentrations in drinking water,
 
blood, urine and toenail and BC, FMC (blood 

and urine only) and TMC. Statistically
 
significant associations are shown below.





- BC: -0.43 (-0.77, -0.06); p<0.05
 
- FMC: -0.54 (-1.03. -0.05); p<0.05
 
- TMC: -1.18 (-2.13, -0.10); p<0.05
 
Blood:
- BC: -1.61 (-2.70, 0.51); p<0.01
- FMC: -1.68 (-3.18, -0.18); p<0.05
- TMC: -3.63 (-6.72, -0.54); p<0.05
Urine:
- BC: -1.43 (-2.67, -0.61); p<0.05
- TMC: -3.59 (-6.50, -0.68); p<0.01
Urine (corrected for creatinine):
- BC: -1.60 (-2.61, -0.60); p<0.01
- TMC: -3.42 (-6.27, -0.57); p<0.05
Toenails:
- BC: -1.86 (-2.83, -0.89); p<0.01
- TMC: -3.77 (-6.52, -1.03); p<0.01
No significant association was observed 
between urinary arsenic concentration and 
any behavioral outcome as rated by parents,
or for the overall mean behavior score as
rated by either parents or teachers.
For behavioral outcomes rated by teachers,
significant odds ratios were observed for
ADHD index in Q3 (adjusted OR: 2.4; 95%
CI: 1.1, 4.9) and oppositional behavior in Q4 
(Adjusted OR: 2; 95%CI: 1.0, 4.3).













































































     








Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 














values obtained at 8 and 
30 weeks of gestation)
As concentration: 







301 children, 6 years
of age
Data collection period: 
2004–2005
Exposure measures: 
drinking water from tube 








- Q1: 0.1–20.9 µg/L
- Q2: 21–77.9 µg/L
- Q3: 78–184.9 µg/L




Analysis: logistic regression for
odds ratios; linear regression 
for betas.
Variables assessed: problem








intellectual function based on 
Wechsler Preschool and 






manganese concentration in 
drinking water
Analysis: linear regression
However, no significant effects were 
observed for other behavioral variables and 
no dose-response relationships were 
observed for any variable.
No significant effects of gestational arsenic
exposure on infants’ problem solving 
abilities, motor ability, or behavior were 
observed.
Water arsenic concentration was negatively
associated with performance score and
processing speed score, although no 
association was observed between water
arsenic and verbal score or general ability
score.  Adjusted betas (SE):
- Performance: -0.48 (0.24); p≤0.05
- Processing: -0.54 (0.28); p≤0.05
Based on comparisons between quartiles, a 
significant negative dose-response 
relationship was observed for performance 
score (p=0.05), but not for other variables
(data were not presented).
No significant associations were observed 
between urinary arsenic concentration and 
intellectual function variables.
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Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 


















272 children in grades
3–5; males 53.3%,
females 46.7%










Blood arsenic mean (SD):
 
- 4.81 (3.2) µg/L
Water arsenic mean (SD):
- 43.32 (73.65) µg/L
Exposure measures: 
arsenic concentration in 
drinking water, measured in 





- Q1: <5 µg/L
- Q2: ≥5-<10 µg/L
- Q3: ≥10-<20 µg/L
- Q4: ≥20 µg/L
Variables assessed: children’s
intellectual function based on 
Wechsler Intelligence Scale for











intellectual function based on 
Wechsler Intelligence Scale for
Children; measured by full






children in the home, maternal
IQ, maternal education, school
district, home environment
Analysis: linear regression
A significant negative association was
observed between concentration of arsenic
in blood and verbal comprehension 
(adjusted beta: -1.49; SE: 0.71; p<0.05). No 
associations were observed between blood 
arsenic and other variables.
Compared to Q1, significant negative
associations were observed between water
arsenic and full scale IQ, working memory,
perceptual reasoning, and verbal
comprehension in Q2, and between for
perceptual reasoning in Q3.  Scores were 
reduced by approximately 5–6 points.  No 
significant associations were observed 
between water arsenic and any variable for
Q4.  Adjusted beta±SE:
Q2:
- FSIQ: -6.09±1.98; p<0.01
- WM: -4.88±2.24; p<0.05
- PR: -4.97±2.14; p<0.05
- VC: -6.22±2.49: p<0.05
Q3:
- PR: -5.10±2.06; p<0.05
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Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 






















4 months of age
Data collection period: 
2009
Exposure measures: 
arsenic concentration in 
maternal blood collected at
14 weeks of gestation and 
maternal urine collected at
8 or 14 and 30 weeks of
gestation
As concentration:
Blood: 4.7 µg/L µg/kg
Urine (8 or 14 wk): 69 µg/L
Urine (30 wk): 85 µg/L
Exposure measures: 
arsenic concentration in 
maternal urine and in 






- median: 3.7 µg/L
Water:
- mean: 5.2 µg/L
- range: 0.01–67.5 µg/L
Variables assessed: thymic
function measured by signal-
joint T-cell receptor-
arrangement excision circles
(sjTRECs) mononuclear cells in 
cord blood
Adjustments: season of birth,
socio-economic status, number




Respiratory tract infections and 
related prescription medication
and physician visits
Adjustments: sex, maternal 
age, gestational age, birth 
weight, breast feeding, day care 
attendance, parity
Analysis: Logistic and Poisson 
regression
Gestational exposure to arsenic was
associated with decreased sjTRECs in cord 
blood, indicating impaired production of
naïve T cells. Adjusted betas (95% CI):
Urine (8 or 14 weeks)
- -0.25 (-0.48, -0.01); p=0.03
Urine (30 weeks)
- <5 µg/L: -0.53 (-0.93, -0.13); p=0.009
- ≥5 µg/L: 0.15 (-0.55, 0.85); p=0.67
Blood (14 weeks)
- <1.8 µg/kg: -1.27 (-1.89, -0.66); p<0.001
- ≥ 1.8 µg/kg: 0.70 (-0.01, 1.41): 0.06
Significant dose-response relationship was
observed for maternal urinary arsenic
concentration and infant respiratory tract
infections (RTII; upper, URTI; lower LRTI).
Relative risk (95% CI) for respiratory tract
outcome per one-fold increase in urinary
arsenic (ln-transformed):
- RTI symptoms: 4.0 (1.0, 15.9)
- LRTI treated with prescription 
medication: 3.3 (1.2, 9.0)
- URTI: 1.6 (1.0, 2.5)
- Cold symptoms treated with prescription 
medication: 2.3 (1.0, 5.2)
Relative risk (95% CI) for cumulative number
of infections per one-fold increase in urinary
arsenic (ln-transformed):
- URTI treated with prescription 
medication: 1.6 (1.1, 2.4)
- URTI with physician visit: 1.5 (1.0, 2.1)







































   























Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Study design and 
Reference population Exposure Variables assessed Outcomes






Data collection period: 
2002–2004
Exposure measures: 
maternal urine, mean of
collections at 8 and






- Q1: <39 µg/L
- Q2: 39–64 µg/L
- Q3: 65–132 µg/L
- Q4: 133–261 µg/L
- Q5: >261 µg/L
Variables assessed: incidence 
and severity of lower respiratory
tract infection (LRTI) and 
diarrhea in infants during the 
first 12 months of life, as
reported by mothers
Adjustments: mother’s
education, asset index, BMI,
gestational age, infant sex
Analysis: Poisson regression
Based on maternal urinary arsenic
concentrations, the risk of LRTI, severe 
LRTI, and diarrhea was significantly
increased in infants during the first year of
life. A positive trend (p<0.05) across
quintiles was also observed for LRTI and 





- Q2: 1.28 (1.02, 1.61)
 
- Q3: 1.33 (1.07, 1.67
 
- Q4: 1.57 (1.27, 1.96)
 






- Q2: 1.33 (1.03, 1.71)
 
- Q3: 1.31 (1.02, 1.69)
 
- Q4: 1.54 (1.21, 1.97)
 






- Q2: 0.99 (0.83, 1.19)
 
- Q3: 0.96 (0.80, 1.15)
 
- Q4: 1.25 (1.05, 1.48)
 
- Q5: 1.20 (1.01, 1.43)
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Table 3-9.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Humans
Reference
Study design and 









Data collection period: 
not reported
Exposure measures: 
arsenic concentration in 
maternal urine obtained at
30 weeks of gestation
As concentration:  
Median (90% CI):





index (thymus size) assessed 
at 2, 6, and 12 months of age 
by ultrasound
Adjustments: gender, BMI-for­




A significant, negative association was
observed between maternal urine arsenic
concentration at 30 weeks of gestation and 
thymic index of infants at ages 2–12 months.
Adjusted betas (95% CI):
- 2 months: -0.01 (-0.02, -0.001); p=0.03
- 6 months: -0.015 (-0.02, -0.005);
p=0.004
- 12 months: -0.012 (-0.02, -0.002);
p=0.01
ADHD = attention deficit hyperactivity disorder; As = arsenic; BMI = body mass index; CI = confidence interval; SD = standard deviation; SE = standard error
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Associations between exposure to arsenic in drinking water and risk of fetal malformation have been 
examined in case-control and cross-sectional cohort studies (Jin et al. 2013; Rudnai et al. 2014; Wu et al. 
2014).  A large case-control study (9,734 cases, Hungary) found increased risk of congenital heart
anomalies in association with drinking water arsenic levels >10.1 µg/L (adjusted odds ratio: 1.51, 95% CI
1.33, 1.71; Rudnai et al. 2014).  In a smaller case-control study (80 cases, China), exposure to arsenic in 
drinking water was not associated with risk of neural tube defects (Jin et al. 2013).
Several prospective and cross-sectional studies have examined associations between exposure to arsenic 
in drinking water and various metrics of fetal and postnatal growth (Guan et al. 2012; Kippler et al. 2012;
Rahman et al. 2009; Saha et al. 2012; Vall et al. 2012).  Prospective studies conducted found significant
associations between exposure to arsenic and fetal and postnatal growth (Rahman et al. 2009; Saha et al. 
2012).  In the Rahman et al. (2009) study (1,578 mother-infant pairs, Bangladesh), an increase in maternal
urinary arsenic was associated with significant reductions of body weight, head circumference, and chest
circumference at birth.  The Saha et al. (2012) study (2,372 infants, Bangladesh) found significant
associations between increasing urinary arsenic concentrations measured at age 18 months and decreasing
postnatal body weight and length, measured at ages 18–24 months.  Cross-sectional cohort studies also
found significant associations between increasing fetal exposure (maternal urine or cord blood) and 
decreasing birth weight and size (Guan et al. 2012; Kippler et al. 2012).
Several studies have examined associations between exposure to arsenic in drinking water and various 
metrics of neurodevelopment (Hamadini et al. 2010, 2011; Hsieh et al. 2014; Khan et al. 2012; Nahar et
al. 2014; Parvez et al. 2011; Roy et al. 2011; Wasserman et al. 2007, 2011, 2014).  Prospective studies
conducted on the same mother-infant cohort (1,745–2,260 mother-infant pairs, Bangladesh) did not find 
significant associations between fetal exposure to arsenic and mental development index or psychomotor
index when assessed at age ≤18 months (Hamdini et al. 2010; Tofail et al. 2009); however, significant
associations were found between increasing maternal or child urinary arsenic levels and decreasing IQ
assessed at age 5 years (Hamadini et al. 2011).  At age 5 years, in females, a urinary arsenic concentration
of 100 µg/L was associated with 2.6-point decrease in verbal IQ and a 0.9-point decrease in full-scale IQ.
Several cross-sectional studies have also found associations between exposure to arsenic and IQ (Nahar et
al. 2014; Wasserman et al. 2007, 2011, 2014).  A cross-sectional cohort study of children (304 children 
ages 8–11 years, Bangladesh) found significant associations between increasing exposure to arsenic in 
drinking water or arsenic concentrations in blood or urine and decrements in motor function (Parvez et al. 
2011).  A small case-control study (63 cases, 35 controls, age 4–6 years) found a significant association
between risk of developmental delays (any cognitive, speech, motor or social/emotional delay) and 
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urinary arsenic levels (Hsieh et al. 2014). The adjusted odds ratio for any delay was 11.83 (95% CI: 1.52, 
91.82) in association with urinary arsenic levels >24.71 µg/g creatinine.
Several prospective cohort studies have examined associations between maternal exposure to arsenic in 
drinking water and susceptibility to infections and thymic function of infants (Ahmed et al. 2012; Farzan 
et al. 2013; Rahman et al. 2011; Raqib et al. 2009). Prospective studies have found increased risk of
respiratory tract infection in infants in association with maternal exposure to arsenic in drinking water
(Farzan et al. 2013; Rahman et al. 2011).  In the Rahman et al. (2011) study (1,552 mother-infant pairs, 
Bangladesh), risk of infection during the first postnatal 12 months increased in association with increasing
maternal urinary arsenic levels >39 µg/L. The adjusted relative risks associated with maternal urinary
arsenic concentrations 39–64 µg/L were 1.28 (95% CI: 1.02, 1.61) for all respiratory tract infections and
1.33 (95% CI: 1.03, 1.71) for severe lower respiratory tract infections.  Risk of infantile diarrhea was also 
elevated in association with maternal urinary arsenic concentrations of 133–261 µg/L (adjusted relative
risk: 1.25; 95% CI: 1.05, 1.48).  In the Farzan et al. (2013) study (214 mother-infant pairs, United States),
adjusted relative risks at age 4 months associated with doubling maternal urinary arsenic concentration 
were 4.0 (95% CI: 1.0, 15.9) for respiratory tract infection, 3.3 (95% CI: 1.2, 9.0) for lower respiratory
tract infection, and 1.6 (95% CI: 1.0, 2.5) for upper respiratory tract infection.  Prospective studies of the
same cohort (130 or 140 mother-infant pairs, Bangladesh) found significant associations between
maternal urinary arsenic levels and infant thymic index, and cord blood naïve T-cells (indicative of
thymic suppression; Ahmend et al. 2012; Raqib et al. 2009). 
Studies in animals also show adverse developmental effects, including neural tube defects, skeletal
anomalies and decrements in pulmonary function, following in utero and lactational exposure to inorganic
arsenic (Hill et al. 2008; Lantz et al. 2008; Ramsey et al. 2013a, 2013b).  Details of the individual study
designs and outcomes are provided in Table 3-10. Dose-related increases in the incidence of neural tube 
defects (exencephaly) were observed in mouse pups born to dams administered (gavage) 4.8–14.4 mg/kg
on gestational days 7.5–8.5 (Hill et al. 2008).  Dose-related skeletal anomalies also were observed,
including sternebral, rib, vertebral, and, calvarial abnormalities.  Gestational and early life exposure to 
arsenic in drinking water altered pulmonary function and morphology in mice. Lantz et al. (2008)
reported increased airway reactivity following gestational exposure to drinking water concentrations of
50–100 µg/L.  An increase in smooth muscle and collagen surrounding airways was also observed in mice
exposed to 100 µg/L.  In mice exposed to 100 µg/L sodium arsenite in drinking water during gestation, 
several changes in pulmonary function and morphology were observed in pups including decreased
thoracic volume, and decreased number of alveoli and alveolar surface area (Ramsey et al. 2013a, 2013b).






   
 





















































Table 3-10.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Animals
Reference Species Exposure Variables assessed Outcomes
Skeletal anomalies




days 7.5–8.5 to 0, 4.8,




weight, neural tube 
defect, skeletal
anomalies
Implantations and resorptions: No significant differences
between control and exposure groups.
Fetal weight: Significantly (p<0.05) decreased by
approximately 11–21; decreases were not dose-related.
Neural tube defect: Dose-related significant increases in 
exencephaly were observed.  Numbers of litter with 
exencephaly were 0, 1, 5, and 9 in the 0, 4.8, 9.6, and
14.4 mg/kg groups, respectively
Skeletal anomalies: Significantly (p<0.05) dose-related
increases in the incidence of the following effects were 
observed, relative to controls:
- 4.8 mg/kg: calvarial abnormalities
- 9.6 mg/kg: sternebral, rib, vertebral, and calvarial
abnormalities










postnatal day 28 to 
drinking water
containing 0, 5, 10, 50,







Methacholine challenge: At postnatal day 25, airway
reactivity was significantly increased in mice in the 50 or
100 µg/L groups, compared to control.
Lung morphology: In the 100 µg/L group significant
increases were observed in smooth muscle and collagen 
surrounding airways.






   
 


































































Table 3-10.  Developmental Effects of Oral Exposure to Inorganic Arsenicals in Animals









gestational day 8 
through pup age of
2 weeks to 0 or
100 µg/L sodium
arsenite
Lung volume, number of
alveoli in the lung,
alverolar surface area,
alveolar volume and 
airway resistance,
tissue damping and 
elastance, airway
histopathology
Effects observed in C57Bl/6 strain, but not BALB/c or
C3H/HeARC strains.
Lung volume: Significantly decreased (p<0.001) by
approximately 30% compared to control.
Number of alveoli in lung: Significantly decreased (p<0.05)
by approximately 50% compared to control.
Alveolar surface area: Significantly decreased (p<0.001) by
approximately 35% compared to control.
Alveolar volume and airway resistance: No change
compared to control.
Tissue damping and elastance: Significantly (p<0.05)
decreased compared to control.








Dams exposed to 
drinking water
containing 0, 10, or
100 µg/L sodium
arsenite from
gestational day 8 to 
birth
Examinations at pup 






Thoracic gas volume: Significantly (p=0.02) decreased in 
males in the 100 µg/L group, but not in females.
Airway resistance: Significantly decreased in males in the 
10 µg/L group, but not the 100 µg/L group, compared to 
controls.  No significant effect in females.
Tissue damping: significantly decreased (p<0.001) in both 
treatment groups compared to control.
Tissue elastance: No significant decreases.
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Gestational exposure of dams to 10 µg/L resulted in significantly increased airway resistance in male 
pups, but not female pups (Ramsey et al. 2013b).  Mucous cell metaplasia also was observed in pups born 
to dams exposed to 100 µg/L sodium arsenite in drinking water (Ramsey et al. 2013a).
Organic Arsenicals. Taylor et al. (2013) investigated the effects of arsenobetaine exposure during
gestation and lactation on developmental outcomes in rats.  Dams were administered 0, 0.1, 1, or
10 mg/kg/day arsenobetaine by gavage from gestational day 8 through lactation, and offspring were 
evaluated at birth, postnatal day 13, and postnatal day 90. For pups examined at birth and postnatal
day 13, no effects were observed on litter size, birth weight or length, sex ratio, behavior, posture, gross 
malformations, or tissue weights (major organs and reproductive organs). Clinical chemistry and
hematology parameters were not evaluated.  Pups examined on postnatal day 90 were normal in 
appearance, posture, and behavior and no adverse changes in clinical chemistry parameters were 
observed.  Statistically (p<0.05) and clinically (change >5% compared to control) significant changes in
hematology parameters, compared to controls, were observed for males and females.  In males, decreased
hematocrit (10 mg/kg/day: 20% decrease), percentage of monocytes (1 and 10 mg/kg/day: 50% decrease), 
and number of eosinophils (10 mg/kg/day: 40% decrease) were observed.  In females, the percentage of
monocytes was decreased (10 mg/kg/day: 23% decrease) and the number of platelets was increased
(1 mg/kg/day: 6% increase; 10 mg/kg/day: 16% increase). In offspring followed for 90 days, the onset of
puberty was delayed in males and females.  In males, prepubital separation was decreased by 1 day in the
0.1 and 1 mg/kg groups compared to controls. In females, vaginal opening was delayed in the 0.1 and 
10 mg/kg/day groups by 7 and 4 days, respectively, compared to controls, although no treatment-related
change was observed for the length of time between vaginal opening and the onset of estrus.
3.2.2.7 Cancer
Inorganic Arsenicals. Inorganic arsenic is recognized by the International Agency for Cancer (IARC
2012) and the National Toxicology Program (NTP 2014) as a carcinogen based on evidence in humans.
Recent epidemiology studies of populations exposed to arsenic in drinking water provide additional 
evidence of that arsenic is a carcinogen in humans. These studies show associations between exposure to
inorganic arsenic in drinking water and cancer of the bladder and urothelium (Chen et al. 2010b; Chung et
al. 2011, 2013a, 2013b; Feki-Tounsi et al. 2013; Ferreccio et al. 2013; Hsu et al. 2013a; Huang et al. 
2008a, 2008b; Smith et al. 2006, 2012; Steinmaus et al. 2013; Wu et al. 2012a, 2013), gastrointestinal
tract (Hsu et al. 2013b), kidney (Huang et al. 2011, 2012; Mostafa and Cherry 2013; Yuan et al. 2010),
liver (Hsu et al. 2013b), lung (Argos et al. 2014; Chen et al. 2010c; Garcia-Esquinas et al. 2013; Heck et
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al. 2009; Khlifi et al. 2014; Sawada et al. 2013; Steinmaus et al. 2013), pancreas (Garcia-Esquinas et al. 
2013; Hsu et al. 2013b), and skin (Gilbert-Diamond et al. 2013; Leonardi et al. 2012).
Results of studies in humans (Smith et al. 2006, 2012; Yuan et al. 2010) exposed to arsenic in drinking 
water suggest that exposure to oral arsenic in utero and/or early life is carcinogenic. Details of the 
individual study designs and outcomes are provided in Table 3-11.  Smith et al. (2006) conducted a 
retrospective study on two birth cohorts in Chile exposed to high concentrations of arsenic in drinking
water (approximately 870 µg/L) during1958–1970 to examine the relationship between high exposure in
utero and early childhood and cancer deaths in adults aged 30–49 years.  For the period before and after
the high exposure period, arsenic concentrations in drinking water were approximately 40–100 µg/L. The
cohort born during the period before the high exposure (1950–1957) was exposed during early childhood 
and the cohort born during the high exposure period was exposed in utero with possible childhood 
exposure.  Standard mortality ratios (SMRs) were based on national data for Chile. For mortality due to 
lung cancer, SMRs (combined men and women) for the 1950–1957 and 1958–1970 birth cohorts were
7.0 (95% CI: 5.4, 8.9) and 6.1 (95% CI: 3.5, 9.9), respectively (Smith et al. 2006). For the same 
population, Smith et al. (2012) examined cohorts born 1940–1957 (pre-high exposure period) and 1958– 
1970 (high exposure period).  For combined birth cohorts (1940–1970), SMRs were significantly
increased for mortality due to bladder cancer (18.1; 95% CI: 11.3, 27.4), laryngeal cancer (8.1; 95% CI:
3.5, 16.0), lung cancer (7.0; 95% CI: 5.9, 8.2), kidney cancer (3.5; 95% CI: 2.1, 5.4), liver cancer (2.5;
95% CI: 1.6, 3.7), and other cancer (1.2; 95% CI: 1.1, 1.3). In the same Chilean population, early life
exposure was associated with increased mortality due to kidney cancer (Yuan et al. 2010).  For a birth 
cohort born just before or during the high exposure period (1950–1970), the SMR for men and women 
(combined) aged 30–39 was 7.08 (95% CI: 3.05, 14.0).  Finding of these studies suggest that exposure to 
high concentration of arsenic in drinking water in utero and/or early childhood is associated with
increased mortality due to several types of cancer.
A study conducted at the NTP Laboratory showed that lifetime exposure of CD1 mice to arsenic in
drinking water at concentrations that are relevant to human exposures increased the incidence of lung
cancer (Waalkes et al. 2014).  Mice were exposed to 0, 50, 500, or 5,000 µg/L arsenic (as sodium
arsenite) from gestation to up to 2 years. In male mice exposed to 50 and 500 µg/L (but not 5,000 µg/L), 
the incidence of bronchiolo-alveolar tumor (adenoma or carcinoma) was significantly increased to 51%
(p<0.05) and 54% (p<0.01), compared to control (22%).  In female mice exposed to 50 µg/L, but not
higher concentrations, a significant increase (p<0.05) in the incidence of bronciolo-alveolar adenoma was 
observed, compared to control (50 µg/L: 25%; control: 11%).





























   
   
   
   








    
 













   
 





   
 






   
 




Table 3-11.  Cancer in Humans Following In Utero and/or Early Life Exposure to Arsenic in Drinking Water
Reference Study design and population Exposure	 Variables assessed Outcomes
Smith et al. 	 Study design: retrospective
2006	 cohort
Location: Cities of Antofagastra 
and Mejillones, Chile; this
location had a defined period 
(1958–1970) of exposure to high 
concentrations of arsenic in
drinking water
Population: Approximately
60,000 children (as reported in
Smith et al. 2012) exposed
during the high exposure period.
Two birth cohorts: (1) born prior
to high exposure period (1950– 
1957), with probable in 
childhood exposure; (2) born 
during high exposure period 
(1958–1970) with probable in
utero (and possible childhood)
exposure. Standard group:
national data for Chile, excluding 
the high exposure area.
Data collection period: 1989– 
2000
Exposure measures: Variables assessed: Mortality due to lung cancer was increased in 
drinking water mortality due to lung persons with probable in utero and childhood 
As concentrations cancer in the age exposure to high arsenic concentrations in 
(approximate): group 30–49 during drinking water. Standard mortality ratios
- 1950–1957: 90 µg/L 1989–2000; data (95% CI):
 
- 1958–1970: 870 µg/L collected from death 

- 1971–1980: 100 µg/L certificates Born 1950–1957:
 
- 1981–1990: 70 µg/L Adjustments: none - 30–39 years (male):12.8 (7.1–21.1);
 
- 1991–2000: 40 µg/L Analysis: standard p<0.001
 
mortality ratios with - 30–39 years (female): 4.2 (0.5–15.1);
 
Chile as the p=0.084
 




- 40–49 years (male): 7.2 (5.1, 9.9);
p<0.001
- 40–49 years (female): 4.8 (2.6, 8.1);
p<0.001
- 40–49 years (combined): 6.3 (4.7, 8.3)
p<0.001
- 30–49 years (male): 8.2 (6.2, 10.8);
p<0.001
- 30–49 years (female): 4.7 (2.7, 7.7);
p<0.001
- 30–49 years (combined): 7.0 (5.4, 8.9);
p<0.001
Born 1958–1970:
- 30–39 years (male): 9.2 (4.8, 16.1);
p<0.001
- 30–39 years (female): 3.6 (0.7, 10.5);
p=0.052
- 30–39 years (combined): 7.0 (3.9, 11.6);
p<0.001








     
  
 






   
 













   
 
 
Exposure measures: Variables assessed:  Exposure to drinking water with high 
drinking water mortality due to  concentrations of arsenic (1958–1970) 
As concentrations cancer in the age   increased risk of mortality due to all cancer,
(approximate, as reported group 30–49 during bladder cancer, laryngeal cancer, and liver 
  in Smith et al. 2006:  1989–2000; data cancer.    Standard mortality ratios (95% CI): 
  -  1940–1947: not collected from death  
 reported  certificates  1940–1957 cohort:
 -  1950–1957: 90 µg/L  Adjustments: none  -  all cancer males: 2.1 (1.9, 2.4); p<0.001 
 -  1958–1970: 870 µg/L Analysis: standard  -  all cancer females: 1.4 (1.2, 1.6);
 -  1971–1980: 100 µg/L  mortality ratios with  p<0.001
 -  1981–1990: 70 µg/L Chile as the  -  bladder cancer males: 13.7 (6.8, 24.5);
 -  1991–2000: 40 µg/L reference, Poisson  p<0.001
regression  -   bladder cancer females: 7.9 (1.0, 28.6);
 p=0.03
 -  laryngeal cancer males: 8.9 (3.6, 18.3);
 p<-0.001
 - laryngeal cancer females: none observed 
 -  liver cancer males: 2.4 (1.2, 4.4); p=0.01 
 -  liver cancer females: 1.5 (0.5, 3.2);
  p=0.23
 -  all other cancers males: 1.0 (0.8, 1.2);
 p=0.64
 -  all other cancers females: 1.2 (1.0, 1.4);
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Table 3-11.  Cancer in Humans Following In Utero and/or Early Life Exposure to Arsenic in Drinking Water
Reference Study design and population Exposure	 Variables assessed Outcomes
Smith et al. 	 Study design: retrospective
2012	 cohort
Location: Cities of Antofagastra 
and Mejillones, Chile; this
location had a defined period 
(1958–1970) of exposure to high
concentrations of arsenic in
drinking water
Population: Approximately
60,000 children exposed during 
the high exposure period. Two 
birth cohorts: (1) born prior to 
high exposure period (1940– 
1957), with probable in 
childhood exposure; (2) born 
during high exposure period 
(1958–1970) with probable in
utero and possible childhood 
exposure. Standard group:
national data for Chile, excluding
the high exposure area.
Data collection period: 1989– 
2000
- 40–49 years (male): 3.4 (0.01, 18.9);
p=0.255
- 40–49 years (female): 0
- 40–49 years (combined): 2.0 (0.01,
11.2); p=0.391
- 30–49 years (male): 8.1 (4.3, 13.9);
p<0.001
- 30–49 years (female): 2.9 (0.6, 8.5);
p=0.087
- 30–49 years (combined): 6.1 (3.5, 9.9);
p<0.001
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Table 3-11.  Cancer in Humans Following In Utero and/or Early Life Exposure to Arsenic in Drinking Water
Reference Study design and population Exposure Variables assessed Outcomes
p<0.01
1958–1970 cohort:
- all cancer males: 2.2 (1.7, 2.8); p<0.001
- all cancer females: 1.4 (1.1, 1.8); p<0.01
- bladder cancer males: 65.7 (24.1, 143);
p<0.001
- bladder cancer females: 43.0 (8.9, 126);
p<0.001
- laryngeal cancer males: 27.4 (0.7, 153);
p=0.04
- laryngeal cancer females: none observed
- liver cancer males: 5.9 (1.9, 13.7);
p<0.01
- liver cancer females: 4.7 (1.3, 12.0);
p=0.01
- all other cancers males: 1.5 (1.1, 2.0);
p=0.01
- all other cancers females: 1.2 (0.9, 1.6);
p=0.09
Combined cohorts (1940–1970):
- bladder cancer: 18.1 (11.3, 27.4);
p≤0.001 laryngeal cancer: 8.1 (3.5, 16.0);
p≤0.001 
- lung cancer: 7.0 (5.9, 8.2); p≤0.001
- kidney cancer: 3.5 (2.1, 5.4); p≤0.001
- liver cancer: 2.5 (1.6, 3.7); p≤0.001
- other cancer: 1.2 (1.1, 1.3); p=0.002



























   
   
   
   
   
   
   




















   
 









Table 3-11.  Cancer in Humans Following In Utero and/or Early Life Exposure to Arsenic in Drinking Water





Location: Cities of Antofagastra 
and Mejillones, Chile; this 
location had a defined period 
(1958–1970) of exposure to high 
concentrations of arsenic in
drinking water
Population: Approximately
60,000 children exposed during 
the high exposure period. Two 
birth cohorts: (1) born prior to 
high exposure period (before 
1950), with no early life 
exposure; (2) born before or
during high exposure period 
(1950–1970) with probable in
utero and childhood exposure.
Standard group: national data 




- 1950–1954: 90 µg/L
- 1955–1959: 870 µg/L
- 1960–1969: 870 µg/L
- 1970–1974: 260 µg/L
- 1975–1979: 110 µg/L
- 1980–1984: 80 µg/L
- 1985–1990: 60 µg/L
- 1990–1994: 40 µg/L
Variables assessed: 
mortality due to kidney
cancer in the age
group 30–49 born 
during 1950–1970 and 






mortality ratios with 
Chile as the 
reference, Poisson 
regression
Early life exposure was associated with 
increased mortality due to kidney cancer.  For
the cohort born just before or during the high 
exposure period (1950–1970), the standard 
mortality ratio for men and women (combined)
aged 30–39 was 7.08 (95% CI: 3.05–14.0;
p<0.001).  Standard mortality ratios (95% CI):
1950–1970 birth cohort (death at 30–39 years
of age):
- men: 5.63 (1.52, 14.4)
- women: 9.52 (2.56, 24.4)
- combined: 7.08 (3.05, 14.0)
Before 1950 birth cohort (death at 40+ years
of age):
- men: 2.68 (2.19, 3.26)
- women: 3.91 (3.12, 4.84)
- combined: 3.12 (2.69, 3.61)
exposure area.
Data collection period: 1971– 
2000
As = arsenic; CI = confidence interval
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Organic Arsenicals. Studies in animals have evaluated carcinogenic effects of the arsenic metabolites 
methylarseonous acid [MMA(III)] and dimethylarsenic acid [DMA(III)] (Tokar et al. 2012a, 2012b).
Gestational exposure of CD1 mice to MMA(III) produced cancer in offspring (Tokar et al. 2012a).  
Pregnant mice were exposed to 0, 12.5, or 25 mg/L MMA(III) in drinking water on days 8–18 of
gestation.  Offspring were assessed for tumors for up to 2 years. In male offspring, the incidences of
hepatocellular carcinoma in the 25 mg/L group (control: 0%; 12.5 mg/L: 12%; 25 mg/L: 22%), 
adrenalademona in both treatment groups (control: 0%; 12.5 mg/L: 28%; 25 mg/L: 17%), and lung
adenocarcinoma 12.5 mg/L group only (control: 17%; 12.5 mg/L: 44%) were significantly (p<0.05)
increased. For hepatocellular carcinoma, a significant dose-related trend was observed (p=0.018).  In 
female offspring, the incidences of adrenal cortical adenoma at 25 mg/L (control: 0%; 25 mg/L: 26%) and 
total epithelial uterine tumors in both treatment groups (control: 0%; 12.5 mg/L: 26%; 25 mg/L: 30%)
were significantly (p>0.05) increased. The carcinogenic potential of DMA(III) was examined in
offspring of CD1 mice exposed to 0 or 85 mg/L sodium arsenite (As[III]) in drinking water on gestational
days 8–18, followed by life-time exposure (post-lactation) to DMA(III) (0 or 200 mg/L) in drinking water
(Tokar et al. 2012b). Exposure to As(III) plus DMA(III) significantly (p<0.05) increased the incidence of
renal cellular carcinoma (control: 0; As(III): 2%; DMA(III): 0; As(III) plus DMA(III): 13%) compared to 
control. The incidence of hepatocellular carcinoma was significantly (p<0.05) increased for As(III) alone
and As(III) plus DMA(III) compared to control (control: 6%; As(III): 20%; DMA(III): 8%; As(III) plus
DMA: 43%) and for As(III) plus DMA(III) compared to As(III) alone. Significant increases (p<0.05, 
compared to control) in the incidences of adenocarcinoma of the lung and adenoma of the adrenal cortex
were observed, but there were no statistically significant differences between treatment groups. Results 
indicate that exposure of adults mice to DMA(III) alone induced tumors of the kidney, lung and adrenal
cortex and promoted development of hepatocellular carcinoma induced by prenatal exposure to As(III).
3.3 GENOTOXICITY
Inorganic Arsenicals. Recent studies in humans chronically exposed to arsenic by environmental or
occupational exposure show that exposure to arsenic is associated with non-specific and oxidative DNA
damage (Basu et al. 2005; Mendez-Gomez et al. 2008; Pei et al. 2013; Vuyyuri et al. 2006), chromosome
damage (Paiva et al. 2006), increase micronuclei frequency (Banergee et al. 2013; Bartolotta et al. 2011;
Gamino-Gutierrez et al. 2013; Martinez et al. 2005; Paiva et al. 2008; Paul et al. 2013a; Vuyyuri et al.
2006), and decrease DNA repair (Mendez-Gomez et al. 2008). Details of these studies are summarized in
Table 3-12.






   
 





























   
 
   
 
  














   




   











Table 3-12.  Genotoxicity in Humans Exposed to Oral Arsenic
Cell type and variables









30 exposed; 30 controls
Location: Mexico
Population: 3 groups of
elementary school
children based on 
location to a smelter:
Group A (distant): n=21;
Group B (intermediate);











- Group A: 26.05
- Group B (control): 6.8
- Group C: 13.16
Urine (µg/L):
- Group A: 143
- Group B (control): 100
- Group C: 115
Cell type:  peripheral blood
lymphocytes
Assessment: nonspecific
DNA damage (comet assay);




Cell type: peripheral blood 
lymphocytes
Assessment: nonspecific
DNA damage (comet assay)
Exposure to arsenic in drinking water
significantly increased non-specific and 
oxidative DNA damage, compared to 
controls.
Comet assay (comet length; mean±SE)
- control: 22.193±0.908
- exposed: 86.296±1.846 (p<0.01)
Comet assay plus enzyme digestion (comet
length; mean±SE):
- control: 25.879±1.266
- exposed: 111.075±2.385 (p<0.01)
For Group C, but not Group A, comet assay
results show a significant increase in comet
tail length (13% increase compared to 
control; p<0.05) and the percentage of cells
with tail length >20 µm (26% increase 
compared to control; p<0.05).






   
 




























































Table 3-12.  Genotoxicity in Humans Exposed to Oral Arsenic
Cell type and variables







75 adult males with
arsenicosis (severity of
mild, moderate, and 
severe based on degree 
of skin lesions); controls:




165; exposed: 200 glass 
























- exposed: 56.76±0.48 
(p<0.05 compared to
control)







Cell type: peripheral blood 
leukocytes
Assessment: DNA damage 
(comet assay: tail length)
In PMNs, but not monocytes, positive 
8-OHdG reactions were observed, indicating 
oxidative damage to DNA.
Compared to control, a statistically
significant (p<0.05) increase in basal DNA
damage was observed in exposed workers.
Comet tail length (µm; mean±SE):
- control: 8.29±0.71
- exposed: 14.95±0.48
No differences were observed between 
males and females.






   
 











































   
  
 

















   
   
   
   
   
   
 
 
   
   
   
   
   









Table 3-12.  Genotoxicity in Humans Exposed to Oral Arsenic
Cell type and variables
Reference Study population Exposure assessed Outcomes
Chromosome aberrations/sister chromatid exchange



















- Ref 1: 64.60±5.05**
- Ref 2: 21.34±2.64
*Significantly different
(p<0.001) Ref 1 and Ref 2.
**Significantly (p<0.001)
difference from Exposed and 
Ref 2.
Cell type: peripheral blood 
lymphocytes
Assessment: SCE and
percentage of HFCs, defined 
as cells that displayed SCE
values above the 95th 
percentile of the SCE/cell
distribution for the study
population.
Sister chromatid exchanges (SCEs) and 
high frequency cells (HFCs) were 
significantly increased in the exposed group 
compared to the reference groups.
SCE/cell (mean±SE):
- exposed: 6.28±0.09 (p<0.01 versus 
external control)
 
- Ref 1: 6.21±0.23
 
- Ref 2: 5.84±0.14
 
HFC (%) (mean±SE):
- exposed: 2.21±0.20 (p<0.01 versus
external and internal controls)
 
- Ref 1: 1.30±0.24
 
- Ref 2: 1.20±0.23
 
Micronuclei formation
Banerjee et Location: India Total As concentrations:
al. 2013 Population: 6 groups Cooked rice (µg/kg):
based on arsenic range - Group 1: ≤100 
in rice; Group 1 (n=113); - Group 2: >100–≤150
Group 2 (n=118); - Group 3: >150–≤200
Group 3 (n=84); - Group 4: >200–≤250
Group 4 (n=35); - Group 5: >250–≤300
Group 5 (n=30); - Group 6: >300
Group 6 (n=37
Urine (µg/L; mean±SD):
- Group 1: 32±37
- Group 2: 38±40
- Group 3: 48±51
- Group 4: 76±74
- Group 5: 87±64
- Group 6: 96±81
Cell type: urothelial cells Micronuclei frequency was significantly
Assessment: micronuclei higher (p<0.001) for groups with cooked rice 
formation arsenic concentrations >200 µg/kg, compare 
to the group with the lowest arsenic
concentrations ≤100 µg/kg.






   
 
















    
   
  
























































Table 3-12.  Genotoxicity in Humans Exposed to Oral Arsenic
Cell type and variables








rural (4 male and 
4 adults: control rural
(5 males and 
5 females); exposed
urban (8 males and 
11 females); control
urban (10 males and
12 females)








98 children (ages 4–
 
10 years) residing in
 
Villa de la Paz for at
 
least 2 years; control:
 
42 unexposed children 











- exposed rural: 45–400
- control rural: <30 
- exposed urban: <10
- control urban: 80












- range: 212–16,595 

- mean 1,062 



















Micronuclei formation was significantly
increased in exposed rural and urban
groups, compared to respective controls.
No differences between males and females
were observed for either population.
Percentage of micronuclei (mean±SE):
Rural population:
- exposed: 2.15±0.13 (p=0.0005)
- control: 0.94±0.06
Urban population:
- exposed: 0.27±0.01 (p=0.002)
- control: 0.15±0.02
Micronuclei formation in exposed children 
was associated with urine arsenic levels.
- correlation coefficient: 0.49
- p<0.001






   
 






















































Table 3-12.  Genotoxicity in Humans Exposed to Oral Arsenic
Cell type and variables




















workers with no arsenic
exposure (n=50)
As concentrations:













- Ref 1: 63.30±4.97**
- Ref 2: 23.65±3.45
*Significantly different
(p<0.001) Ref 1 and Ref 2.
**Significantly (p<0.001)
difference from exposed and 
Ref 2.
Cell type: buccal cells
Assessment: frequency of
micronuclei




No increase in micronuclei formation was




No differences in micronuclei frequencies
were observed between the three groups.






   
 
















   
   
   
 
   
   




   
   
   
 
   
   


















































Table 3-12.  Genotoxicity in Humans Exposed to Oral Arsenic
Cell type and variables







studied in 2004–2005 
and 2010–2011.
Cohort 1: exposed with
no skin lesions (n=61 for
follow-up study); Cohort
2: exposed with skin 
lesions (n=67 for follow-
up study; Cohort 3:




165; exposed: 200 glass






- Cohort 1: 348.23
- Cohort 2: 327.56
- Cohort 3: not detected
Urine (µg/L):
- Cohort 1: 642.31
- Cohort 2: 598.64
- Cohort 3: 11.62
2010–2011 assessment:
Drinking water (µg/L):
- Cohort 1: 5.60
- Cohort 2: 8.53
- Cohort 3: not detected
Urine (µg/L):
- Cohort 1: 21.99
- Cohort 2: 26.14




- exposed: 56.76±0.48 
(p<0.05 compared to
control)
Cell type: urothelial cells
Assessment: micronuclei
formation; to determine if
micronuclei formation 
decreased following 
implementation of measure to 
decreased arsenic
concentration in drinking 
water
Cell type: Buccal cells
Assessment: micronucleus
frequency
Reduction in Arsenic concentration in 
drinking water was associated with a 
decreased in micronuclei formation. In 
exposed cohorts, significant reductions in 
micronuclei formation were observed in the 
assessment conducted 2010–2011 
compared to the assessment conducted in 




- 2010–2011: 1.84±0.38 (p<0.001)
Cohort 2:
- 2004–2005: 4.51±1.27




Compared to control, a statistically
significant (p<0.05) increase in micronuclei
formation was observed in exposed workers.
Percent micronuclei formation (mean±SE):
- control: 0.21±0.36
- exposed: 1.52±0.41
No differences were observed between 
males and females.
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Table 3-12.  Genotoxicity in Humans Exposed to Oral Arsenic
Cell type and variables
Reference Study population Exposure assessed Outcomes
Decreased DNA repair
Mendez- Location: Mexico As concentrations: Cell type: peripheral blood DNA repair was significantly reduced in 
Gomez et al. Population: 3 groups of Drinking water (µg/L): lymphocytes Groups A (48% decrease; p=0.01) and C
2008 elementary school - Group A: 26.05 Assessment: DNA repair (74% decrease; p=0.001) compared to 
children based on - Group B (control): 6.8 capacity (analysis of breaks Group B
location to a smelter: - Group C: 13.16 following treatment of cells
Group A (distant): n=21; with H2O2
Group B (intermediate); Urine (µg/L):
n=19; Group C (near): - Group A: 143
n=21 - Group B (control): 100
- Group C: 115
As = arsenic; DNA = deoxyribonucleic acid; HFC = high frequency cell; SD = standard deviation; SCE = sister chromatid exchange; SE = standard error












     
     
     
  
    
 
 
    
  
    
  
  
   
   
   
    
    
 
   
    
  
   
  
 
   
  
   
  





Absorption of Water Soluble Inorganic and Organic Arsenic. Absorption of inorganic and organic
arsenic has been studied in a juvenile swine model (Juhasz et al. 2006).  Arsenic bioavailability (fraction 
of dose absorbed into blood) was lower for MMA(V) and DMA(V) compared to inorganic arsenite
(As(III)) or arsenate (As(V)).  Following a gavage dose of 80 or 100 µg As/kg, bioavailability was
103.9% (±25.8 SD) for As(III), 92.5% (±22.3 SD) for As(V), 16.7% (+5.0 SD) MMA(V) and 33.3%
(+1.7 SD) for DMA(V).
Absorption of Inorganic Arsenic in Food. A mass balance approach was used to estimate absorption of
arsenic from ingested food in a small group of human subjects (n=13 adults including 7 females; Stanek
et al. 2010).  The study consisted of two phases conducted approximately 2–3 years apart, with partial
overlap of subjects in both phases.  The subjects consumed self-prepared meals of their choosing and 
refrained from consuming foods that may have had high arsenic levels such as seafood, sea vegetables,
rice, mushrooms, spinach, and grape juice.  The subjects collected duplicate diet samples for all foods and 
beverages consumed during the study.  Arsenic absorption was estimated from measurements of daily
arsenic intakes (based on the duplicate diet samples) and excretion (fecal and urine) over a period of
7 days.  The estimated average absorption of arsenic from food was 87.5% (95% CI: 81.2, 93.8) in the
first phase of the study and 89.7% (95% CI: 83.4, 96.0) in the second phase of the study.
Absorption of arsenic from grains and vegetables has been studied in a juvenile swine model (Juhasz et al.
2006, 2008).  Arsenic in rice was identified as a mixture of organic and inorganic compounds and the
relative amounts of each varied with rice variety.  Arsenic in market-purchased Basmati white rice cooked
in water containing 1,000 µg/L As(V) was identified as 100% inorganic arsenic.  Bioavailability (fraction 
of dose absorbed into blood) of arsenic from the cooked white rice was 89% ±9 (SD).  Arsenic in 
greenhouse grown Quest rice was identified as 86% organic arsenic (primarily DMA; valence not
specified).  Bioavailability from the greenhouse grown Quest rice was 33.1% ±3.2 (SD).  Lower
bioavailability of arsenic from Quest rice was consistent with lower bioavailability of MMA and (16.7%
±5.0 SD) and DMA (33.3% ±1.7 SD) compared to As(III) (103.9% ±25.8 SD) or As(V) (92.5%
±22.3 SD) when administered by gavage.  In swine, bioavailability of arsenic in rinsed edible portions of
vegetables was estimated to be 52% ±18 (SD) for chard, 50% ±13 (SD) for lettuce, 77% ±20 (SD) for 






   
   
 
       
  
    
       
    
     
   
  
 
     
    
    
 
    
  
    
     
  
  
     
      
  
     
     
  
    




radish and 98% ±23 (SD) for mung bean (Juhasz et al. 2008).  All of the arsenic in the vegetables was 
identified as either inorganic As(III) or As(V).
Absorption of Inorganic Arsenic in Soil. Absorption of arsenic from soil was estimated in a mass 
balance study (Stanek et al. 2010).  Arsenic absorption was estimated from measurements of daily arsenic 
intakes and excretion over a period of 7 days in a group of 11 adults. Soil was ingested daily in a capsule 
containing approximately 0.6 g soil and 112 µg arsenic.  Characteristics of the soil were not reported, 
other than one soil sample having been collected at a cattle dip site where, presumably, arsenate pesticides
had been used. The estimated average absorption of arsenic from soil was 48.7% (95% CI: 36.2, 61.3)
compared to 89.7% (95% CI: 83.4, 96.0) from food. This study suggests that absorption of arsenic from
soil was approximately 46% lower than absorption from food (soil/food ratio=54%).
Studies conducted in animals show that bioavailability of arsenic in soil tends to be lower than that of
arsenic that is dissolved in water.  An analysis of animal bioassay data on relative bioavailability (RBA)
of soil arsenic (i.e., absorption from ingested soil relative to absorption of ingested sodium arsenate)
included 103 RBA estimates on 88 soils collected from sites contaminated as a result of mining and/or
smelting operations, pesticide or herbicide application, and/or manufacture (EPA 2012a).  Estimates of
RBA included in the analysis were derived from bioassays conducted in juvenile swine, mice, or monkeys
(Bradham et al. 2011; Brattin and Casteel 2013; Juhasz et al. 2007a, 2014a; Roberts et al. 2002, 2007;
Rodriguez et al. 1999). The average RBA for the 88 soils was 30%, the median was 28% and the 5th and 
95th percentiles were 4.1 and 56%, respectively.  The highest RBA observed was 78%.  A major portion 
of the observed variability in RBA for different soils can be explained by variations in bioaccessibility of
arsenic (solubility of arsenic in the gastrointestinal tract).  Bioaccessibility, measured with in vitro
extraction assays, has been shown to strongly correlate with RBA measured in animals (Basta et al. 2007;
Bradham et al. 2011; Brattin et al. 2013; Bruce et al. 2007; Denys et al. 2012; Juhasz et al. 2007a, 2007b, 
2009, 2011, 2014a, 2014b; Makris et al. 2008; Roberts et al. 2007; Rodriquez et al. 1999; Ruby et al. 
1996; Wragg et al. 2011). This suggests that physical and chemical factors that influence the dissolution
of arsenic from arsenic-bearing particles in the gastrointestinal tract are important determinants of
absorption of soil arsenic.  These may include particle morphology, including the degree to which arsenic
is surficial or occluded within particles, and arsenic mineralogy, which may affect solubility within the
gastrointestinal tract (Bradham et al. 2011; Brattin et al. 2013).
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3.4.1.3 Dermal Exposure
Dermal absorption of arsenate and arsenic in soil has been studied in Rhesus monkeys (Lowney et al. 
2007).  Soil or a sodium arsenate solution was applied to the shaved abdomen of monkeys (n=3) for a
period of 8 hours and urinary arsenic excretion was measured for a period of 7 days during and following
dosing. The sodium arsenate dose was 1.3 or 1.4 mg arsenic. Soils were dried and sieved to <150 µm
particle size and applied at a dose of 4 mg soil/cm2 to achieve a monolayer on the skin surface. Soils
were applied dry or wet. The dosing area (100 cm2) was covered to prevent removal of the soil from the 
skin (e.g., ingestion). Absorption was estimated as the ratio of the cumulative urinary excretion of arsenic 
0–96 hours following the dermal dose to the cumulative urinary excretion following an intravenous dose
of sodium arsenate. Soil samples from Colorado (1,230 mg As/kg soil) and New York (1,400 mg As/kg 
soil) were studied. Arsenic in the Colorado soil was identified as being primarily iron-arsenic oxide 
(95%).  Arsenic in the New York soil was primarily arsenic oxide (87%) and lead arsenate (10%). In two
dosing trials, absorption following dermal application of sodium arsenate ranged from 0.3 to 4.3% (mean 
2.5% ±2.3 SD) in the first trial and from 1.9 to 16% (mean 6.7% ±7.8 SD) in the second trial.  Arsenic
was not detectable above background following dermal dosing with either soil.  Estimated absorption 
from soil doses ranged from 0.19 to 0.33% when applied dry (mean 0.24% ±0.08 SD) and from 0 to 
0.85% when applied wet (mean 0.50% ±0.44 SD).
3.4.2 Distribution
3.4.2.1 Inhalation Exposure
Distribution of arsenic following inhalation exposure has been studied in mice (Burchiel et al. 2009, 
2010). Mice (male C57B1/6N) were exposed (nose-only) to aerosols of arsenic trioxide at concentrations 
of 50 or 1,000 µg As/m3 for 3 hours/day for 14 days. The mass median diameters of the two exposures
were 2.5 µm (±1.7 geometric standard deviation [GSD]) and 2.3 µm (±2.3 GSD).  Immediately following
exposure, dose-related increases in absorbed arsenic were observed in bladder, blood, brain, kidney, liver, 
lung, and spleen. The highest concentrations were observed in liver, followed by bladder and kidney. 
3.4.3 Metabolism
Two metabolic pathways for inorganic arsenic, an enzymic arsenic reduction/methylation pathway and an
alternative pathway involving nonenzymatic formation of arsenic-glutathione complexes, are described in
Agency for Toxic Substances Disease Registry (2007).  A third metabolic pathway recently has been 
proposed (Bhattacharjee et al. 2013a; Rehman and Naranmandura 2012).  This novel pathway involves
initial binding of inorganic arsenic to sulfhydryl groups of cysteinyl moieties on proteins, followed by






    
     
    
 




     
  
   
    
 
    
   
   
   
   
    
  
     
      
     




    
   
    
        
  
 
     
95ARSENIC
reductive methylation catalyzed by arsenic(III) methyltransferase (AS3MT) and using the methyl group 
donor S-adenosylmethionine (SAM) to form MMA(V) and DMA(V).  The products of this proposed 
pathway are the same as for the reduction/methylation and alternative pathways.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
3.4.5.1 Summary of PBPK Models
El-Masri and Kenyon (2008) Model. El-Masri and Kenyon (2008) developed a human PBPK model for
simulating ingested inorganic arsenate [As(V)], arsenite As(III), MMA(V), and DMA(V).  The model
consists of four interconnected submodels representing each of the above arsenic species.  Each submodel
includes compartments representing blood, brain, heart, kidney, liver, lung, skin and gastrointestinal tract.
Exchanges of arsenic between blood and tissues are simulated as flow-limited clearances governed by
tissue blood flow. First-order absorption from the gastrointestinal tract is assumed for all four arsenic 
species. Arsenic metabolism activity is assigned to kidney, liver, and lung, with lung being a lumped 
compartment representing the contribution from all other tissues other than kidney and liver. Oxidation 
and reduction of As(V) and As(III) is assumed to be first order and governed by rate constants for each
species.  Reduction of MMA(V) and DMA(V) is also assumed to be first order.  Methylation of As(III)
and MMA(III) is assumed to be capacity-limited with the rates governed by Km and Vmax and Ki, where Ki 
is the noncompetitive inhibition constant for As(III) or MMA(III).  All of the simulated arsenic species 
are excreted in urine. Excretion of As(III), As(V), MMA(V), or DMA(V) is simulated as first-order
transfer from kidney to urine.  Urinary excretion of MMA(III) or DMA(III) formed from reduction of
MMA(V) or DMA(V), respectively, is simulated as a direct first-order transfer of the reduced metabolite
to the urine (without entering the circulation). This non-physiologic simplification eliminates the need to 
parameterize the blood and tissue kinetics of MMA(III) and DMA(III).
Absorption rate constants were optimized from data on blood arsenic concentration kinetics in mice that
received oral doses of As(V), As(III), MMA(V), or DMA(V) (Hughes et al. 2005; Kenyon et al. 2005a,
2005b). Rate constants for urinary excretion were optimized from data on urinary excretion in adults who 
were administered a single oral dose of arsenic (500 µg) as As(III), MMA(V), or DMA(V) (Buchet et al.
1981a). Values for Km and Ki for methylation were derived from in vitro studies of the purified
methyltransferases (Wildfang et al. 1998; Zakharyan et al. 1999).  Values for methylation Vmax and all
other metabolism rate constants were optimized from data on urinary excretion humans dosed with 
As(III), MMA(V), or DMA(V) (Buchet et al. 1981a). Values for tissue/blood partition coefficients were
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derived from tissue/blood arsenic ratios measured in autopsy samples from poisoning cases (Yu 1999a);
however, alternative values based on studies conducted in rodents were also evaluated. 
The model was evaluated by comparing predictions with observation made in humans of urinary
excretion of total arsenic, inorganic arsenic, DMA, and MMA from studies not used in model calibration 
(Aposhian et al. 2000; Mandal et al. 2001; Mann et al. 1996b; Valenzuela et al. 2005).  Sensitivity
analyses showed that urinary predictions were sensitive to values assigned to rate constants for urinary
excretion, reduction, and Vmax for methylation. Metrics used to evaluate agreement between predictions
and observations included median performance error and PBPK index (El-Masri and Kenyon 2008;
Krishnan et al. 1995).  The model performed better at predicting excretion of inorganic arsenic (error
<10%) than methylated arsenic.  At arsenic doses up to 500 µg, median percent error was <60% for
methylated arsenic; however, error was larger at higher arsenic doses. The model overpredicted DMA
excretion following a 1,000 µg arsenic dose (percent error >300%), which may reflect a dose-dependence 
of methylation not simulated in the model (Buchet et al. 1981b).
Evans et al. (2008) Model. Evans et al. (2008) developed a mouse PBPK model for simulating injected
and ingested DMA(V) (see Figure 3-1). The model includes compartments representing blood, plasma, 
red blood cells, kidney, liver, lung, skin, urinary bladder, and gastrointestinal tract. Exchanges of arsenic 
between blood and tissues are simulated as either flow-limited or diffusion-limited clearances.
Absorption from the gastrointestinal tract and excretion of DMA(V) from kidney to urine were assumed 
to be first order. The blood compartment included subcompartments representing red blood cells and 
plasma, with exchanges between the two governed by binding constants or DMA(V) in both 
subcompartments. Metabolism of DMA(V) (to TMAO) was assigned to the liver and was assumed to be 
first order.
Partition coefficients were optimized from data on tissue DMA(V) concentration in mice that received 
singe intravenous injections of DMA(V) (1.11 or 111 mg DMA(V)/kg; Hughes and Kenyon 1998). 
Urinary excretion data from the intravenous studies were used to estimate the urinary excretion rate 
constant (Hughes and Kenyon 1998). The metabolism rate constant was calculated from urinary
excretion kinetics of TMAO in mice that received and oral dose of DMA(V) (Marafante et al. 1987). 
Parameters were first optimized for the flow-limited model, with diffusion permeability constants set to
zero.  Parameters, including permeability coefficients, were re-optimized for the diffusion limited model, 
keeping values of the metabolism and urinary excretion rate constants the same in both models. The
partition coefficients for the two models were similar.  The absorption rate constant was optimized from













      










































































Ca = arterial blood; DMA = dimethylarsinic acid; Kabs = absorption from stomach; Kel = kidney clearance;
Ktmao = metabolism; PBPK = physiologically based pharmacokinetic
Source:  Evans et al. 2008; reproduced by permission of Oxford University Press in the format reuse in 
government report via Copyright Clearance Center.











     
      
    
      
   
  
   
     
     
  
 
   
 
     
   
    




    
 
   
 
















   
 






data on tissue DMA concentrations following a single gavage dose (1.11 or 111 mg DMA(V)/kg; Hughes
et al. 2008).
Model performance was evaluated using the PBPK index statistic for comparing predictions and 
observations (Krishnan et al. 1995).  For most tissues (plasma, kidney, liver, red blood cells), the
diffusion-limited model yielded PBPK indices that were approximately 30% lower than the flow-limited
model, for both the intravenous calibration data and the oral data (only the absorption rate constant was
optimized to the oral data). Lower PBPK indices indicate that the diffusion-limited model provided a
better fit to the observations than the flow-limited model. Sensitivity analyses showed that sensitivity
apparent soon after dosing (e.g., <5 hours) was not always evident at later time periods.  Urinary
predictions were sensitive to values assigned to rate constants for urinary excretion, reduction, and Vmax 
for methylation.  With the exception of kidney, standardized coefficients for diffusion permeability
coefficients were zero for predictions of all other tissues, suggesting that the diffusion-limited model had 
its largest impact on kidney kinetics.  This is consistent with improved PBPK indices for the kidney in the
diffusion-limited model (0.03–0.07) compared to the flow-limited model (0.13–0.25).  
3.4.5.2 Arsenic PBPK Model Comparison
The El-Masri and Kenyon (2008) and Evans et al. (2008) models supplement two other models, the Mann 
model (Gentry et al. 2004; Mann et al. 1996a, 1996b) and the Yu model (Yu 1998a, 1998b, 1999a, 
1999b) that are described in the ATSDR Toxicological Profile for Arsenic (Agency for Toxic Substances
and Disease Registry 2007).  Major features of the four models are compared in Table 3-13.  






















AsIII, AsV, MMAV, or
DMAV.  Metabolism in 
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tissues).  Tissue-plasma 
exchanges flow-limited.




















    
 












































   
   









   
    
   
   
    
   
    



























AsIII, AsV, or DMA.  
Methylation assigned to 
liver; oxidation and 





















BI, FE, UR Simulates kinetics
following dosing with
AsIII, AsV, MMA, or DMA.  
Metabolism is assigned 
to kidney and liver.
Tissue-plasma 
exchanges flow-limited.
aSpecies: HUM = human; HAM = hamster; MOU = mouse; RAB =  rabbit; RAT =  rat.
 
bAbsorption pathways: INH = inhalation; IT, intratracheal; IV = intravenous; OR = oral.
 
cTissues: BL = blood; BLAD = bladder; BR = brain; KI = kidney; LI = liver; LINT = large intestine; MU = muscle;
 




dExcretion pathways: BI = biliary; FE = fecal; UR = urine.
 




3.4.5.3 Discussion of Models
Risk assessment applications of the El-Masri and Kenyon (2008) and Evans et al. (2008) models have not
been reported.  The Evans et al. (2008) model simulates DMA(V) absorption and kinetics in the mouse
and applications would be limited to dosimetry predictions in mice dosed with DMA(V). The El-Masri
and Kenyon (2008) model simulated absorption and kinetics of As(III), As(V), MMA(V), or DMA(V)
and simulates all of the major metabolic pathways for these species. The model was used to predict
urinary MMA(III) and DMA(III) excretion in populations exposed to inorganic arsenic in drinking water
(Aposhian et al. 2000; Mandal et al. 2001). When average drinking water concentrations and typical
drinking water intakes (1.5–2.0 L/day) were assumed in these simulations, predictions agreed well with
population means for metabolite excretion.
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3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Cellular Uptake. Cellular uptake of arsenic depends upon the arsenic oxidation state and cell type.
Arsenic can cross cell membranes by passive diffusion or carrier protein mediated transport.  For passive 
diffusion, cell membranes are more permeable to As(III) than As(V).  For carrier-mediate transport,
aquaglycoprotein channels and phosphate transporters have been proposed as mechanisms for carrier-
mediated transport of arsenite and arsenate, respectively (Bustaffa et al. 2014; Druwe and Vaillancourt
2010; Kumagai and Sumi 2007).
Genetic Polymorphisms of Arsenic-metabolizing Enzymes. As reviewed by Agency for Toxic
Substances Disease Registry (2007), As(III) is more toxic than As(V) and, similarly, methylated forms of
arsenite appear to be more toxic than methylated forms of arsenate. Therefore, alterations in arsenic 
metabolism that result in increased formation or decreased oxidation of As(III) compounds to As(V)
compounds may increase arsenic-induced toxicity. As noted in several reviews, genetic polymorphisms
for several enzymes involved in arsenic metabolism have been associated with increased As(III) 
metabolites in urine. Alterations in arsenic metabolism may, in part, provide a basis for interindividual 
sensitivity to arsenic (Bailey and Fry 2014a, 2014b; Bhattacharjee et al. 2013a; Bustaffa et al. 2014; Faita
et al. 2013; Naujokas et al. 2013; Sumi and Himeno 2012; Smith and Steinmaus 2009). Recent studies 
have examined the relationship between polymorphisms of arsenic metabolizing enzymes and urine
profiles of metabolites and/or risk of arsenic-induced effects in human populations.  Polymorphisms
examined include AS3MT (Agusa et al. 2009; Engstrom et al. 2009, 2011; Porter et al. 2010; Rodrigues
et al. 2012; Tellez-Plaza et al. 2013), cystathione-β-synthase (Porter et al. 2010), glutathione S-transferase 
π1 (Agusa et al. 2012; Antonelli et al. 2014; Marcos et al. 2006), glutathione S-transferase ω1 (Ahsan et
al. 2007; Antonelli et al. 2014; Marcos et al. 2006; Porter et al. 2010; Rodrigues et al. 2012), 
methylenetetrahydrofolate reductase (Ahsan et al. 2007; Chung et al. 2010; Porter et al. 2010), and 
N-6-adenine-specific DNA methyltransferase 1 (Harari et al. 2013).  In general, results show that genetic 
polymorphisms of arsenic-metabolizing enzymes in humans are associated with differences in the
MMA:DMA ratio in urine.
3.5.2 Mechanisms of Toxicity
The toxicity of arsenic, including cancer, is most likely due to multiple mechanisms, with some 
mechanisms acting sequentially or synergistically. Two general types of mechanisms appear to be
involved in arsenic-induced toxicity: (1) formation of reactive oxygen species (ROS) and subsequent
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damage to cellular macromolecules and oxidative stress and (2) interaction of reactive arsenic or arsenic 
metabolite species with cellular macromolecules. In addition, recent advances in mechanisms of arsenic-
induced toxicity have focused on epigenetic changes.
ROS. Results of mechanistic studies of arsenic toxicity suggest a role of ROS in the toxicity of inorganic
arsenic (Bailey and Fry 2014b; Bhattacharjee et al. 2013a, 2013b; Bustaffa et al. 2014; Druwe and 
Vaillancourt 2010; Faita et al. 2013; Kumagai and Sumi 2007; Martinez et al. 2011; Salinkow and 
Zhitkovich 2008). Superoxide anion and subsequent formation of hydrogen peroxide and hydroxyl
radical have been proposed as the primary ROS associated with arsenic-induced oxidative stress.
Oxidative stress is considered to be one of the initial biological effects in arsenic-induced toxicity, 
including carcinogenesis.
Arsenic-induced ROS generation has been associated with numerous effects on cellular targets, which can 
directly damage cellular targets or lead to a cascade of effects in response to oxidative stress. The 
following effects have been associated with arsenic-induced ROS: reduced steady-state levels of nitric 
oxide; alterations in intracellular oxidation/reduction reactions, which can alter intracellular redox status; 
decreased glutathione levels; lipid peroxidation; damage to proteins; inhibition of pyruvate
dehydrogenase; disruption of the mitochondrial membrane and inhibition of mitochondrial enzymes;
altered protein phosphorylation and subsequent disruption of various signal-transduction pathway;
increased expression of stress-response transcription factors, and genomic instability through damage to 
DNA (single and double strand breaks, DNA adducts, base-pair mutations, rearrangement of deletions
insertions, and sequence amplifications), irreversible inhibition of DNA repair, telomere dysfunction, and 
mitotic arrest.
Interactions of Arsenic and Arsenic Metabolites with Cellular Targets. Interaction of reactive arsenic or
arsenic metabolite species with cellular macromolecules are associated with alterations in cell function
(Bhattacharjee et al. 2013a; Bustaffa et al. 2014; Druwe and Vaillancourt 2010; Salinkow and Zhitkovich 
2008; Wantanabe and Hirano 2013). Due to the reactivity of arsenic and metabolites, several cellular
targets for arsenic-induced effects have been identified, with most having numerous cascading effects.
Arsenate, arsenite, MMA, and DMA directly interact with thiol groups of macromolecules (e.g., cysteine 
and glutathione).  As a result, arsenic can inhibit the activity of thiol-rich enzymes, including pyruvate
dehydrogenase, 2-oxoglutarate dehydrogenase, and tyrosine phosphatases, and interact with zinc finger
proteins.  Arsenic also has been shown to interfere with oxidative phosphorylation through the formation 
an unstable arsenate ester. Arsenic species participate in several biochemical reactions including covalent 
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interactions, methylation and demethylation reactions, acid-base reactions, and oxidation-reduction 
reactions.  Arsenic alters proteins in the insulin signaling pathway, leading to a disruption of glucose
homeostasis. Other cellular effects attributed to arsenic include stimulation of the sphingosine­
1-phosphate receptor (a G protein-coupled receptor), mitotic arrest, and interactions with tubulin (leading
to mitotic arrest).  
Epigenetic Changes. The epigenome refers to chemical compounds that function as gene regulators
without altering DNA sequences. Recent research has shown the importance of the epigenome in 
maintaining development, growth, and cellular homeostasis.  Epigenetic changes can lead to changes in
gene expression and cause genetic instability. Changes to the epigenome have been proposed as 
important mechanisms in arsenic-induced toxicity, developmental effects, and carcinogenesis (Arita and 
Costa 2009; Bailey and Fry 2014b; Bhattacharjee et al. 2013a, 2013b; Bustaffa et al. 2014; Martinez et al. 
2011; Salinkow and Zhitkovich 2008). However, specific biological consequences and causal
relationships of epigenetic changes have not been established and are likely to vary with cell types and
arsenic dose and exposure duration.
Arsenic has been shown to affect the epigenome by alterations in DNA methylation, histones, and
microRNAs (miRNAs). DNA methylation is the addition of a methyl group to a cytosine or adenine 
nucleotide in DNA; methylation is an important mechanism for regulating gene expression.  Results of in 
vitro and animal studies and studies of human population, have shown that arsenic induces both hypo-
and hypermethylation of DNA. Alterations in DNA methylation have been associated with development
of arsenic-induced diseases, including carcinogenesis and developmental effects. It has been proposed
that hypomethylation upregulates oncogenes and that hypermethylation downregulates tumor suppressor
genes. Histones, the main protein component of chromatin, are involved in regulation of gene expression.  
DNA wraps around histones, forming nucleosomes.  Recent studies show that arsenic can produce post-
translational modifications to histones through methylation, acetylation, phosphorylation, and 
ubiquination of specific amino acids within the histone, and thereby affect gene transcription. miRNAs
are small noncoding RNAs that are involved in post-transcriptional regulation of gene expression.  
Arsenic has been shown to alter expression of miRNAs and it has been proposed that miRNAs are 
involved in the development and progression of cancer.
3.7 CHILDREN’S SUSCEPTIBILITY
As discussed in Section 3.2.2.6, developmental and neurodevelopmental effects have been observed in 
infants and children following prenatal and early life exposure to arsenic in drinking water (Ahmed et al.
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2012; Farzan et al. 2013; Guan et al. 2012; Hamadini et al. 2010, 2011; Hsieh et al. 2014; Jin et al. 2013;
Khan et al. 2012; Kippler et al. 2012; Nahar et al. 2014; Parvez et al. 2011; Rahman et al. 2007, 2009, 
2010, 2011; Raqib et al. 2009; Roy et al. 2011; Rudnai et al. 2014; Saha et al. 2012; Vall et al. 2012;
Wasserman et al. 2007, 2011, 2014; Wu et al. 2014). In addition, prenatal exposure of humans and 
animals to arsenic is associated with the development of cancer in offspring later in life (see 
Section 3.2.2.7; Smith et al. 2006, 2012; Tokar et al. 2012a, 2012b; Yuan et al. 2010).
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
Genetic polymorphisms of enzymes involved in the metabolism of arsenic, including AS3MT and 
glutathione transferases (Bailey and Fry 2014a, 2014b; Bhattacharjee et al. 2013a; Bustaffa et al. 2014;
Faita et al. 2013; Naujokas et al. 2013; Sumi and Himeno 2012; Smith and Steinmaus 2009) are
associated with differences in the MMA:DMA ratio in urine.  Individuals with polymorphisms associated 
with a higher MMA:DMA ratio in urine may be more susceptible to arsenic-induced toxicity.
4. CHEMICAL AND PHYSICAL INFORMATION
No updated data.
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
U.S. production of metallic arsenic and arsenic trioxide ceased in 1985; limited quantities of metallic 
arsenic, however, may be recovered from gallium arsenide semiconductor scrap (USGS 2014).
5.2 IMPORT/EXPORT
China was the major import source for elemental arsenic during the years 2009–2012, supplying 87%, 
followed by Japan (12%) and others (1%).  Morocco was the major import source for arsenic trioxide
during the years 2009–2012, supplying 67%, followed by China (20%), Belgium (12%), and others (1%)
(USGS 2014).  
U.S. exports of elemental arsenic were 354 metric tons in 2009, 481 metric tons in 2010, 705 metric tons 
in 2011, and 439 metric tons in 2012, and are estimated to be 1,750 metric tons in 2013 (USGS 2014). 
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5.3 USE
According to the National Pesticide Information Retrieval System (NPIRS), arsenic acid, arsenic 
pentoxide, and sodium methanearsonate are currently registered as pesticides in the United States; there 
are no active registrants listed for arsenic trioxide, calcium arsenate, lead arsenate, sodium arsenite,
arsanilic acid, dimethylarsinic acid, disodium methanearsonate, methanearsonic acid, or sodium
dimethylarsinate (NPIRS 2015).
Gallium-arsenide (GaAs) is used in third- and fourth-generation “smartphones” (USGS 2014).
5.4 DISPOSAL
As of February 2014, both metallic arsenic from gallium arsenide semiconductor manufacturing and
arsenic contained in the process water of wood treatment plants using CCA were recycled (USGS 2014).  
However, metallic arsenic was not recovered during metal recycling of electronic circuit boards, relays,
and switches, which may contain arsenic, nor was metallic arsenic recovered from arsenic-containing
residues or dust generated at nonferrous smelters in the United States (USGS 2014).
The EPA issued a reregistration eligibility decision (RED) for wood preservatives containing chromated 
arsenicals, including chromated copper arsenate (CCA) and ammoniacal copper arsenate (ACA) (EPA
2008).  Based on the results of the RED, the EPA concluded that current registered uses of chromated
arsenicals are eligible for reregistration upon meeting specific risk mitigation procedures, proper end-use, 
and labeling.  Active ingredients containing arsenic evaluated in the assessment include arsenic acid and
arsenic oxide.
Wastes generated from the treatment of wood are regulated under the Resource Conservation and 
Recovery Act (RCRA). Waste water generated from wood preservation is listed as Hazardous Waste 
number F035 (EPA 2008).
CCA-treated wood is commonly disposed of in construction or demolition landfills, municipal solid waste 
landfills, or industrial nonhazardous waste landfills.  Existing federal hazardous waste regulations require 
testing procedures to evaluate if a representative sample of the waste leaches arsenic above a certain
threshold concentration.  This value determines whether wastes containing arsenic are defined as 
hazardous waste.  Some CCA-treated wood may meet this definition; however, because of an existing
exemption by the federal register (40 CFR 261.4(b)(9)), CCA-treated wood is generally not defined as a 














   









     
 






    
   
   










hazardous waste (EPA 2008).  Disposal may occur with household trash, where the disposal would be
defined by state and local waste management authorities (EPA 2008).
6. POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
Arsenic has been identified in at least 860 of the 1,754 proposed (47), final (1,322), and deleted (385)
hazardous waste sites listed on the EPA Superfund National Priorities List (NPL) (EPA 2013a; NLM
2014).  However, the number of sites evaluated for arsenic is not known.
Exposure to the general population occurs through contaminated groundwater and can also occur from the
ingestion of foods containing arsenic compounds.  Exposure from drinking water, water used for food 
preparation, or water used in crop (especially rice) irrigation, is a source of concern, as elevated
concentrations have been reported.
6.2 RELEASES TO THE ENVIRONMENT
Of the 20,853 Toxics Release Inventory (TRI) facilities reporting nationwide, elemental arsenic has been
reported in 40 on site-releases and inorganic arsenic compounds have been reported in no on-site releases,
for the reporting year 2012 (NLM 2014).
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
6.4.1 Air
Ambient air and precipitation samples were collected at a site in Washington, DC (Melaku et al. 2008).  
The ambient air samples collected every 6 days over 7 months had total arsenic concentrations ranging of
from 0.800 to 15.7 ng/m3.  Wet deposition samples collected every 6 days for 1 year resulted in total
arsenic concentrations ranging from 0.20 to 1.3 µg/L.
6.4.2 Water
A Washington State Environmental Biomonitoring Survey was conducted with tap water samples from
82 households in South Whidbey from July to September 2011.  Results indicated that 54% of the water
samples exceeded the EPA drinking water standard (maximum contaminant level [MCL]=10 μg/L)
(WA DOH 2015).






     
  
       
 
    
      
   
    
     
  
    
 
  
    
   
   
       
     
 
  
    
 
   
   
  
  
    




Wasserman et al. (2014) measured kitchen tap water in Maine households; the average value found was 
9.88 μg/L.  Close to one-third of the water samples exceeded the EPA drinking water standard 
(MCL=10 μg/L). The highest level found was 115.3 μg/L. 
In September and October 2005, samples from eight sites located in Lake Mohawk, a man-made body of
water in New Jersey, were assessed for arsenic concentrations (Barringer et al. 2011).  Shallow and deep
lake water and sediment samples were collected.  Lakes depths ranged from 1 to 7 m.  The source water
for the lake is predominantly groundwater.  The lake is surrounded by approximately 2,200 homes and a
golf course located on the western shore.  It was reported that in the mid-20th century, an estimated
300,000 kg of arsenical pesticides were applied to the lake.  Concentrations of arsenic in sediment cores
ranged from 91 to 460 mg/kg (91–460 µg/g).  Concentrations in filtered (27.5–31.5 µg/L) and unfiltered 
(23–26 µg/L) water samples appeared to be evenly distributed in the lake.
In 2006, arsenic concentrations were measured in samples of runoff water, from two detention basins in
Raccoon Creek, New Jersey (USGS 2011a).  Arsenic concentrations in water samples collected in
September, 2006 upstream of the outfall of basin one, at the basin, and at the outfall reported for detention 
basin one were 0.663, 2.56, and 2.44 μg/L, respectively, for filtered samples and 2.28, 2.68, and 
2.45 μg/L, respectively, for unfiltered samples.  Arsenic concentrations in water samples collected in
May, 2006 upstream of the outfall of basin two, at the basin, and at the outfall reported for detention basin 
two were 0.872, 1.54, and 2.10 μg/L, respectively, for filtered samples and 1.39, 1.63, and 2.21 μg/L, 
respectively, for unfiltered samples. Arsenic concentrations in water samples collected in September,
2006 upstream of the outfall of basin two, at the basin, and at the outfall reported for detention basin two 
were 1.00, 4.35, and 3.11 μg/L, respectively, for filtered samples and 3.10, 4.35, and 3.71 μg/L,
respectively, for unfiltered samples.
In Sutherlin, Oakland, and Yoncalla, Oregon, naturally occurring arsenic in groundwater was studied by
the Environmental Health Assessment Program (EHAP), a part of the Oregon Department of Human
Services (DHS) Office of Environmental Public Health (Agency for Toxic Substances and Disease 
Registry 2009).  Well water analysis was performed for 124 samples collected from 114 private wells 
between June 9 and June 18, 2008.  Arsenic was detected in 29 of the wells at concentrations ranging
from 1 to 460 ppb (0.001–0.460 µg/L). Water samples that exceeded the EPA drinking water standard
(MCL=10 μg/L) occurred in 13 of the wells located in areas east of Sutherlin, 11 of which were intended
for domestic use.











   
   
  
   
 
  
    




     
 
  
    
   
     
 
   
 
 
   





Arsenic in groundwater has been correlated to the geology of the region, including aquifer characteristics, 
pH, redox conditions, and concentrations of inorganic minerals (Jones and Pilcher 2007; Meliker et al. 
2009; Root et al. 2010; USGS 2011b).  Aquifer recharge and aquifer storage and recovery (ASR) are 
processes employed in storing available water in aquifers and using the water when it is needed.  Arsenic 
mobilization was investigated in Southwest Central Florida (Jones and Pilcher 2007) and southeastern 
Michigan groundwater (Meliker et al. 2009).  From 300 core samples of 19 wells, a mean concentration 
of 3.5 µg/L arsenic was found in the Limestone of wells, in Southwest Central Florida region, used in 
groundwater recharge.  Study results confirmed that arsenic is released from minerals containing arsenic,
such as pyrite.  Pyrite becomes unstable and dissolves when redox conditions shift towards a more 
oxidizing environment, increasing the potential of leaching arsenic into the stored water.  Conditions in 
the Suwannee Limestone were reducing; therefore, low levels of arsenic were found.  Arsenic 
concentrations in well water from 13 of the 19 wells were <0.02 µg/L; 6 of the 19 samples had levels
ranging from 0.022 to 0.036 µg/L (Jones and Pilcher 2007).  The spatial relationships in groundwater
recharge wells, well characteristics, and dissolved arsenic in unconsolidated and bedrock aquifers of
southeastern Michigan were studied (Meliker et al. 2009). Total arsenic concentrations in water from
641 bedrock wells in the Southeastern Michigan region ranged from not detectable to 161 µg/L; the mean 
total arsenic concentration was 4 µg/L and the median was 3 µg/L (Meliker et al. 2009).  Total arsenic
concentrations in water from 71 unconsolidated wells in the Southeastern Michigan region ranged from
not detectable to 46 µg/L; the mean total arsenic concentration was 11 µg/L and the median was 17 µg/L.
During the spring and summer of 2009 in east-central Massachusetts, 478 private bedrock wells were 
sampled for analysis of arsenic concentrations by the U.S. Geological Survey (USGS 2011b).  In 24% of
the samples, arsenic concentrations were below the method detection limit of 0.2 µg/L.  Concentrations
up to 1,540 µg/L were reported.  Concentrations >10 µg/L were found in 13–15% of samples.
Correlations with bedrock units were made in order to calculate the probability of elevated arsenic in area
wells.  It was estimated that 5,741 wells in the State of Massachusetts may contain arsenic concentrations 
>10 µg/L. 
Arsenic concentrations in mine groundwater and sediment from the Judge Tunnel, a water treatment
facility in Park City, Utah, were measured.  Total arsenic concentrations of 0.009–0.010 mg/L (9– 
10 µg/L) and <5 µg/L were reported in unfiltered and filtered water samples, respectively.  The total
arsenic concentrations in sediments collected from water storage tanks was 320 mg/kg (320 µg/g)
(Pawlak et al. 2008).  In one area of the Park City distribution system, hydrant-flushed water had elevated
arsenic concentrations of 21.2–151 µg/L.
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Arsenopyrite and pyrite, present in gold-bearing quartz veins of the Lucky Shot Gold Mine in Alaska, 
were attributed to the elevated arsenic concentrations in mine tailings and drainage water (Torrance et al.
2012).  The mine was in operation from 1920 to 1942, producing 252,000 ounces of gold.  Water samples
were collected in August 2010 and September 2011 from 17 established monitoring wells.  Total arsenic
concentrations ranged from <1.0 µg/L found downstream to 752.5 µg/L found in water seeping from
mine tailings. The main source of arsenic was found to be discharge from the mine adits.  Less than half
of the monitoring wells (five total) had total arsenic concentrations >10 µg/L.  Arsenite accounted for
close to 100% of the total arsenic present in the majority of the wells.  A <2% difference in arsenic 
concentrations from filtered versus unfiltered samples indicated that the majority of arsenic present was in
aqueous form.
In 2008, speciation of arsenic was performed in groundwater samples of a former ammunition depot and 
filling station in Germany operating in the 1940s (Daus et al. 2010).  Remediation of the site was
performed in 2005 by soil excavation.  In June 2008, samples were taken at the source 2.0–15 m below
the surface. Total arsenic reported in this study includes the summation of arsenite, arsenate, 
phenylarsonic acid, phenylarsine oxide, and diphenylarsinic acid.  The highest concentration of total
arsenic in source samples of groundwater was reported as 16 mg/L (16,000 µg/L), detected 4.4–5.4 m
below the surface.  Concentrations >1 mg/L (1,000 µg/L) were typically confined to depths ≤10 m.  In 
November 2008, groundwater samples were taken 1 km from the source in the flow direction of the
groundwater, at depths ranging from 4.8 to 25.0 m below the surface. Total arsenic concentrations were
<400 µg/L.  The species found here included arsenite, arsenate, phenylarsonic acid, phenylarsine oxide,
and diphenylarsinic acid.  Proportions of the species changed with the sampling depth. 
Ayotte et al. (2015) analyzed five datasets containing arsenic concentrations in wells in the United States.
Data were compiled for 1,245 public and private drinking water wells. The two most recent samples
available for each well were used for this analysis.  Data from filtered samples of 312 public and private 
wells collected from 1993 to 2008 at aquifers across the United States were obtained from the USGS
National Water-Quality Assessment (NAWQA) Program dataset.  Samples in New England were 
obtained from 607 public bedrock wells sampled from 1995 to 2008.  A dataset for the Lamprey River
basin was compiled from unfiltered water samples from 148 domestic wells across the basin in 2004 and
2005. The Lamprey River basin samples were analyzed at the New Hampshire Department of
Environmental Services (NHDES) Laboratory, an EPA contract laboratory, and the EPA National Air and 
Radiation Environmental Laboratory.  Unfiltered samples from 35 private bedrock wells near the Mottolo 
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Superfund site sampled from 2009 to 2010 and analyzed at the NHDES laboratory and 143 domestic 
bedrock wells sampled from 2002 to 2012 by homeowners and analyzed by EPA laboratory were also 
included.  Concentrations of arsenic in a specific well did not vary greatly over time:  <±4 μg/L
variability in 87% of the wells considered in this analysis. Variability in arsenic concentrations occurred
more often in public water supplies compared to private wells.  Variability was dependent upon multiple
factors including geochemical parameters.  Data indicated a weak correlation to seasonal variability in the 
New England area but not in California; concentrations in New England during the first half of the year
were lower than arsenic concentrations in the second half of the year. Variability in California wells
appeared to be a result of geochemical processes as well as aquifer storage and recovery practices,
including groundwater recharge methods.
Speciation tests were performed in 65 wells from 59 sites across the United States with naturally
occurring arsenic (Sorg et al. 2014). The sites chosen for the study were either part of the EPA Arsenic 
Demonstration Program (ADP) (n=50), proposed sites for the ADP program (n=5), or EPA research
project sites (n=4).  Analysis was conducted monthly for up to 3 years in select wells.  Arsenate was 
found as the dominant species in 31 wells, arsenite was the dominant species in 29 wells, and almost
equal amounts of the two species were found in 5 wells.  Overall concentrations of arsenic species in a 
specific well did not vary greatly over time. The average iron content was 29, 1,544, 30, and 129 µg/L
for the wells located in the East, Midwest, West, and Farwest regions, respectively. The average 
oxidation/reduction potentials were 244, -17, 179, and 213 mV for the wells located in the East, Midwest, 
West, and Farwest regions, respectively. The average pH of the wells in this assessment ranged from
7.4 to 7.9 in all four regions. On average, 92–100% of arsenic in the samples was in soluble form, and 
arsenate occurred as the dominant species in the East, West, and Farwest wells. Sites in the East region
included wells in Maine, New Hampshire, Vermont, Rhode Island, Connecticut, Delaware, Maryland, 
New York, and Pennsylvania. In the East region, the average concentration of total arsenic found was 
27.6 µg/L, the average particulate concentration was 0.3 µg/L, the average soluble arsenic concentration 
was 27.8 µg/L, and the average concentrations of arsenate and arsenite were 19.8 and 8.0 µg/L,
respectively.  Sites in the West region included wells in Texas, South Dakota, Nebraska, New Mexico,
Arizona, and Montana. In the West region, the average concentration of total arsenic found was
36.3 µg/L, the average particulate concentration was 1.5 µg/L, the average soluble arsenic concentration
was 35.0 µg/L, and the average concentrations of arsenate and arsenite were 30.4 and 5.2 µg/L, 
respectively.  Sites in the Farwest region included wells in California, Oregon, Washington, Idaho, 
Nevada, and Utah.  The average concentration of total arsenic found was 34.1 µg/L, the average
particulate concentration was 1.3 µg/L, the average soluble arsenic concentration was 33.1 µg/L, and the






    
  
 
   
     
   
 
   
     
    
     
    
   
   
    
      
      
    
 
     
   
  
  
     
  
 
     
   
   





average concentrations of arsenate and arsenite were 28.2 and 4.8 µg/L, respectively.  Arsenite occurred
as the dominant species in anoxic Midwest wells with elevated iron concentrations. Sites in the Midwest
region included wells in Ohio, Michigan, Indiana, Illinois, Wisconsin, Minnesota, and Louisiana.  The
average concentration of total arsenic found was 28.6 µg/L, the average particulate concentration was
2.6 µg/L, the average soluble arsenic concentration was 26.1 µg/L, and the average concentrations of
arsenate and arsenite were 2.3 and 24.1 µg/L, respectively.
Erikson and Barnes (2005) evaluated arsenic concentrations in public water systems located inside 
(1,764 wells) and outside (2,182 wells) an area where glacial sediment had been deposited, known as the
northwest provenance Wisconsin-aged drift. Bedrock and glacial drift wells in North Dakota, South
Dakota, Minnesota, and Iowa were also investigated. The study found that inside the drift, 12.0% of
public water systems exceed 10 µg/L, while only 2.4% of public water systems exceed 10 µg/L outside
the area.  Of the wells located inside the drift, 1.5% exceeded 10 µg/L arsenic bedrock with well depths
ranging from 800 to 186 m (n=132), 3.8% exceeded 10 µg/L arsenic with well depths ranging from 185 to 
92 m (n=263), and 22.1% exceeded 10 µg/L arsenic with well depths ranging from 91 to 4 m (n=131). Of
the wells located inside the drift, 8.5% exceeded 10 µg/L with well depths ranging from 157 to 65 m 
(n=120), 27.0% exceeded 10 µg/L arsenic with well depths ranging from 64 to 28 m (n=236), and 7.4%
exceeded 10 µg/L arsenic depths ranging from 28 to 7 m (n=118).
Pichler et al. (2008) investigated arsenic concentrations and seasonal variations in 28 golf course lakes at
four golf courses in Hillsborough County, Florida.  Each of the four sites studied used private wells as 
their water source and applied monosodium methanearsonate as an herbicide.  Surface water samples 
were collected monthly from February 2001 through January 2002. Total arsenic concentrations detected
in lake samples ranged from 0 to 124 µg/L and an annual mean of 10.9 µg/L was reported for all lakes.
The most recently renovated course had the lowest levels of total arsenic.
Hudak et al. (2008) compiled data on arsenic concentrations in 64 wells supplied by the Seymour Aquifer.
Data were obtained from the Ground Water Database of the Texas Water Development Board sampled
during 2001 and 2004.  The median concentrations of arsenic in water were 3.5, 2.7, and <2.0 µg/L in
irrigation wells, domestic wells, and public wells, respectively. Well depths ranged from 7.3 to 55.5 m,
with a median value of 16.8 m. No statistically significant correlation was found between arsenic 
concentrations and well depths.
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6.4.3 Sediment and Soil
Background concentrations of total arsenic in farming soils collected from Poland ranged from 4.98 to 
17.40 mg/kg (4.98–17.40 μg/g) soil, with an average arsenic concentration of 8.83 mg/kg (8.83 μg/g) soil
(Loska et al. 2005).  Xu et al. (2008) evaluated growing practices (aerobic and flooded) and their effects
on soil arsenic concentrations using soil from the upper layer (0–20 cm) of a field on the Rothamsted 
farm, Southeast England.  The initial total arsenic concentration of the soil was reported as 15.1 mg/kg
(15.1 μg/g).  It was shown that flooding practices result in soil solutions with higher overall arsenic
concentrations, arsenite was the predominant species. In samples collected between 12 and 97 days after
flooding treatments, arsenite accounted for 81–95% of the total arsenic.  In aerobic practices arsenate was 
the predominant species, accounting for >88% of the total arsenic.  In soils under flooded conditions, the
concentration of total arsenic (mainly arsenite) increased from 4 to 16.9 μg/L from day 3 to 97, while in 
soils under aerobic treatment, total arsenic levels decreased from 3.3 to 1.0 μg/L.  In two soil samples in 
which 10 mg/kg (10 µg/g) arsenic was added to the soil, total arsenic concentrations remained at an 
elevated level (between 35 and 60 μg/L) from day 3 to 97 during the flooded treatment, but decreased
during the aerobic treatment from 23–27 to 4 μg/L.  Soil samples from 10 sites in Serbia, where high 
levels of arsenic had been found in suspended particles in the air, were analyzed with inductively coupled 
plasma-atomic emission spectroscopy (ICP-AES) and atomic absorption spectroscopy (AAS) to evaluate 
airborne heavy metal contamination (Serbula et al. 2012).  Arsenic levels ranged from 16.8 to 95.5 mg/kg
soil. The highest concentrations of arsenic were located in the urban industrial sampling zone and the
lowest concentrations were located in the rural sampling zone. The control sample from Sumrakovac, 
Serbia had an arsenic concentration of 9 mg/kg soil.
Presley et al. (2010) reported measured concentrations of arsenic in New Orleans, Louisiana soils before 
Hurricane Katrina (June 2005) and after Hurricane Rita (January 2006).  A total of 39 sites were sampled, 
37 of which were schoolyards.  Total arsenic concentration ranged from 1.20 to 11.30 mg/kg (1.20– 
11.30 μg/g) in four soil samples collected before Hurricane Katrina.  Total arsenic concentration ranged
from below reliable detection limits up to 24.30 mg/kg (24.30 μg/g) in 18 soil samples collected after
Hurricane Rita. The 17 soil samples collected both before and after Hurricane Katrina had a geometric 
mean arsenic concentration of 4.73 μg/g before and 6.99 μg/g after.  Warren et al. (2012) reported 
measured concentrations of arsenic in surface estuarine and marine sediments from 10 sites along the 
Mississippi Gulf Coast in New Orleans, Louisiana after Hurricane Katrina, from September 2005 to 2006.  
ICP-mass spectrometry (MS) was used to detect concentrations of arsenic ranging from 0.37 to 7.43 μg/g 
for the <2 mm particle size fractions and 2.50–17.1 μg/g for the <63 μm particle size fractions. 






   
   
 
    
     
  
    
 
   
  
  
    
    
  
      






   
    
 
  
   
  
    
     
  
   
    
ARSENIC 112
At an arsenic contaminated site in Kidsgrove, Staffordshire, soil sampled at 0–30, 30–70, and 70–100 cm
depth had arsenic detected at concentrations of 280, 200, and 96 mg/kg soil, respectively, when the soil
samples were microwave digested in concentrated 14 M nitric acid (Beesley et al. 2010).  Arsenic-
contaminated soil samples from a former nonferrous metal refinery plant and an abandoned mine tailing
site in Korea were collected from 0- to 30-cm depths (Kim et al. 2014).  A mean arsenic concentration of
61.2 mg/kg soil was detected from the smelter location samples and 82,300 mg/kg soil from the mine
location samples.  X-ray photoelectron spectroscopy was used to determine that As(V)-O was the major
chemical form of arsenic at both sites investigated.
In 2006, arsenic concentrations were measured in soils, sediments, clay, and grab samples of runoff water,
from two detention basins in Raccoon Creek, New Jersey (USGS 2011a).  Soil and sediment samples 
collected in October at basin one had total arsenic concentrations ranging from 3.0 to 16.1 mg/kg (3.0– 
16.1 μg/g).  Soil and sediment samples collected in June and July at basin two had total arsenic
concentrations ranging from 12.0 to 45.4 mg/kg (12.0–45.4 μg/g). Total arsenic concentrations in soil
from Victoria, Australia, collected in areas with a history of gold mining activity, ranged from 3.3 to 
130 μg/g; the geometric mean was 11.5 μg/g (Pearce et al. 2010).  Tsuji et al. (2005) analyzed total
arsenic and arsenic species in urine, toenails, and soil of Middleport, New York residents. The range of
total arsenic detected in urine was 2.1–773 μg/L in all participants. The arsenic concentration levels in 
soil and dust averaged 18.8 and 10.6 mg/kg (18.8 and 10.6 μg/g), respectively.
6.4.4 Other Environmental Media
Total arsenic levels in rice have shown notable variations with geographical region, cultivation methods,
rice strain, and degree of polishing/milling practices.  In addition, arsenic speciation can vary in different
rice strains (Gilbert-Diamond 2011; Lei et al. 2013; Sommella 2013; Zavala et al. 2008).  In a field study
conducted in Chenzhou City Hunan, China, 34 rice genotypes grown in arsenic-contaminated fields had 
arsenic concentrations ranging from 9.07 to 25.26 g/dry weight plant (Lei et al. 2013).  Rice grown and 
cultivated using flooded conditions contained 10–15-fold higher levels of arsenic species, specifically in
the form of DMA, compared to rice grown under aerobic (i.e., non-flooded, well drained) conditions (Xu 
et al. 2008).  Grain samples from flooded treatments had total arsenic concentrations ranging from 1 to 
2.5 mg/kg (1–2.5 µg/g).  Narukawa et al. (2014) evaluated 10 brown rice samples from six regions in 
Japan. The study found that the species of arsenic in the samples was directly related to the degree of
polishing and milling; the concentrations of DMA in milled rice tended to be lower than polished rice.  
The concentration of inorganic arsenic decreased with increased milling and the concentration of
inorganic arsenic in milled rice was higher than that in polished rice.










   
   
    
   
    
      
      
       
  
    
      
   
  
    
  
 
      
  
    
 
   
 
  
   
  
ARSENIC 113
Rice grown in the south-central region of the United States tends to contain a higher average 
concentration of total arsenic (0.30 µg/g) compared to rice grown in California (0.17 µg/g) (Gilbert-
Diamond 2011).  Sommella et al. (2013) performed a survey of commercial rice purchased in Italian 
stores.  Based on analysis of eight varieties from four different regions, it was confirmed that arsenic 
concentrations are not homogeneous.  The highest mean concentration of total arsenic was 0.28 mg/kg
found in Emilia, while the lowest mean concentration was 0.11 mg/kg (0.11 µg/g) found in Calabria.  A
study and review of rice crops in the United States, Australia, China, Asia, and Europe showed that the
percentage of total arsenic in rice is dominated by either DMA or inorganic arsenic.  Rice in the United
States, Italy, and China was found to be dominated by the DMA species.  Speciation of arsenic was 
assessed in U.S. commercially produced rice (Zavala et al. 2008). Of the 24 samples evaluated, 2 brown 
rice samples contained the highest concentrations of 0.45 and 0.71 mg/kg (0.45–0.71 µg/g). White rice 
samples had total arsenic concentrations of 0.162–0.383 mg/kg (0.162–0.383 µg/g) and brown rice
samples had total arsenic concentrations of 0.201–0.71 mg/kg (0.201–0.71 µg/g). In general, brown rice
had overall higher levels of As(III); As(III) concentrations ranged from 0.097 to 0.168 mg/kg (0.097– 
0.168 µg/g).  White rice samples had As(III) concentrations of 0.049–0.122 mg/kg (0.049–0.122 µg/g).  
The total arsenic concentrations reported for 3 types of rice grain cultivated in Arkansas ranged from
0.253 to 0.356 mg/kg (0.253-0.356 µg/g), for 5 types of rice grain cultivated in California ranged from
0.162 to 0.345 mg/kg (0.160–0.710 µg/g) and for 16 types of rice grain cultivated in Texas ranged from
0.190 to 0.710 mg/kg (0.190–0.710 µg/g) (Zavala et al. 2008). Table 6-1 provides the concentrations of
arsenic speciation in the U.S. commercial rice samples from the study.
Food products purchased both over the internet and from stores in the Hanover, New Hampshire area
were evaluated for arsenic concentrations.  Organic brown rice syrup (OBRS) and products containing
OBRS, such as toddler formula, cereal and energy bars, were included. Total arsenic in three rice syrups 
tested ranged from 78 to 406 ng/g (0.08–0.4 µg/g).  Inorganic arsenic accounted for 80–90% of the total
arsenic in two of the syrups and 50% in the third.  The third, however, had the highest concentration of
arsenic overall at 406 ng/g.  Fifteen of the 17 baby formulas evaluated did not have OBRS as an 
ingredient and contained levels of arsenic ranging from 2 to 12 ng/g (0.002–0.012 µg/g).  OBRS was
listed as an ingredient in 2 of the 17 baby formulas.  Levels of inorganic arsenic in these two reconstituted
formulas were 8–9 µg/L for dairy-based formulas and approximately 15–25 µg/L for soy-based formulas. 
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Table 6-1.  Speciation of Arsenic in U.S. Commercial Rice 
Species (TFA extraction) (µg/g)
Rice color/state of Total arsenic Species recovery
production (HNO3/H2O2) DMA As(III) As(V) Sum percent total arsenica 
Brown
Arkansas 0.253 0.068 0.133 0.012 0.212 84
California 0.201±0.005 0.036 0.115 0.013 0.164 81
California 0.236 0.067 0.145 0.009 0.221 94
California 0.354 0.186 0.097 0.006 0.289 82
California 0.273 0.171 0.102 <0.005 0.273 100
Texasb 0.710±0.028 0.572 0.168 <0.005 0.769 108
Texas 0.450±0.021 0.320 0.116 <0.005 0.437 97
Texas 0.241±0.003 0.068 0.157 0.011 0.236 98
Texas 0.258 0.069 0.142 0.008 0.218 85
White
Arkansas 0.287 0.142 0.081 0.008 0.231 80
Arkansas 0.356±0.008 0.190 0.066 <0.005 0.256 72
California 0.162±0.006 0.040 0.112 0.017 0.169 104
Texas 0.242 0.171 0.049 0.023 0.242 100
Texasc 0.253±0.002 0.138 0.076 0.095 0.312 123
Texasd 0.383±0.003 0.302 0.071 0.003 0.382 100
Texas 0.369±0.008 0.221 0.069 0.013 0.302 82
Texas 0.190±0.002 0.061 0.122 0.008 0.192 101
Texas 0.203±0.005 0.095 0.094 0.013 0.201 99
Texas 0.195±0.017 0.106 0.086 0.014 0.207 106
Texas 0.270±0.020 0.179 0.098 0.008 0.285 106
Texas 0.256 0.128 0.118 0.014 0.259 101
Texas 0.351 0.239 0.078 0.007 0.323 92
Texas 0.240±0.014 0.171 0.081 0.013 0.265 111
Texas 0.222 0.143 0.084 0.003 0.230 104
aValues >100% represent experimental error between two different analytical methods.
 
bContained MMA at 0.013 and an unidentified arsenic species at 0.017 µg/g.
 
cContained MMA at 0.003 µg/g.

dContained MMA at 0.006 µg/g.

DMA = dimethylarsinic acid; MMA = monomethylarsonic acid; TFA = trifluoroacectic acid
Source:  Zavala et al. 2008
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Total arsenic concentrations in 100 cereal and energy bars tested ranged from 8 to 128 ng/g (0.08– 
0.128 µg/g).  Analysis of 12 of the bars containing rice had an average of 70% inorganic arsenic (Jackson
et al. 2012).
Jackson et al. (2012) analyzed 15 infant formulas and 41 first foods for arsenic concentrations and found 
that rice-containing products had elevated levels of total arsenic.  Of the formulas that were speciated,
inorganic arsenic accounted for 100% of the total arsenic present. The highest concentrations of total
arsenic reported for rice-based formula and first food puree in pears/raspberries were 11.89±0.64 ng/g
(0.01189 µg/g) and 20.20 ng/g (0.02020 µg/g), respectively.  Tables 6-2 and 6-3 summarize the results.
Table 6-2.  Total Arsenic Concentrations for Main Brand Infant Formulas
Total arsenic (µg/g) Dairy Rice Percent inorganic arsenic
0.00536 ±0.00021 Yes No Not speciated
0.01127±0.00035 No No 100%
0.00929±0.00043 No No 100%
0.01189±0.00064 No Yes 100%
0.00576±0.0004 Yes No Not speciated
0.00695±0.00043 No No 100%
0.01143±0.00109 No No 100%
0.00602±0.00026 Yes Yes Not speciated
0.00819±0.00063 Yes Yes 100%
0.00814±0.00077 Yes No 100%
0.00938±0.00031 Yes No 100%
0.00292±0.00033 Yes No Not speciated
0.00962±0.00135 No No 100%
0.00342±0.0002 Yes No Not speciated
0.0026±0.00044 Yes No Not speciated
Source:  Jackson et al. 2012
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Table 6-3. Total Arsenic Concentration in First-Food Purees
Ingredients Total arsenic (µg/g)
Apples 0.00069–0.00674
Apples and apricots 0.00148
Apples and blueberries 0.00093
Apples and plums 0.00097









Pears and mango 0.01501
Pears and raspberries 0.02020
Pears and wild blueberries 0.00100
Peas 0.00314
Prunes 0.00201
Prunes and oatmeal 0.00174
Select prunes 0.00163






Source:  Jackson et al. 2012
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A review done by the World Health Organization (WHO 2011a) reported that washing rice with water
can eliminate up to 23% of arsenic, with As(III) being the species with the highest elimination potential.  
In addition, cooking methods such as boiling and baking may remove arsenic from foods such as
vegetables, cereals, and seafood. The majority of studies conducted have been on rice boiling, and results
indicate that large volumes of water are required to remove total arsenic (up to 35%) and inorganic 
arsenic (up to 45%) (WHO 2011a).  Cooking with arsenic-contaminated water, however, has been shown 
to increase arsenic concentrations.
Arsenic speciation in 31 infant rice cereals sold in U.S. stores was performed via ICP-MS-high 
performance liquid chromatography (HPLC) (Juskelis et al. 2013).  Mixed grain, single grain, whole
grain, organic, white, and brown rice cereals were assessed.  Cereals were purchased in Illinois, Texas,
California, and North Dakota. The average concentrations of total arsenic and inorganic arsenic found
were 174.4–101.4 µg/kg (0.1744–0.1014 µg/g).  Total inorganic arsenic concentrations ranged from
55.5 to 158.0 µg/kg (0.0555–0.1580 µg/g). The major organic arsenic species detected was DMA; MMA
was not typically detected unless at trace amounts. There were no notable differences in the inorganic 
arsenic concentrations of organic cereals versus conventional rice cereals. The lowest concentrations of
inorganic arsenic were found in mixed-grain cereals. The levels of inorganic arsenic per serving ranged
from 0.8 (mixed grain cereal) to 2.4 µg (organic whole grain cereal).  
Arsenic concentrations were analyzed for 32 gluten-free food products purchased in Spain (Munera-
Picazo et al. 2014a). The gluten-free foods products evaluated in this study, such as baking flour, 
breadcrumbs, pasta, breads, pastries, beer, and rice milk, had a rice content of 5–100%.  The pastas
contained the highest levels of total arsenic (0.109–0.120 µg/g) and inorganic arsenic (0.0730– 
0.0842 µg/g).
Dust samples were analyzed near a former wood treatment facility in southern Alabama (Hensley et al.
2007).  Attic dust samples from 11 buildings located in a 1-mile radius of the facility had an average total
arsenic concentration of 29.8 mg/kg (29.8 µg/g).  The range was from 2.0 to 261.0 µg/g.
Speciation of arsenic in several mid-Atlantic fish and shellfish samples was achieved via ICP-MS (Green
and Crecelius 2006).  Summer flounder, Atlantic croaker, and Hard clam samples were collected from
Delaware Inland Bays in 2002.  Striped bass samples were collected from the Delaware Estuary and
lower to mid Delaware Bay.  Total arsenic concentrations in all 27 samples ranged from 0.36 to 3.33 µg/g
(limit of detection [LOD] of 0.04 µg/g).  Inorganic arsenic concentrations were reported as detected above






     
    







    
   
     
   
     
       
     
   
    
   
   
      
   
   
 
     
    
    
     
   
    
ARSENIC 118
the blank but less than the detection limit in 5 samples and not detected in 22 samples (LOD=0.03 µg/g).  
MMA concentrations were not detected in 10 samples and reported as detected above the blank but less 
than the detection limit in 17 samples (LOD=0.01 µg/g).  DMA was reported as detected above the blank
but less than the detection limit in 20 samples, below the LOD in 1 sample, and in concentrations ranging
from 0.0412 to 0.528 in 6 samples(LOD=0.04 µg/g).
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
The Updated Fourth National Report on Human Exposures to Environmental Chemicals, published and 
updated by the Centers for Disease Control and Prevention (CDC 2015), reported 2003–2012 data from
the National Health and Nutrition Examination Survey (NHANES).  These data are summarized in
Tables 6-4 through 6-19. Total arsenic levels in the urine (see Table 6-4) and urine, creatinine corrected 
(see Table 6-5) were evaluated for various ages and ethnicities.  In addition values were reported of
concentrations in urine for arsenic(V) acid, arsenobetaine, arsenocholine, arsenous (III) acid, DMA(V),
monomethylarsonic acid (MMA(V)), and TMAO. Mean values of total arsenic (creatinine corrected) in
the urine were 8.24 and 9.15 µg/g for 2,557 members of the general U.S. population sampled during
2003–2004 and 2,576 members of the general U.S. population sampled during 2005–2006, respectively. 
Mean values of total arsenic (creatinine corrected) in the urine were 8.46 and 9.90 µg/g for 2,605 
members of the general U.S. population sampled during 2007–2008 and 2,860 members of the general
U.S. population sampled during 2009–2010, respectively. The mean value for toal arsenic (creatinine
corrected) in the urine for 2,502 members of the general U.S. population sampled during was 7.77 µg/g. 
The two highest geometric means (creatinine corrected) during 2009–2010 of 10.8 and 10.6 µg/g resulted
from 2,028 samples from participants ≥20 years old and 1,459 samples from female participants, 
respectively.  Throughout all survey years, females had a higher geometric mean of total arsenic 
(creatinine corrected) than males and the age group of ≥20 years had higher means than the 6–11-year-old 
group, which had higher means than ages 12–19 years (CDC 2015).  Concentrations of arsenic(V) acid
(corrected for creatinine) throughout all NHANES survey years were below the detection limits of the 
analytical methods (1.0 µg/L).  Concentrations of arsenous (III) acid (corrected for creatinine) were below 
the dectection  limits of the analytical methods (1.2 µg/L) for reporting years 2003–2010, but were at
detectable levels for the reporting years 2011–2012 (Table 6-13).
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Table 6-4.  Geometric Mean and Selected Percentiles of Urinary Total Arsenic 
(in μg/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)
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Table 6-4.  Geometric Mean and Selected Percentiles of Urinary Total Arsenic 
(in μg/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)































































































































































































































































   













































   









Table 6-4.  Geometric Mean and Selected Percentiles of Urinary Total Arsenic 
(in μg/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)




































































CI = confidence interval
Source:  CDC 2015
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Table 6-5.  Geometric Mean and Selected Percentiles of Urinary Total Arsenic 
(Creatinine Corrected) (in μg/g of Creatinine) for the U.S. Population from the
National Health and Nutrition Examination Survey (NHANES)
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Table 6-5.  Geometric Mean and Selected Percentiles of Urinary Total Arsenic 
(Creatinine Corrected) (in μg/g of Creatinine) for the U.S. Population from the
National Health and Nutrition Examination Survey (NHANES)
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Table 6-5.  Geometric Mean and Selected Percentiles of Urinary Total Arsenic 
(Creatinine Corrected) (in μg/g of Creatinine) for the U.S. Population from the
National Health and Nutrition Examination Survey (NHANES)




































































CI = confidence interval
Source:  CDC 2015
Table 6-6.  Geometric Mean and Selected Percentiles of Urinary Arsenic(V) Acid
(in μg As/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)




























2009–2010 * <LOD <LOD <LOD <LOD 2,852
2011–2012 * <LOD <LOD <LOD <LOD 2,517
Age group
6–11 years 2003–2004 * <LOD <LOD <LOD 1.10 (<LOD–1.30) 292
2005–2006 * <LOD <LOD <LOD <LOD 354
2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 379
2011–2012 * <LOD <LOD <LOD <LOD 401
12–19 years 2003–2004 * <LOD <LOD <LOD 1.20 (<LOD–1.60) 728
2005–2006 * <LOD <LOD <LOD 1.00 (<LOD–1.30) 703
2007–2008 * <LOD <LOD <LOD <LOD 366
2009–2010 * <LOD <LOD <LOD <LOD 453
2011–2012 * <LOD <LOD <LOD <LOD 392
≥20 years 2003–2004 * <LOD <LOD <LOD 1.10 (<LOD–1.50) 1,548
2005–2006 * <LOD <LOD <LOD 1.09 (<LOD–1.71) 1,531
2007–2008 * <LOD <LOD <LOD <LOD 1,820
2009–2010 * <LOD <LOD <LOD <LOD 2,020
2011–2012 * <LOD <LOD <LOD <LOD 1,724






    








        
        




























         




























         





























































































         
 
   







Table 6-6.  Geometric Mean and Selected Percentiles of Urinary Arsenic(V) Acid






(95% CI) 50th 
Selected percentiles (95% CI)















































































2007–2008 * <LOD <LOD <LOD <LOD 513
2009–2010 * <LOD <LOD <LOD <LOD 618

















2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 543































2011–2012 * <LOD <LOD <LOD <LOD 825
<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
 
CI = confidence interval
 
Source:  CDC 2015
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Table 6-7.  Geometric Mean and Selected Percentiles of Urinary Arsenic(V) Acid
(Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population from





(95% CI) 50th 
Selected percentiles (95% CI)















































2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 378






















2009–2010 * <LOD <LOD <LOD <LOD 453










































































































2007–2008 * <LOD <LOD <LOD <LOD 513
2009–2010 * <LOD <LOD <LOD <LOD 618

















2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 542
2011–2012 * <LOD <LOD <LOD <LOD 672
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Table 6-7.  Geometric Mean and Selected Percentiles of Urinary Arsenic(V) Acid
(Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population from
the National Health and Nutrition Examination Survey (NHANES)






























2009–2010 * <LOD <LOD <LOD <LOD 1,210
2011–2012 * <LOD <LOD <LOD <LOD 824
<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
CI = confidence interval
Source:  CDC 2015
Table 6-8.  Geometric Mean and Selected Percentiles of Urinary Arsenobetaine 
(in μg As/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)




CI) 50th 75th 90th 95th 
Sample 
size
Total 2003–2004 1.55 (1.31– 1.00 (0.800– 5.20 (4.00– 16.8 (12.7– 35.0 (27.6– 2,568
1.83) 1.40) 6.50) 22.3) 44.6)
2005–2006 1.86 (1.43– 1.53 (0.980– 6.73 (4.80– 22.6 (16.5– 40.6 (30.7– 2,588
2.41) 2.26) 8.91) 30.3) 59.4)
2007–2008 * 0.670 (0.510– 4.26 (3.53– 16.6 (12.5– 29.5 (22.8– 2,576
0.910) 4.88) 20.2) 37.1)
2009–2010 1.59 (1.38– 0.940 (0.720– 6.18 (4.67– 23.5 (19.8– 50.4 (35.7– 2,870
1.83) 1.26) 7.87) 30.1) 63.2)
2011–2012 * <LOD 4.62 (3.25– 18.0 (13.7– .5 (25.7– 2,517
6.25) 23.2) 51.9)
Age group
6–11 years 2003–2004 * <LOD 1.80 8.80 (3.90– 29.9 (6.20– 292
(0.800– 29.9) 190)
2005–2006 * <LOD 4.00) 7.14 (2.34– 18.9 (5.46– 354
2.22 29.9) 45.0)
2007–2008 * <LOD (0.620– 6.71 (3.37– 13.0 (7.22– 390
5.35) 8.38) 25.2)






2011–2012 * <LOD 1.58 15.2 (6.60– ) 49.6 401
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Table 6-8.  Geometric Mean and Selected Percentiles of Urinary Arsenobetaine 
(in μg As/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)

















































































































































































































































        






































     






































    







































     
      
 
 
   







Table 6-8.  Geometric Mean and Selected Percentiles of Urinary Arsenobetaine 
(in μg As/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)


















































































































































































<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
 
CI = confidence interval
 
Source:  CDC 2015
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Table 6-9.  Geometric Mean and Selected Percentiles of Urinary Arsenobetaine 
(Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population from
the National Health and Nutrition Examination Survey (NHANES)






























































































































































































































   
    








        
        



































     
      
 



































     
      
 






































     






































    
        
 
ARSENIC 131
Table 6-9.  Geometric Mean and Selected Percentiles of Urinary Arsenobetaine 
(Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population from
the National Health and Nutrition Examination Survey (NHANES)













































































































































































































































   
    














































     
      
 
 
    






      






































        


































































         






















Table 6-9.  Geometric Mean and Selected Percentiles of Urinary Arsenobetaine 
(Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population from
the National Health and Nutrition Examination Survey (NHANES)































































<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
CI = confidence interval
Source:  CDC 2015
Table 6-10. Geometric Mean and Selected Percentiles of Urinary Arsenocholine
(in μg As/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)
Geometric Selected percentiles (95% CI)
Survey mean (95% Sample 





























2011–2012 * <LOD <LOD <LOD <LOD 2,517
Age group
6–11 years 2003–2004 * <LOD <LOD <LOD <LOD 292
2005–2006 * <LOD <LOD <LOD <LOD 354
2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 380
2011–2012 * <LOD <LOD <LOD <LOD 401
12–19 years 2003–2004 * <LOD <LOD <LOD <LOD 728
2005–2006 * <LOD <LOD <LOD <LOD 703
2007–2008 * <LOD <LOD <LOD <LOD 366
2009–2010 * <LOD <LOD <LOD <LOD 456
2011–2012 * <LOD <LOD <LOD <LOD 392
≥20 years 2003–2004 * <LOD <LOD <LOD <LOD 1,548
2005–2006 * <LOD <LOD <LOD <LOD 1,531
2007–2008 * <LOD <LOD <LOD <LOD 1,820






      









        
       
         
        




























         




























         





























































































         
 
   







Table 6-10. Geometric Mean and Selected Percentiles of Urinary Arsenocholine
(in μg As/L) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES)




CI) 50th 75th 90th 95th 
Sample 
size
2009–2010 * <LOD <LOD <LOD <LOD 2,035
2011–2012 * <LOD <LOD <LOD <LOD 1,724
Gender
Males 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,276
2007–2008 * <LOD <LOD <LOD <LOD 1,289
2009–2010 * <LOD <LOD <LOD <LOD 1,403
2011–2012 * <LOD <LOD <LOD <LOD 1,264
Females 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,312
2007–2008 * <LOD <LOD <LOD <LOD 1,287
2009–2010 * <LOD <LOD <LOD <LOD 1,468
2011–2012 * <LOD <LOD <LOD <LOD 1,264
Race/ethnicity
Mexican 2003–2004 * <LOD <LOD <LOD <LOD 621
Americans 2005–2006 * <LOD <LOD <LOD <LOD 651
2007–2008 * <LOD <LOD <LOD <LOD 513
2009–2010 * <LOD <LOD <LOD <LOD 618
2011–2012 * <LOD <LOD <LOD <LOD 317
Non-Hispanic 2003–2004 * <LOD <LOD <LOD <LOD 725
blacks 2005–2006 * <LOD <LOD <LOD <LOD 695
2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 546
2011–2012 * <LOD <LOD <LOD <LOD 672
Non-Hispanic 2003–2004 * <LOD <LOD <LOD <LOD 1,078
whites 2005–2006 * <LOD <LOD <LOD <LOD 1,050
2007–2008 * <LOD <LOD <LOD <LOD 1,063
2009–2010 * <LOD <LOD <LOD <LOD 1,226
2011–2012 * <LOD <LOD <LOD <LOD 825
<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
 
CI = confidence interval
 
Source:  CDC 2015
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Table 6-11. Geometric Mean and Selected Percentiles of Urinary Arsenocholine 
(Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population from
the National Health and Nutrition Examination Survey (NHANES)




CI) 50th 75th 90th 95th 
Sample 
size
Total 2003–2004 * <LOD <LOD <LOD <LOD 2,568
2005–2006 * <LOD <LOD <LOD <LOD 2,588
2007–2008 * <LOD <LOD <LOD <LOD 2,576
2009–2010 * <LOD <LOD <LOD <LOD 2,870
2011–2012 * <LOD <LOD <LOD <LOD 2,516
Age group
6–11 years 2003–2004 * <LOD <LOD <LOD <LOD 292
2005–2006 * <LOD <LOD <LOD <LOD 354
2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 379
2011–2012 * <LOD <LOD <LOD <LOD 401
12–19 years 2003–2004 * <LOD <LOD <LOD <LOD 728
2005–2006 * <LOD <LOD <LOD <LOD 703
2007–2008 * <LOD <LOD <LOD <LOD 366
2009–2010 * <LOD <LOD <LOD <LOD 456
2011–2012 * <LOD <LOD <LOD <LOD 392
≥20 years 2003–2004 * <LOD <LOD <LOD <LOD 1,548
2005–2006 * <LOD <LOD <LOD <LOD 1,531
2007–2008 * <LOD <LOD <LOD <LOD 1,820
2009–2010 * <LOD <LOD <LOD <LOD 2,035
2011–2012 * <LOD <LOD <LOD <LOD 1,723
Gender
Males 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,276
2007–2008 * <LOD <LOD <LOD <LOD 1,289
2009–2010 * <LOD <LOD <LOD <LOD 1,403
2011–2012 * <LOD <LOD <LOD <LOD 1,263
Females 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,312
2007–2008 * <LOD <LOD <LOD <LOD 1,287
2009–2010 * <LOD <LOD <LOD <LOD 1,468
2011–2012 * <LOD <LOD <LOD <LOD 1,253
Race/ethnicity
Mexican 2003–2004 * <LOD <LOD <LOD <LOD 621
Americans 2005–2006 * <LOD <LOD <LOD <LOD 651
2007–2008 * <LOD <LOD <LOD <LOD 513
2009–2010 * <LOD <LOD <LOD <LOD 618
2011–2012 * <LOD <LOD <LOD <LOD 317
Non-Hispanic 2003–2004 * <LOD <LOD <LOD <LOD 725
blacks 2005–2006 * <LOD <LOD <LOD <LOD 695
2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 545
2011–2012 * <LOD <LOD <LOD <LOD 672
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Table 6-11. Geometric Mean and Selected Percentiles of Urinary Arsenocholine 
(Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population from
the National Health and Nutrition Examination Survey (NHANES)
Geometric Selected percentiles (95% CI)
Survey mean (95% Sample 

































<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
CI = confidence interval
Source:  CDC 2015
Table 6-12. Geometric Mean and Selected Percentiles of Urinary Arsenous (III)

Acid (in μg As/L) for the U.S. Population from the National Health and 

Nutrition Examination Survey (NHANES)
 
Geometric Selected percentiles (95% CI)
Survey mean (95% Sample 
years CI) 50th 75th 90th 95th size
Total 2003–2004 * <LOD <LOD <LOD <LOD 2,568
2005–2006 * <LOD <LOD <LOD <LOD 2,588
2007–2008 * <LOD <LOD <LOD <LOD 2,576
2009–2010 * <LOD <LOD <LOD <LOD 2,871






















2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 380
2011–2012 * <LOD 0.540 0.870 1.03 (0.820–1.22) 401
(<LOD– (0.710– 
0.660) 1.00)
12–19 years 2003–2004 * <LOD <LOD <LOD 1.40 (<LOD–1.70) 728
2005–2006 * <LOD <LOD <LOD 1.20 (<LOD–1.40) 703
2007–2008 * <LOD <LOD <LOD <LOD 366
2009–2010 * <LOD <LOD <LOD <LOD 456
2011–2012 * <LOD 0.610 0 .920 1.18 (0.980–1.43) 392
(0.480– (0.810– 
.720) 1.14)
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Table 6-12. Geometric Mean and Selected Percentiles of Urinary Arsenous (III)

Acid (in μg As/L) for the U.S. Population from the National Health and 

Nutrition Examination Survey (NHANES)
 




CI) 50th 75th 90th 95th 
Sample 
size
≥20 years 2003–2004 * <LOD <LOD <LOD <LOD 1,548
2005–2006 * <LOD <LOD <LOD <LOD 1,531
2007–2008 * <LOD <LOD <LOD <LOD 1,820
2009–2010 * <LOD <LOD <LOD <LOD 2,035




Males 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD 1.26 (<LOD–1.73) 1,276
2007–2008 * <LOD <LOD <LOD <LOD 1,289
2009–2010 * <LOD <LOD <LOD 1.24 (<LOD–1.50) 1,403
2011–2012 * <LOD 0.600 0.980 1.31 (1.11–1.59) 1,264
(0.520– (0.840– 
0.680) 1.13)
Females 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,312
2007–2008 * <LOD <LOD <LOD <LOD 1,287
2009–2010 * <LOD <LOD <LOD <LOD 1,468




Mexican 2003–2004 * <LOD <LOD <LOD 2.00 (<LOD–3.00) 621
Americans 2005–2006 * <LOD <LOD <LOD <LOD 651
2007–2008 * <LOD <LOD <LOD 1.20 (<LOD–1.76) 513
2009–2010 * <LOD <LOD <LOD <LOD 618
2011–2012 * <LOD 0.570 0 .830 1.14 (0.880–1.37) 317
(0.490– (0.770– 
0.660) 1.03)
Non-Hispanic 2003–2004 * <LOD <LOD <LOD 1.20 (<LOD–1.80) 725
blacks 2005–2006 * <LOD <LOD <LOD <LOD 695
2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 546
2011–2012 * <LOD 0.520 0.880 1.21 (0.980–1.57) 672
(<LOD– (0.700– 
0.680) 1.10)
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Table 6-12. Geometric Mean and Selected Percentiles of Urinary Arsenous (III)

Acid (in μg As/L) for the U.S. Population from the National Health and 

Nutrition Examination Survey (NHANES)
 






























2009–2010 * <LOD <LOD <LOD <LOD 1,226




<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
CI = confidence interval
Source:  CDC 2015
Table 6-13. Geometric Mean and Selected Percentiles of Urinary Arsenous (III)
Acid (Creatinine Corrected) (in μg As/g of creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)
Geometric Selected percentiles (95% CI)
Survey mean (95% Sample 
years CI) 50th 75th 90th 95th size
Total 2003–2004 * <LOD <LOD <LOD <LOD 2,568
2005–2006 * <LOD <LOD <LOD <LOD 2,588
2007–2008 * <LOD <LOD <LOD <LOD 2,576
2009–2010 * <LOD <LOD <LOD <LOD 2,870






















2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 379
2011–2012 * <LOD 1.03 1.54 2.00 (1.55–2.62) 401
(<LOD– (1.26– 
1.13) 1.79)
12–19 years 2003–2004 * <LOD <LOD <LOD 1.95 (<LOD–2.76) 728
2005–2006 * <LOD <LOD <LOD 2.02 (<LOD–3.04) 703
2007–2008 * <LOD <LOD <LOD <LOD 366
2009–2010 * <LOD <LOD <LOD <LOD 456
2011–2012 * <LOD 0.709 1.11 1.36 (1.03–2.50) 392
(0.607– (0.971– 
0.850) 1.31)
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Table 6-13. Geometric Mean and Selected Percentiles of Urinary Arsenous (III)
Acid (Creatinine Corrected) (in μg As/g of creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)




CI) 50th 75th 90th 95th 
Sample 
size
≥20 years 2003–2004 * <LOD <LOD <LOD <LOD 1,548
2005–2006 * <LOD <LOD <LOD <LOD 1,531
2007–2008 * <LOD <LOD <LOD <LOD 1,820
2009–2010 * <LOD <LOD <LOD <LOD 2,035




Males 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD 2.43 (<LOD–3.15) 1,276
2007–2008 * <LOD <LOD <LOD <LOD 1,289
2009–2010 * <LOD <LOD <LOD 2.93 (<LOD–3.54) 1,402
2011–2012 * <LOD
Females 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,312
2007–2008 * <LOD <LOD <LOD <LOD 1,287
2009–2010 * <LOD <LOD <LOD <LOD 1,468




Mexican 2003–2004 * <LOD <LOD <LOD 3.08 (<LOD–4.44) 621
Americans 2005–2006 * <LOD <LOD <LOD <LOD 651
2007–2008 * <LOD <LOD <LOD 3.54 (<LOD–4.72) 513
2009–2010 * <LOD <LOD <LOD <LOD 618
2011–2012 * <LOD <LOD 1.42 1.89 (1.70–2.27) 1,253
(1.36– 
1.62)
Non-Hispanic 2003–2004 * <LOD <LOD <LOD 2.00 (<LOD–2.29) 725
blacks 2005–2006 * <LOD <LOD <LOD <LOD 695
2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 545
2011–2012 * <LOD 0.723 1.13 1.55 (1.13–2.20) 317
(0.630– (0.919– 
0.850) 1.42)
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Table 6-13. Geometric Mean and Selected Percentiles of Urinary Arsenous (III)
Acid (Creatinine Corrected) (in μg As/g of creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)






























2009–2010 * <LOD <LOD <LOD <LOD 1,226







<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
CI = confidence interval
Source:  CDC 2015
Table 6-14.  Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 
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Table 6-14.  Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 
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Table 6-14.  Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 
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Table 6-14.  Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 









































































CI = confidence interval
Source:  CDC 2015
Table 6-15. Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 
Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)
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Table 6-15. Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 
Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)
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Table 6-15. Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 
Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)
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Table 6-15. Geometric Mean and Selected Percentiles of Urinary Dimethylarsinic 
Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)




































































CI = confidence interval
Source:  CDC 2014
Table 6-16. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (in μg As/L) for the U.S. Population from the National Health 

and Nutrition Examination Survey (NHANES)
 




(95% CI) 50th 75th 90th 95th 
Sample 
size
Total 2003–2004 * <LOD 1.20 (1.00– 1.90 (1.60– 2.40 (2.00– 2,567
1.30) 2.10) 2.80)
2005–2006 * <LOD 1.19 (1.05– 1.72 (1.51– 2.12 (1.79– 2,588
1.34) 1.94) 2.70)
2007–2008 * <LOD 1.11 (1.00– 1.61 (1.51– 2.09 (1.91– 2,576
1.20) 1.69) 2.26)
2009–2010 * <LOD 1.02 (.920– 1.64 (1.41– 2.01 (1.82– 2,871
1.10) 1.83) 2.28)
2011–2012 * <LOD <LOD 1.36 (1.17– 1.83 (1.57– 2,517
1.55) 2.07)
Age group
6–11 years 2003–2004 * <LOD 1.00 (<LOD– 1.80 (1.30– 2.30 (1.70– 292
1.40) 2.60) 2.90)
2005–2006 * <LOD 1.03 (<LOD– 1.54 (1.37– 2.12 (1.51– 354
1.37) 2.12) 2.73)
2007–2008 * <LOD 1.05 (<LOD– 1.60 (1.32– 2.04 (1.64– 390
1.28) 1.83) 2.86)
2009–2010 * <LOD <LOD 1.38 (1.00– 1.81 (1.26– 380
1.84) 2.13)
2011–2012 * <LOD <LOD 1.21 (0.970– 1.42 (1.24– 401
1.40) 1.54)
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Table 6-16. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (in μg As/L) for the U.S. Population from the National Health 

and Nutrition Examination Survey (NHANES)
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Table 6-16. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (in μg As/L) for the U.S. Population from the National Health 

and Nutrition Examination Survey (NHANES)
 









































































































































































































     



















































      
    
 
 
   






     
     

















































     
    
 







































Table 6-16. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (in μg As/L) for the U.S. Population from the National Health 

and Nutrition Examination Survey (NHANES)
 
Geometric Selected percentiles (95% CI)
Survey mean Sample 
















































<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
CI = confidence interval
Source:  CDC 2014
Table 6-17. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the
	








(95% CI) 50th 75th 90th 95th 
Sample 
size
Total 2003–2004 * <LOD 1.33 (1.18– 2.22 (1.82– 2.86 (2.40– 2,567
1.54) 2.57) 3.53)
2005–2006 * <LOD 1.28 (1.14– 2.37 (1.94– 3.13 (2.67– 2,588
1.52) 2.78) 3.76)
2007–2008 * <LOD 1.31 (1.23– 2.24 (2.00– 3.19 (2.78– 2,576
1.42) 2.56) 3.58)
2009–2010 * <LOD 1.36 (1.25– 2.16 (2.00– 2.91 (2.67– 2,870
1.45) 2.29) 3.15)
2011–2012 * <LOD <LOD 2.21 (2.03– 2.86 (2.63– 2,516
2.42) 3.32)
Age group
6–11 years 2003–2004 * <LOD 1.63 (<LOD– 2.31 (1.88– 2.52 (2.31– 292
1.81) 2.50) 3.07)
2005–2006 * <LOD 1.44 (<LOD– 2.37 (1.65– 3.13 (2.29– 354
1.83) 3.20) 4.92)
2007–2008 * <LOD 1.69 (<LOD– 2.46 (2.09– 3.20 (2.56– 390
2.06) 2.91) 4.32)
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Table 6-17. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the
	








(95% CI) 50th 75th 90th 95th 
Sample 
size
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Table 6-17. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the
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Table 6-17. Geometric Mean and Selected Percentiles of Urinary Monomethyl­
arsonic Acid (Creatinine Corrected) (in μg As/g of Creatinine) for the
	




Geometric Selected percentiles (95% CI)
Survey mean Sample 
















































<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
CI = confidence interval
Source:  CDC 2014
Table 6-18. Geometric Mean and Selected Percentiles of Urinary Trimethylarsine 

Oxide (in μg As/L) for the U.S. Population from the National Health and 

Nutrition Examination Survey (NHANES)
 
Geometric Selected percentiles (95% CI)
Survey mean (95% Sample 





























2011–2012 * <LOD <LOD <LOD <LOD 2,517
Age group
6–11 years 2003–2004 * <LOD <LOD <LOD <LOD 292
2005–2006 * <LOD <LOD <LOD <LOD 354
2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 380
2011–2012 * <LOD <LOD <LOD 0.300 401
(<LOD– 
0.960
12–19 years 2003–2004 * <LOD <LOD <LOD <LOD 728
2005–2006 * <LOD <LOD <LOD <LOD 703
2007–2008 * <LOD <LOD <LOD <LOD 366
2009–2010 * <LOD <LOD <LOD <LOD 456
2011–2012 * <LOD <LOD <LOD <LOD 392
824






    
    








        




























         
        




























         




























         





























































































         
 
   







Table 6-18. Geometric Mean and Selected Percentiles of Urinary Trimethylarsine 

Oxide (in μg As/L) for the U.S. Population from the National Health and 

Nutrition Examination Survey (NHANES)
 




CI) 50th 75th 90th 95th 
Sample 
size
≥20 years 2003–2004 * <LOD <LOD <LOD <LOD 1,548
2005–2006 * <LOD <LOD <LOD <LOD 1,531
2007–2008 * <LOD <LOD <LOD <LOD 1,820
2009–2010 * <LOD <LOD <LOD <LOD 2,035
2011–2012 * <LOD <LOD <LOD <LOD 1,724
Gender
Males 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,276
2007–2008 * <LOD <LOD <LOD <LOD 1,289
2009–2010 * <LOD <LOD <LOD <LOD 1,403
2011–2012 * <LOD <LOD <LOD <LOD 1,264
Females 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,312
2007–2008 * <LOD <LOD <LOD <LOD 1,287
2009–2010 * <LOD <LOD <LOD <LOD 1,468
2011–2012 * <LOD <LOD <LOD <LOD 1,253
Race/ethnicity
Mexican 2003–2004 * <LOD <LOD <LOD <LOD 621
Americans 2005–2006 * <LOD <LOD <LOD <LOD 651
2007–2008 * <LOD <LOD <LOD <LOD 513
2009–2010 * <LOD <LOD <LOD <LOD 618
2011–2012 * <LOD <LOD <LOD <LOD 317
Non-Hispanic 2003–2004 * <LOD <LOD <LOD <LOD 725
blacks 2005–2006 * <LOD <LOD <LOD <LOD 695
2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 546
2011–2012 * <LOD <LOD <LOD <LOD 672
Non-Hispanic 2003–2004 * <LOD <LOD <LOD <LOD 1,078
whites 2005–2006 * <LOD <LOD <LOD <LOD 1,050
2007–2008 * <LOD <LOD <LOD <LOD 1,063
2009–2010 * <LOD <LOD <LOD <LOD 1,226
2011–2012 * <LOD <LOD <LOD <LOD 825
<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
 
CI = confidence interval
 
Source:  CDC 2014
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Table 6-19. Geometric Mean and Selected Percentiles of Urinary Trimethylarsine 
Oxide (Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)




CI) 50th 75th 90th 95th 
Sample 
size
Total 2003–2004 * <LOD <LOD <LOD <LOD 2,568
2005–2006 * <LOD <LOD <LOD <LOD 2,588
2007–2008 * <LOD <LOD <LOD <LOD 2,576
2009–2010 * <LOD <LOD <LOD <LOD 2,870
2011–2012 * <LOD <LOD <LOD <LOD 2,516
Age group
6–11 years 2003–2004 * <LOD <LOD <LOD <LOD 292
2005–2006 * <LOD <LOD <LOD <LOD 354
2007–2008 * <LOD <LOD <LOD <LOD 390
2009–2010 * <LOD <LOD <LOD <LOD 379
2011–2012 * <LOD <LOD <LOD 1.06 (<LOD­ 401
1.39
12–19 years 2003–2004 * <LOD <LOD <LOD <LOD 728
2005–2006 * <LOD <LOD <LOD <LOD 703
2007–2008 * <LOD <LOD <LOD <LOD 366
2009–2010 * <LOD <LOD <LOD <LOD 456
2011–2012 * <LOD <LOD <LOD <LOD 392
≥20 years 2003–2004 * <LOD <LOD <LOD <LOD 1,548
2005–2006 * <LOD <LOD <LOD <LOD 1,531
2007–2008 * <LOD <LOD <LOD <LOD 1,820
2009–2010 * <LOD <LOD <LOD <LOD 2,035
2011–2012 * <LOD <LOD <LOD <LOD 1,723
Gender
Males 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,276
2007–2008 * <LOD <LOD <LOD <LOD 1,289
2009–2010 * <LOD <LOD <LOD <LOD 1,403
2011–2012 * <LOD <LOD <LOD <LOD 1,263
Females 2003–2004 * <LOD <LOD <LOD <LOD 1,284
2005–2006 * <LOD <LOD <LOD <LOD 1,312
2007–2008 * <LOD <LOD <LOD <LOD 1,287
2009–2010 * <LOD <LOD <LOD <LOD 1,468
2011–2012 * <LOD <LOD <LOD <LOD 1,253
Race/ethnicity
Mexican 2003–2004 * <LOD <LOD <LOD <LOD 621
Americans 2005–2006 * <LOD <LOD <LOD <LOD 651
2007–2008 * <LOD <LOD <LOD <LOD 513
2009–2010 * <LOD <LOD <LOD <LOD 618
2011–2012 * <LOD <LOD <LOD <LOD 317
Non-Hispanic 2003–2004 * <LOD <LOD <LOD <LOD 725
blacks 2005–2006 * <LOD <LOD <LOD <LOD 695
2007–2008 * <LOD <LOD <LOD <LOD 586
2009–2010 * <LOD <LOD <LOD <LOD 545
2011–2012 * <LOD <LOD <LOD <LOD 672






    
   







































         
 
   







Table 6-19. Geometric Mean and Selected Percentiles of Urinary Trimethylarsine 
Oxide (Creatinine Corrected) (in μg As/g of Creatinine) for the U.S. Population 
from the National Health and Nutrition Examination Survey (NHANES)




CI) 50th 75th 90th 95th 
Sample 
size
2003–2004 * <LOD <LOD <LOD <LOD 1,078
2005–2006 * <LOD <LOD <LOD <LOD 1,050
2007–2008 * <LOD <LOD <LOD <LOD 1,063
2009–2010 * <LOD <LOD <LOD <LOD 1,226
2011–2012 * <LOD <LOD <LOD <LOD 824
Non-Hispanic
whites
<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
 
CI = confidence interval
 
Source:  CDC 2014
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MMA and DMA are excreted methylated metabolites commonly assessed to aid in evaluation of exposure 
(WHO 2011a).  Concentrations of MMA throughout all NHANES survey years reported in the updated 
Fourth National report were below the detection limits of the methods (0.9 µg/L) (CDC 2014).  The two 
highest geometric means (creatinine corrected) of DMA reported during 2009–2010 of 4.77 and 4.28 µg/g
resulted from 379 samples from 6–11 year olds and 1,468 samples from female participants, respectively.  
Throughout all survey years, females had a higher geometric mean of DMA (creatinine corrected) than
males.  The age group 6–11 years had the highest mean of DMA (creatinine corrected) each period 
compared to 12–19- and 20-year-old groups.  Mean values ranged from 4.34 to 5.07 µg/g for the 6– 
11-year-old age group (CDC 2014).  
The NHANES data from 2003 to 2006 were analyzed to evaluate the correlation between rice
consumption and concentrations of total urinary arsenic and urinary DMA in 3,027 and 2,653 U.S. adult
participants, respectively, 20–85 years of age (Wei et al. 2014).  The study took into consideration factors
such as demographic variables, fish consumption, and drinking water.  The study found a distinct
relationship of increased total urinary arsenic and urinary DMA concentrations (both creatinine corrected)
of participants who consumed rice more than twice per week compared to a reference group.  Participants
who consumed rice and grain less than twice per week had mean levels of 2.21 (total arsenic) µg/g
creatinine and 1.32 (DMA) µg/g creatinine.  Participants who consumed rice and grain at least twice per
week had mean total arsenic levels of 2.42 µg/g creatinine and 1.58 (DMA) µg/g creatinine.
A Washington State Environmental Biomonitoring Survey was conducted with 172 participants and tap 
water samples from 82 households in South Whidbey from July to September 2011.  Results indicated 
that the average urine levels (28.4 µg/g creatinine corrected) for total arsenic of the participants were 
higher than statewide and national levels.  Urine arsenic levels were above the CDC’s reporting level
(50 µg/L) among 28% of the participants and 54% of the water samples were above the EPA’s drinking 
water standard (MCL=10 μg/L) (WA DOH 2015).
In an ongoing study by the Maternal and Infant Environmental Exposure Project measures chemical
exposures in pregnant women at the San Francisco General Hospital, a geometric mean of 7.71 µg/L
arsenic was reported for 89 urine samples from pregnant women collected from 2010 to 2011 
(LOD=0.158 µg/L) (OEHHA 2015).  
In 2009, 229 pregnant women were evaluated for urinary arsenic excretion and recent rice consumption in 
an area of the United States with known elevated levels of arsenic in well waters (Gilbert-Diamond et al. 
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2011).  A multiple regression model accounting for age, urinary creatinine, rice consumption, and water
exposure was employed.  Of the 229 pregnant women, 73 consumed rice and 156 did not consume rice.  
A range of total urinary arsenic levels from 2.86 to 8.72 µg/L (median=5.27 µg/L) was detected for the
rice-consuming women, while 1.64–5.39 µg/L (median=3.38 µg/L) was detected for women who did not
eat rice. The women who ate rice had a range of inorganic arsenic between 0.13 and 0.51 µg/L
(median=0.28 µg/L), while the non-rice eaters had a range of inorganic arsenic between 0.13 and
0.36 µg/L (median=0.21 µg/L).
Occupational exposure to arsenic in the semiconductor manufacturing industry was reviewed (Park et al.
2010).  A statistical analysis of air and wipe samples was used to classify fabrication workers with respect
to observed arsenic levels in their surroundings.  The study review concluded that people involved with 
maintenance work have higher potential for exposure than people in charge of routine production work.  
Maintenance processes result in arsenic-containing compounds being deposited on surrounding surfaces.  
These particles may become airborne or may accumulate on surfaces increasing the potential for
exposure.  Afridi et al. (2011) collected whole blood, urine, and hair samples from 42 steel mill
production workers and 33 steel mill quality control workers aged 25–55 years who were affected by
paralysis, and 62 non-paralyzed steel mill workers.  A control group of 75 non-paralyzed male subjects
was also included.  Mean arsenic concentrations in hair samples from the control group, non-paralyzed
steel mill workers, paralyzed quality control workers, and paralyzed production workers were 1.06±0.09, 
1.67±0.17, 2.89±0.3, and 3.99±0.5 µg/g, respectively.  Mean arsenic concentrations in whole blood 
samples from the control group, non-paralyzed steel mill workers, paralyzed quality control workers, and
paralyzed production workers were 1.7±0.4, 2.56±0.3, 4.07±0.38, and 5.48±0.39 µg/L, respectively.  
Mean arsenic concentrations in urine samples from the control group, non-paralyzed steel mill workers,
paralyzed quality control workers, and paralyzed production workers were 4.4±1.5, 5.3±0.84, 8.7±01.7, 
and 11.5±1.3 µg/L, respectively.
6.6 EXPOSURES OF CHILDREN
The NHANES data from 2003 to 2008 were analyzed to evaluate the correlation between rice 
consumption and dietary arsenic exposure in 2,323 participants under 18 years of age (Davis et al. 2012). 
The study took into consideration factors such as fish consumption and metabolic rates according to age.  
Results indicated that total urinary arsenic and urinary DMA concentrations were higher among the 
participants who had reported consumption of ≥0.25 cups of rice within 24 hours of the sampling time.  
The total urinary arsenic concentration of children who had consumed rice was 8.9 µg/L, while the
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concentration was 5.5 µg/L among children who had not (Davis et al. 2012).  The evaluation suggests that
rice consumption has the potential to increase exposure to arsenic for U.S. children.
Munera-Picazo et al. (2014b) investigated Spanish gluten-free food products intended for young children
and found levels of arsenic as high as 256 µg/kg.  Rice-based pasta samples had the highest concentration
of inorganic arsenic.  Control samples for each food group had levels reported as not detected or below
the limit of quantification for the method (6 µg/kg).  Foods with a higher percentage of rice content
typically contained higher levels of total arsenic and inorganic arsenic.  A daily intake of inorganic 
arsenic for children ≤5 years old was found to range between 0.61 and 0.78 µg/kg body weight. 
Wasserman et al. (2014) investigated arsenic exposure and intelligence in 272 children residing in Maine 
with an average age of 9.67 years.  In 248 of the children, a notable correlation of nail arsenic 
concentrations and arsenic concentrations in household tap water was found.  However, it was added that
nail concentrations may be less accurate for children due to rapid growth of other systems.  Measured
household kitchen tap water had an average value of 9.88 μg/L, almost a third of samples exceeded the
EPA MCL (10 μg/L).  The studied concluded that children residing in homes with arsenic water
concentration ≥5 μg/L demonstrated reduced Full Scale IQ scores compared to households with 
concentrations <5 μg/L. 
A maximum amount of 4 μg arsenic was detected in hand washing samples for 66 children from eight
playgrounds.  Children’s hands were rinsed immediately after playing on playground equipment
constructed with CCA-treated wood in Edmonton, Alberta (Hamula et al. 2006).
Exposure to arsenic via contaminated soils has been investigated.  Pearce et al. (2010) analyzed the 
concentration of arsenic in children's toenail clippings and household soils from areas with a history of
gold mining activity in Victoria, Australia.  The arsenic concentrations in children’s toenails ranged from
0.15 to 2.1 μg/g; the geometric mean was 0.49 μg/g.  The arsenic concentrations in soil ranged from 3.3 to
130 μg/g; the geometric mean was 11.5 μg/g.  The distribution of arsenic in the nail clippings suggested
periodic exposure patterns and a positive correlation between the nail concentrations, and soil
concentrations indicated that contaminated soils can contribute to arsenic uptake by children.
Tsuji et al. (2005) analyzed total arsenic and arsenic species in urine from 77 children <7 years old, in
urine from 362 subjects >7 years old, and in toenails from 67 subjects >7 years old living in Middleport, 
New York.  The overall range of total arsenic detected in urine was 2.1–773 μg/L.  The arsenic
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concentrations in toenail samples were <1 mg/kg.  Household soil and dust arsenic levels were also
measured; the arsenic concentration levels averaged 18.8 and 10.6 mg/kg, respectively.
Children may be exposed to arsenic via consumption of apple juices. Exposure of children to arsenic
from apple juice consumption was investigated (FDA 2013a). Based on data from NHANES, children 
aged 0–6 years consume an estimated 4.1 g/kg/day of apple juice.  Monitoring data from the Toxic
Elements Program (TEP) and an apple juice survey (AJS) were evaluated. Total arsenic concentrations 
are reported noting that levels of organic arsenic species were below the level of quantification,
suggesting that inorganic arsenic accounts for the arsenic present in the samples. For TEP survey years 
2008–2011, there were 153 samples ranging in concentrations ranging from not detected up to 45 ppb 
(0.045 µg/g) with an average concentration of 4.7 ppb (0.0047 µg/g). The average total arsenic 
concentrations reported for 2008, 2009, 2010, and 2011 were 8.8, 7.8, 6.6, and 2.7 ppb, respectively
(0.0088, 0.0078, 0.0066, and 0.0027 µg/g).  For AJS survey year 2011, there were 94 samples ranging in 
concentrations from not detected up to 36 ppb (0.036 µg/g), with an average concentration of 4.4 ppb 
(0.0044 µg/g).
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
An ongoing study by the Firefighter Occupational Exposures Project measures chemical exposures in
firefighters in Southern California.  A geometric mean of 10.8 µg/L arsenic was reported for 101 urine
samples collected from 2010 to 2011; the detection frequency was 100% (LOD=0.158 µg/L) (OEHHA
2015).
Medicinal use of arsenite results in direct exposure of arsenic for patients who are administered this type 
of therapy.  A study by Nicolis et al. (2009) analyzed the hair of two patients receiving arsenic trioxide
treatments.  High arsenic levels in the patient’s hair directly corresponded to treatment and decreased
accordingly when treatment ceased.
Children and adults with celiac disease who consume a gluten-free diet tend to eat more rice-based foods;
additionally, people who reside with children or adults with celiac disease may consume a similar diet.
Food manufactured for people with celiac disease often contains rice and elevated levels of inorganic 
arsenic (Munera-Picazo et al. 2014a, 2014b).
Urine samples from 322 residents of an area in France with naturally high arsenic levels in soil were 
analyzed for arsenic (Fillol et al. 2010). The residents included adults and children >7 years of age.
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Urinary arsenic concentrations ranged from below the limit of quantification to 28.2 µg/g creatinine and a
geometric mean arsenic concentration of 4.4 µg/g creatinine. Two urine samples contained arsenate, half
of the samples contained arsenite, MMA was in 19% of the samples, and DMA was the only arsenic 
species detected in all samples containing arsenic.
6.8 ADEQUACY OF THE DATA BASE
6.8.1 Identification of Data Needs
Children are exposed to arsenic by the same exposure routes as adults (e.g., ingestion of food and water)
as well as possible exposure in utero. Data from the NHANES survey discussed in Section 6.5 indicated 
that higher urinary levels of DMA, a metabolite of arsenic exposure, were typically observed in children 
6–11 years old as compared to adults.  Continued monitoring of levels in children is needed.
Continued species-specific monitoring of rice, soil, and water sources would add value to exposure
assessments.
6.8.2 Ongoing Studies
Biomonitoring programs in United States include the Minnesota Biomonitoring Program
(http://www.health.state.mn.us/biomonitoring), Rocky Mountain Biomonitoring Consortium
(https://www.colorado.gov/pacific/cdphe/rocky-mountain-biomonitoring-consortium), California
Environmental Contaminant Biomonitoring Program (http://www.biomonitoring.ca.gov/), and 




Inorganic arsenic and organic arsenic exhibit distinctly different toxic health effects.  Speciation of
arsenic in tissues and body fluids improves the evaluation of arsenic exposure.  Seven arsenic compounds
are able to be determined in urine using one method (Verdon et al. 2009). HPLC-ICP-MS with dynamic 
reaction cell (DRC) has been used to separate and quantify arsenobetaine, arsenocholine, TMAO, As(V), 
As(III), monomethylarsonate, and dimethylarsinate.  Interconversion of arsenic species is minimized by
freezing samples until analysis, followed by treatment with a slightly acidified buffer solution.  Samples






   
   









   
   
 
     
 
       
 


























are prepared with 0.1 M ammonium acetate (pH 5) and centrifuged at 4°C.  The clarified supernatant is 
placed in a capped auto-sampler vial for analysis.  Post column addition of arsenic internal standard
improves the distinction of monoisotopic elements.  The DCR mode minimizes interferences from the
carrier gas.  Detection limits for the selected species are As(V)=1.0, As(III)=1.2, DMA=1.7, MMA=0.9, 
arsenobetaine=0.4, arsenocholine=0.6, and TMAO=1.0, reported in μg As/L.
Development of the hydride-generation cryotrapping-AAS (HG-CT-AAS) technique for the analysis of
major arsenic human metabolites, including dimethylmonothioarsinic acid, in biological samples was 
made to improve performance and lower detection limits (see Table 7-1; Hernandez-Zavala et al. 2008).  
Sample preparation involves generation of arsines from As(III) using a buffered mixture of tris-HCl and 
sodium borohydride, along with generation of arsines from both As(III) and As(V) by reduction using
L-cysteine.  The detection limits range from 9 to 20 pg arsenic for trivalent species and from 8 to 20 pg
arsenic for pentavalent species.
Table 7-1. Analytical Methods for Determining Arsenic in Biological Samples
Sample 





















Analysis of hair is used in arsenic biomonitoring studies.  Synchrotron radiation-based X-ray fluorescence 
(XRF) spectroscopy is used to quantify arsenic exposure in relation to time (Nicolis et al. 2009).  In 
addition, micro-XRF cartography and micro- fluorescence-X-ray absorption near-edge spectroscopy
(XANES) spectra was used to show the location and species of arsenic in hair samples.  Exogenous 
absorption from external arsenic exposure would complicate hair biomonitoring results.
7.2 ENVIRONMENTAL SAMPLES
Dietary exposure to inorganic arsenic is of greater concern compared with exposure to organic arsenic 
compounds.  Analytical methods for the speciation of arsenic in foods evaluate specific arsenic 
compounds rather than total arsenic (see Table 7-2). 

















   





   
 
  















    
 
 
   
    
    
 
 
    
       
  
     
   
 
   
  
 
























SPE HPLC-ICP-MS USGS 
method I-2020-05
0.06 μg/L NR USGS 2006




NR NR Kopittke et
al. 2014
Rice Extraction with 2%
v/v nitric acid








HG-AAS = hydride-generation atomic absorption; spectrometry; HPLC-ICP-MS = high-performance liquid
chromatography = inductively coupled plasma-mass spectrometry; NR = not reported; SDDC = silver
diethyldithiocarbamate; SPE = solid phase extractions; USGS = U.S. Geological Survey; XANES = X-ray absorption 
near-edge spectroscopy
The USGS National Water Quality laboratories have updated analytical methods for the determination of
elements in environmental media, including arsenic (USGS 2006).  A new ICP-MS method using
collision/reaction cell technology was developed to improve accuracy in the analysis of aqueous matrices.
The method is valid for both speciated and unspeciated arsenic evaluation.
Nitric acid extraction is a common technique employed for the successful separation of inorganic arsenic
in rice samples (Baba et al. 2014; Maher et al. 2013; Rasmussen et al. 2013).  Baba et al. (2014) and 
Maher et al. (2013) have validated the measurement and speciation of arsenic in rice using HPLC-ICP­
MS.  Baba et al. (2014) optimized a rapid speciation analysis of arsenic in rice using HPLC-ICP-MS.
Arsenous acid, arsenic acid, methylarsonic acid, and dimethylarsinic acid were determined with the use of
silica-based pentafluorophenyl (PFP) HPLC columns with an isocratic mobile phase of formic acid and
methanol in 5 minutes.  Arsenic species are extracted from finely ground rice samples using 0.15 M nitric
acid. The LOD is reported as 0.002 mg arsenic/kg (0.002 µg/g).  
Chen and Chen (2014) reported a LOD of 1.3 ng/g using solid phase extraction (SPE).  Arsenic is
extracted from rice samples via microwave assisted digestion with nitric acid-hydrogen peroxide.  As(III)
is oxidized to As(V) during digestion.  Silica-based anion exchange cartridges separate As(V) form







   
 
   
   
  
 
    
 






    
 
 
    
    
    
















    
 
   
    





     
     
     







organic arsenic compounds and quantification is achieved with hydride-generation atomic fluorescence 
spectrometry (HG-AFS).
XANES has been employed for arsenic speciation in rice.  Kopittke et al. (2014) developed a method to 
illustrate the accumulation and transformation of arsenic within root tissues.  Roots are sealed between
two 8-µm thick polyimide films and analyzed continuously using X-ray fluorescence microscopy.
Visible and near-infrared diffuse reflectance spectroscopy (VNIRS) has been used for rapid monitoring of
arsenic contamination in soils.  Using the reflectance spectra of rice plants, arsenic concentrations in soils 
can be calculated using regression analysis methods (Shi et al. 2014).  The method and techniques require
optimization and validation.
8. REGULATIONS AND ADVISORIES




Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification IARC 2014
Arsenic and inorganic arsenic Group 1a 
compounds
WHO Air quality guidelines
Arsenic 1.5x10-3 unit riskb 
WHO 2000
Drinking water quality guidelines WHO 2011b





ACGIH TLV-TWA ACGIH 2014
Arsenic and inorganic compounds 0.01 mg/m3 
AIHA ERPGs No data AIHA 2014
NIOSH REL (15-minute ceiling limit)










    
 
 
    
     










































































































































    
 
 
    
     











































































    
















































Arsenic and inorganic compounds,
including arsine
OSHA PEL (8-hour TWA) for general industry
Arsenic, organic compounds (as As)
Inorganic arsenic
PEL (8-hour TWA) for construction
Arsenic, organic compounds (as As)
Inorganic arsenic
PEL (8-hour TWA) for shipyards
Arsenic, organic compounds (as As)
Inorganic arsenic
b. Water
EPA Designated as hazardous substances in 
accordance with Section 311(b)(2)(A) of
the Clean Water Act
Arsenic pentoxide, arsenic trioxide,
calcium arsenate, and sodium
arsenite
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Agency Description	 Information Reference
NATIONAL (cont.)
EPA National recommended water quality
criteria for inorganic arsenic
Water + organism
Organism only
Reportable quantities of hazardous
substances designated pursuant to 
Section 311 of the Clean Water Act
Arsenic pentoxide, arsenic trioxide,
calcium arsenate, sodium arsenite
c. Food
FDA	 Allowable levels for contaminants in
bottled water for arsenic; proposed
action level for inorganic arsenic in 
apple juice
USDA	 Nonsynthetic substances prohibited for
use in organic crop production
d. Other
ACGIH Carcinogenicity classification
Arsenic and inorganic compounds
BEI for inorganic arsenic plus
methylated metabolites in urine at the 






Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous
substance and reportable quantity
Arsenic, arsenic acid, arsenic
pentoxide, arsenic trioxide,
dimethyl arsenic acid, calcium
arsenate, sodium arsenate, and 
sodium arsenite
Final RQ pounds
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Agency Description Information Reference
Extremely hazardous substances EPA 2013e
and its threshold planning quantity 40 CFR 355,
(pounds) Appendix A
Arsenic pentoxide, arsenous oxide, 100/10,000
sodium cacodylate
Calcium arsenate, sodium arsenite 500/10,000
Sodium arsenate 1,000/10,000
NATIONAL (cont.)
DHHS Carcinogenicity classification NTP 2014
Arsenic and inorganic arsenic Known to be human 
compounds carcinogens
aGroup 1: Carcinogenic to humans.
 
bCancer risk estimates for lifetime exposure to a concentration of 1 μg/m3.
 




dNIOSH potential occupational carcinogen.
 
eBased on applicable 60-minute AEGLs, ERPGs, or TEELs.
 
fHolding status AEGLs have been reviewed by the NAC/AEGL Committee and are under further review.
 
gDue to insufficient data.
 
hThis criterion is based on carcinogenicity of 10-6 risk.
 
iA1: Confirmed human carcinogen.
 
jGroup A: Human carcinogen.
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
 
AIHA = American Industrial Hygiene Association; BEI = biological exposure indices; CERCLA = Comprehensive 

Environmental Response, Compensation, and Liability Act; CFR = Code of Federal Regulations; DHHS = Department
 
of Health and Human Services; DOE = Department of Energy; DWEL = Drinking water equivalent level;
 
EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; FDA = Food and Drug 

Administration; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health;
 
IRIS = Integrated Risk Information System; MCL = maximum contaminant level; NAAQS = National Ambient Air
 
Quality Standards; NAC = National Advisory Committee; NIOSH = National Institute for Occupational Safety and 

Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration;
 
PAC = protective action criteria; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery
 
Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose;
 
RQ = reportable quantity; TEEl = temporary emergency exposure limit; TLV = threshold limit values; TSCA = Toxic
 
Substances Control Act; TWA = time-weighted average; WHO = World Health Organization
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